


    
<!DOCTYPE html>
<html lang="en" class="no-js">
<head>

    
            
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />

    <!-- Meta Tags for Parse.ly -->
        
    
  
  
          
    
<meta name="parsely-title" content="Zolgensma Creation Story Reveals Truths About Drug Pricing" />
<meta name="parsely-link" content="https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis" />
<meta name="parsely-type" content="post" />
<meta name="parsely-image-url" content="https://img.assets-c3.propublica.org/images/articles/20250131-ProPublica_Owen_Gent_Zolgensma_Final_Artwork_1200x630.jpg?crop=focalpoint&amp;fit=crop&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=630&amp;imgixProfile=propublicaAssets&amp;q=90&amp;w=1200&amp;s=91e4137e84071d14a021a6c5b48bb2ca" />

<meta name="parsely-pub-date" content="2025-02-12T08:00:00-05:00" />

<meta name="parsely-section" content="National" />
<meta name="parsely-author" content="Robin Fields" />
<meta name="parsely-tags" content="lang:en,storytype:enterprise,topic:Health Care" />
            <!-- Meta Tags for True Anthem -->
            <meta name="socialpost1" content="Zolgensma’s $2M/dose price quickly became the standard for gene therapies. Nine of them cost more than $2M. A tenth, approved in November, is predicted to run about $3.8M, just shy of the most expensive, which costs $4.25M/dose." />
                    <meta name="socialpost2" content="Taxpayers and charities subsidized much of the science that led to Zolgensma. Yet that support came with no conditions — financial or otherwise — for the companies that brought the drug over the finish line, even when it came to setting a price." />
                    <meta name="socialpost3" content="“The narrative of industry is, ‘We’re doing the hard, expensive part of drug development,’ and, at least for cell and gene therapies, the most risky part is actually being done by public or federally supported labs,” said one researcher." />
                    <meta name="socialpost4" content="The seven-figure price tags of Zolgensma and other gene therapies add to the nation’s ballooning bill for prescription drugs, absorbed by all Americans in the form of rising insurance premiums and taxes for public programs like Medicaid." />
                    <meta name="socialpost5" content="By law, Medicare doesn’t pay list price for drugs. Even with its discounted rate, Medicaid still paid out $309 million on just 208 Zolgensma claims — an average of almost $1.5M per claim — over a 3-year period." />
            
    <!-- Critical JS -->
    <script>(function(H){H.className=H.className.replace(/\bno-js\b/,'enhanced')})(document.documentElement)</script>
    <script>(function(win,undefined){win.PP=win.PP||{};win.PP.utils=win.PP.utils||{};var PP=win.PP;// loadJS: load a JS file asynchronously. Included from https://github.com/filamentgroup/loadJS/
function loadJS(src,cb){"use strict";var ref=window.document.getElementsByTagName("script")[0];var script=window.document.createElement("script");script.src=src;script.async=true;ref.parentNode.insertBefore(script,ref);if(cb&&typeof cb==="function"){script.onload=cb}return script}PP.utils.loadJS=loadJS;// cookie function from https://github.com/filamentgroup/cookie/
function cookie(name,value,days){// if value is undefined, get the cookie value
if(value===undefined){var cookiestring="; "+window.document.cookie;var cookies=cookiestring.split("; "+name+"=");if(cookies.length===2){return cookies.pop().split(";").shift()}return null}else{var expires;var domain;// if value is a false boolean, we'll treat that as a delete
if(value===false){days=-1}if(days){var date=new Date;date.setTime(date.getTime()+days*24*60*60*1000);expires="; expires="+date.toGMTString()}else{expires=""}if(location.hostname.endsWith(".propublica.org")){// Cookie set on www.propublica.org can be read on
// projects.propublica.org (and vice versa)
domain="; domain=.propublica.org"}else{// Cookie limited to current hostname
domain=""}window.document.cookie=name+"="+value+expires+domain+"; path=/"}}// expose it
PP.utils.cookie=cookie;// basic logging function
function log(logLine){const logOn=new URLSearchParams(window.location.search).get("__pp-debug");if(logOn!==null){console.log(logLine)}}// expose it
PP.utils.log=log;// generic event throttler using requestAnimationFrame
function rafEvent(type,name,obj){obj=obj||win;var running=false;var func=function(){if(running){return}running=true;requestAnimationFrame(function(){obj.dispatchEvent(new CustomEvent(name));running=false})};obj.addEventListener(type,func)}PP.utils.rafEvent=rafEvent;PP.utils.rafEvent("resize","rafResize");PP.utils.rafEvent("scroll","rafScroll");// Create a series of breakpoints corresponding to the ones in css/config/_column-settings.scss
//
// Usage:
//
// 1. Check if breakpoint condition matches
//    if (PP.utils.aboveBreakpoint("lg").matches) { console.log("Is Desktop"); }
//    if (PP.utils.belowBreakpoint("lg").matches) { console.log("Is Mobile"); }
//
// 2. Listener that triggers when breakpoint condition changes
//    aboveBreakpoint("lg").addEventListener("change", function () { console.log("Mobile/Desktop breakpoint changed."); });
const breakpoints={xs:0,sm:36,md:48,lg:60,xl:78,xxl:88};PP.utils.breakpoints=breakpoints;function aboveBreakpoint(value){return window.matchMedia(`(min-width: ${PP.utils.breakpoints[value]}em)`)}function belowBreakpoint(value){return window.matchMedia(`(max-width: ${PP.utils.breakpoints[value]}em)`)}PP.utils.aboveBreakpoint=aboveBreakpoint;PP.utils.belowBreakpoint=belowBreakpoint})(this);;(function(){var undefined;var VERSION="4.17.5";var FUNC_ERROR_TEXT="Expected a function";var NAN=0/0;var nullTag="[object Null]",symbolTag="[object Symbol]",undefinedTag="[object Undefined]";var reTrim=/^\s+|\s+$/g;var reIsBadHex=/^[-+]0x[0-9a-f]+$/i;var reIsBinary=/^0b[01]+$/i;var reIsOctal=/^0o[0-7]+$/i;var freeParseInt=parseInt;var freeGlobal=typeof global=="object"&&global&&global.Object===Object&&global;var freeSelf=typeof self=="object"&&self&&self.Object===Object&&self;var root=freeGlobal||freeSelf||Function("return this")();var freeExports=typeof exports=="object"&&exports&&!exports.nodeType&&exports;var freeModule=freeExports&&typeof module=="object"&&module&&!module.nodeType&&module;var objectProto=Object.prototype;var hasOwnProperty=objectProto.hasOwnProperty;var nativeObjectToString=objectProto.toString;var Symbol=root.Symbol,symToStringTag=Symbol?Symbol.toStringTag:undefined;var nativeMax=Math.max,nativeMin=Math.min;var realNames={};function lodash(){}function baseGetTag(value){if(value==null){return value===undefined?undefinedTag:nullTag}return symToStringTag&&symToStringTag in Object(value)?getRawTag(value):objectToString(value)}function getRawTag(value){var isOwn=hasOwnProperty.call(value,symToStringTag),tag=value[symToStringTag];try{value[symToStringTag]=undefined;var unmasked=true}catch(e){}var result=nativeObjectToString.call(value);if(unmasked){if(isOwn){value[symToStringTag]=tag}else{delete value[symToStringTag]}}return result}function objectToString(value){return nativeObjectToString.call(value)}var now=function(){return root.Date.now()};function debounce(func,wait,options){var lastArgs,lastThis,maxWait,result,timerId,lastCallTime,lastInvokeTime=0,leading=false,maxing=false,trailing=true;if(typeof func!="function"){throw new TypeError(FUNC_ERROR_TEXT)}wait=toNumber(wait)||0;if(isObject(options)){leading=!!options.leading;maxing="maxWait"in options;maxWait=maxing?nativeMax(toNumber(options.maxWait)||0,wait):maxWait;trailing="trailing"in options?!!options.trailing:trailing}function invokeFunc(time){var args=lastArgs,thisArg=lastThis;lastArgs=lastThis=undefined;lastInvokeTime=time;result=func.apply(thisArg,args);return result}function leadingEdge(time){lastInvokeTime=time;timerId=setTimeout(timerExpired,wait);return leading?invokeFunc(time):result}function remainingWait(time){var timeSinceLastCall=time-lastCallTime,timeSinceLastInvoke=time-lastInvokeTime,timeWaiting=wait-timeSinceLastCall;return maxing?nativeMin(timeWaiting,maxWait-timeSinceLastInvoke):timeWaiting}function shouldInvoke(time){var timeSinceLastCall=time-lastCallTime,timeSinceLastInvoke=time-lastInvokeTime;return lastCallTime===undefined||timeSinceLastCall>=wait||timeSinceLastCall<0||maxing&&timeSinceLastInvoke>=maxWait}function timerExpired(){var time=now();if(shouldInvoke(time)){return trailingEdge(time)}timerId=setTimeout(timerExpired,remainingWait(time))}function trailingEdge(time){timerId=undefined;if(trailing&&lastArgs){return invokeFunc(time)}lastArgs=lastThis=undefined;return result}function cancel(){if(timerId!==undefined){clearTimeout(timerId)}lastInvokeTime=0;lastArgs=lastCallTime=lastThis=timerId=undefined}function flush(){return timerId===undefined?result:trailingEdge(now())}function debounced(){var time=now(),isInvoking=shouldInvoke(time);lastArgs=arguments;lastThis=this;lastCallTime=time;if(isInvoking){if(timerId===undefined){return leadingEdge(lastCallTime)}if(maxing){timerId=setTimeout(timerExpired,wait);return invokeFunc(lastCallTime)}}if(timerId===undefined){timerId=setTimeout(timerExpired,wait)}return result}debounced.cancel=cancel;debounced.flush=flush;return debounced}function throttle(func,wait,options){var leading=true,trailing=true;if(typeof func!="function"){throw new TypeError(FUNC_ERROR_TEXT)}if(isObject(options)){leading="leading"in options?!!options.leading:leading;trailing="trailing"in options?!!options.trailing:trailing}return debounce(func,wait,{leading:leading,maxWait:wait,trailing:trailing})}function isObject(value){var type=typeof value;return value!=null&&(type=="object"||type=="function")}function isObjectLike(value){return value!=null&&typeof value=="object"}function isSymbol(value){return typeof value=="symbol"||isObjectLike(value)&&baseGetTag(value)==symbolTag}function toNumber(value){if(typeof value=="number"){return value}if(isSymbol(value)){return NAN}if(isObject(value)){var other=typeof value.valueOf=="function"?value.valueOf():value;value=isObject(other)?other+"":other}if(typeof value!="string"){return value===0?value:+value}value=value.replace(reTrim,"");var isBinary=reIsBinary.test(value);return isBinary||reIsOctal.test(value)?freeParseInt(value.slice(2),isBinary?2:8):reIsBadHex.test(value)?NAN:+value}lodash.debounce=debounce;lodash.throttle=throttle;lodash.isObject=isObject;lodash.isObjectLike=isObjectLike;lodash.isSymbol=isSymbol;lodash.now=now;lodash.toNumber=toNumber;lodash.VERSION=VERSION;if(typeof define=="function"&&typeof define.amd=="object"&&define.amd){root._=lodash;define(function(){return lodash})}else if(freeModule){(freeModule.exports=lodash)._=lodash;freeExports._=lodash}else{root._=lodash}}).call(this);;/*! lazysizes - v5.3.2 */!function(e){var t=function(u,D,f){"use strict";var k,H;if(function(){var e;var t={lazyClass:"lazyload",loadedClass:"lazyloaded",loadingClass:"lazyloading",preloadClass:"lazypreload",errorClass:"lazyerror",autosizesClass:"lazyautosizes",fastLoadedClass:"ls-is-cached",iframeLoadMode:0,srcAttr:"data-src",srcsetAttr:"data-srcset",sizesAttr:"data-sizes",minSize:40,customMedia:{},init:true,expFactor:1.5,hFac:.8,loadMode:2,loadHidden:true,ricTimeout:0,throttleDelay:125};H=u.lazySizesConfig||u.lazysizesConfig||{};for(e in t){if(!(e in H)){H[e]=t[e]}}}(),!D||!D.getElementsByClassName){return{init:function(){},cfg:H,noSupport:true}}var O=D.documentElement,i=u.HTMLPictureElement,P="addEventListener",$="getAttribute",q=u[P].bind(u),I=u.setTimeout,U=u.requestAnimationFrame||I,o=u.requestIdleCallback,j=/^picture$/i,r=["load","error","lazyincluded","_lazyloaded"],a={},G=Array.prototype.forEach,J=function(e,t){if(!a[t]){a[t]=new RegExp("(\\s|^)"+t+"(\\s|$)")}return a[t].test(e[$]("class")||"")&&a[t]},K=function(e,t){if(!J(e,t)){e.setAttribute("class",(e[$]("class")||"").trim()+" "+t)}},Q=function(e,t){var a;if(a=J(e,t)){e.setAttribute("class",(e[$]("class")||"").replace(a," "))}},V=function(t,a,e){var i=e?P:"removeEventListener";if(e){V(t,a)}r.forEach(function(e){t[i](e,a)})},X=function(e,t,a,i,r){var n=D.createEvent("Event");if(!a){a={}}a.instance=k;n.initEvent(t,!i,!r);n.detail=a;e.dispatchEvent(n);return n},Y=function(e,t){var a;if(!i&&(a=u.picturefill||H.pf)){if(t&&t.src&&!e[$]("srcset")){e.setAttribute("srcset",t.src)}a({reevaluate:true,elements:[e]})}else if(t&&t.src){e.src=t.src}},Z=function(e,t){return(getComputedStyle(e,null)||{})[t]},s=function(e,t,a){a=a||e.offsetWidth;while(a<H.minSize&&t&&!e._lazysizesWidth){a=t.offsetWidth;t=t.parentNode}return a},ee=function(){var a,i;var t=[];var r=[];var n=t;var s=function(){var e=n;n=t.length?r:t;a=true;i=false;while(e.length){e.shift()()}a=false};var e=function(e,t){if(a&&!t){e.apply(this,arguments)}else{n.push(e);if(!i){i=true;(D.hidden?I:U)(s)}}};e._lsFlush=s;return e}(),te=function(a,e){return e?function(){ee(a)}:function(){var e=this;var t=arguments;ee(function(){a.apply(e,t)})}},ae=function(e){var a;var i=0;var r=H.throttleDelay;var n=H.ricTimeout;var t=function(){a=false;i=f.now();e()};var s=o&&n>49?function(){o(t,{timeout:n});if(n!==H.ricTimeout){n=H.ricTimeout}}:te(function(){I(t)},true);return function(e){var t;if(e=e===true){n=33}if(a){return}a=true;t=r-(f.now()-i);if(t<0){t=0}if(e||t<9){s()}else{I(s,t)}}},ie=function(e){var t,a;var i=99;var r=function(){t=null;e()};var n=function(){var e=f.now()-a;if(e<i){I(n,i-e)}else{(o||r)(r)}};return function(){a=f.now();if(!t){t=I(n,i)}}},e=function(){var v,m,c,h,e;var y,z,g,p,C,b,A;var n=/^img$/i;var d=/^iframe$/i;var E="onscroll"in u&&!/(gle|ing)bot/.test(navigator.userAgent);var _=0;var w=0;var M=0;var N=-1;var L=function(e){M--;if(!e||M<0||!e.target){M=0}};var x=function(e){if(A==null){A=Z(D.body,"visibility")=="hidden"}return A||!(Z(e.parentNode,"visibility")=="hidden"&&Z(e,"visibility")=="hidden")};var W=function(e,t){var a;var i=e;var r=x(e);g-=t;b+=t;p-=t;C+=t;while(r&&(i=i.offsetParent)&&i!=D.body&&i!=O){r=(Z(i,"opacity")||1)>0;if(r&&Z(i,"overflow")!="visible"){a=i.getBoundingClientRect();r=C>a.left&&p<a.right&&b>a.top-1&&g<a.bottom+1}}return r};var t=function(){var e,t,a,i,r,n,s,o,l,u,f,c;var d=k.elements;if((h=H.loadMode)&&M<8&&(e=d.length)){t=0;N++;for(;t<e;t++){if(!d[t]||d[t]._lazyRace){continue}if(!E||k.prematureUnveil&&k.prematureUnveil(d[t])){R(d[t]);continue}if(!(o=d[t][$]("data-expand"))||!(n=o*1)){n=w}if(!u){u=!H.expand||H.expand<1?O.clientHeight>500&&O.clientWidth>500?500:370:H.expand;k._defEx=u;f=u*H.expFactor;c=H.hFac;A=null;if(w<f&&M<1&&N>2&&h>2&&!D.hidden){w=f;N=0}else if(h>1&&N>1&&M<6){w=u}else{w=_}}if(l!==n){y=innerWidth+n*c;z=innerHeight+n;s=n*-1;l=n}a=d[t].getBoundingClientRect();if((b=a.bottom)>=s&&(g=a.top)<=z&&(C=a.right)>=s*c&&(p=a.left)<=y&&(b||C||p||g)&&(H.loadHidden||x(d[t]))&&(m&&M<3&&!o&&(h<3||N<4)||W(d[t],n))){R(d[t]);r=true;if(M>9){break}}else if(!r&&m&&!i&&M<4&&N<4&&h>2&&(v[0]||H.preloadAfterLoad)&&(v[0]||!o&&(b||C||p||g||d[t][$](H.sizesAttr)!="auto"))){i=v[0]||d[t]}}if(i&&!r){R(i)}}};var a=ae(t);var S=function(e){var t=e.target;if(t._lazyCache){delete t._lazyCache;return}L(e);K(t,H.loadedClass);Q(t,H.loadingClass);V(t,B);X(t,"lazyloaded")};var i=te(S);var B=function(e){i({target:e.target})};var T=function(e,t){var a=e.getAttribute("data-load-mode")||H.iframeLoadMode;if(a==0){e.contentWindow.location.replace(t)}else if(a==1){e.src=t}};var F=function(e){var t;var a=e[$](H.srcsetAttr);if(t=H.customMedia[e[$]("data-media")||e[$]("media")]){e.setAttribute("media",t)}if(a){e.setAttribute("srcset",a)}};var s=te(function(t,e,a,i,r){var n,s,o,l,u,f;if(!(u=X(t,"lazybeforeunveil",e)).defaultPrevented){if(i){if(a){K(t,H.autosizesClass)}else{t.setAttribute("sizes",i)}}s=t[$](H.srcsetAttr);n=t[$](H.srcAttr);if(r){o=t.parentNode;l=o&&j.test(o.nodeName||"")}f=e.firesLoad||"src"in t&&(s||n||l);u={target:t};K(t,H.loadingClass);if(f){clearTimeout(c);c=I(L,2500);V(t,B,true)}if(l){G.call(o.getElementsByTagName("source"),F)}if(s){t.setAttribute("srcset",s)}else if(n&&!l){if(d.test(t.nodeName)){T(t,n)}else{t.src=n}}if(r&&(s||l)){Y(t,{src:n})}}if(t._lazyRace){delete t._lazyRace}Q(t,H.lazyClass);ee(function(){var e=t.complete&&t.naturalWidth>1;if(!f||e){if(e){K(t,H.fastLoadedClass)}S(u);t._lazyCache=true;I(function(){if("_lazyCache"in t){delete t._lazyCache}},9)}if(t.loading=="lazy"){M--}},true)});var R=function(e){if(e._lazyRace){return}var t;var a=n.test(e.nodeName);var i=a&&(e[$](H.sizesAttr)||e[$]("sizes"));var r=i=="auto";if((r||!m)&&a&&(e[$]("src")||e.srcset)&&!e.complete&&!J(e,H.errorClass)&&J(e,H.lazyClass)){return}t=X(e,"lazyunveilread").detail;if(r){re.updateElem(e,true,e.offsetWidth)}e._lazyRace=true;M++;s(e,t,r,i,a)};var r=ie(function(){H.loadMode=3;a()});var o=function(){if(H.loadMode==3){H.loadMode=2}r()};var l=function(){if(m){return}if(f.now()-e<999){I(l,999);return}m=true;H.loadMode=3;a();q("scroll",o,true)};return{_:function(){e=f.now();k.elements=D.getElementsByClassName(H.lazyClass);v=D.getElementsByClassName(H.lazyClass+" "+H.preloadClass);q("scroll",a,true);q("resize",a,true);q("pageshow",function(e){if(e.persisted){var t=D.querySelectorAll("."+H.loadingClass);if(t.length&&t.forEach){U(function(){t.forEach(function(e){if(e.complete){R(e)}})})}}});if(u.MutationObserver){new MutationObserver(a).observe(O,{childList:true,subtree:true,attributes:true})}else{O[P]("DOMNodeInserted",a,true);O[P]("DOMAttrModified",a,true);setInterval(a,999)}q("hashchange",a,true);["focus","mouseover","click","load","transitionend","animationend"].forEach(function(e){D[P](e,a,true)});if(/d$|^c/.test(D.readyState)){l()}else{q("load",l);D[P]("DOMContentLoaded",a);I(l,2e4)}if(k.elements.length){t();ee._lsFlush()}else{a()}},checkElems:a,unveil:R,_aLSL:o}}(),re=function(){var a;var n=te(function(e,t,a,i){var r,n,s;e._lazysizesWidth=i;i+="px";e.setAttribute("sizes",i);if(j.test(t.nodeName||"")){r=t.getElementsByTagName("source");for(n=0,s=r.length;n<s;n++){r[n].setAttribute("sizes",i)}}if(!a.detail.dataAttr){Y(e,a.detail)}});var i=function(e,t,a){var i;var r=e.parentNode;if(r){a=s(e,r,a);i=X(e,"lazybeforesizes",{width:a,dataAttr:!!t});if(!i.defaultPrevented){a=i.detail.width;if(a&&a!==e._lazysizesWidth){n(e,r,i,a)}}}};var e=function(){var e;var t=a.length;if(t){e=0;for(;e<t;e++){i(a[e])}}};var t=ie(e);return{_:function(){a=D.getElementsByClassName(H.autosizesClass);q("resize",t)},checkElems:t,updateElem:i}}(),t=function(){if(!t.i&&D.getElementsByClassName){t.i=true;re._();e._()}};return I(function(){H.init&&t()}),k={cfg:H,autoSizer:re,loader:e,init:t,uP:Y,aC:K,rC:Q,hC:J,fire:X,gW:s,rAF:ee}}(e,e.document,Date);e.lazySizes=t,"object"==typeof module&&module.exports&&(module.exports=t)}("undefined"!=typeof window?window:{});;/*! lazysizes - v5.3.2 */!function(e,t){var a=function(){t(e.lazySizes),e.removeEventListener("lazyunveilread",a,!0)};t=t.bind(null,e,e.document),"object"==typeof module&&module.exports?t(require("lazysizes")):"function"==typeof define&&define.amd?define(["lazysizes"],t):e.lazySizes?a():e.addEventListener("lazyunveilread",a,!0)}(window,function(e,i,o){"use strict";var l,d,u={};function s(e,t,a){var n,r;u[e]||(n=i.createElement(t?"link":"script"),r=i.getElementsByTagName("script")[0],t?(n.rel="stylesheet",n.href=e):(n.onload=function(){n.onerror=null,n.onload=null,a()},n.onerror=n.onload,n.src=e),u[e]=!0,u[n.src||n.href]=!0,r.parentNode.insertBefore(n,r))}i.addEventListener&&(l=function(e,t){var a=i.createElement("img");a.onload=function(){a.onload=null,a.onerror=null,a=null,t()},a.onerror=a.onload,a.src=e,a&&a.complete&&a.onload&&a.onload()},addEventListener("lazybeforeunveil",function(e){var t,a,n;if(e.detail.instance==o&&!e.defaultPrevented){var r=e.target;if("none"==r.preload&&(r.preload=r.getAttribute("data-preload")||"auto"),null!=r.getAttribute("data-autoplay"))if(r.getAttribute("data-expand")&&!r.autoplay)try{r.play()}catch(e){}else requestAnimationFrame(function(){r.setAttribute("data-expand","-10"),o.aC(r,o.cfg.lazyClass)});(t=r.getAttribute("data-link"))&&s(t,!0),(t=r.getAttribute("data-script"))&&(e.detail.firesLoad=!0,s(t,null,function(){e.detail.firesLoad=!1,o.fire(r,"_lazyloaded",{},!0,!0)})),(t=r.getAttribute("data-require"))&&(o.cfg.requireJs?o.cfg.requireJs([t]):s(t)),(a=r.getAttribute("data-bg"))&&(e.detail.firesLoad=!0,l(a,function(){r.style.backgroundImage="url("+(d.test(a)?JSON.stringify(a):a)+")",e.detail.firesLoad=!1,o.fire(r,"_lazyloaded",{},!0,!0)})),(n=r.getAttribute("data-poster"))&&(e.detail.firesLoad=!0,l(n,function(){r.poster=n,e.detail.firesLoad=!1,o.fire(r,"_lazyloaded",{},!0,!0)}))}},!(d=/\(|\)|\s|'/)))});
//# sourceMappingURL=initial.js.map
</script>

        <script>
    window.dataLayer = window.dataLayer || [];
    window.dataLayer.push({
        'contentType': 'Item', // updated taxonomy TK
        'publicationDate': 'February 12, 2025 08:00:00',
        'articleTopic': 'Health Care',
        'articleTitle': 'What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing',
        'authorName': 'Robin Fields',
        'seriesName': '',
        'contentRegion': 'National',
        'contentLanguage': 'en',
        'craftId' : '2685350',
        'articleVersion' : 'V5',
        'contentLocation' : '',
        'storyType': 'enterprise',
        'impact': "false"
    });
</script>

    <!-- PRECONNECT -->
        <link href="https://assets.propublica.org" rel="preconnect">
    <link href="https://assets.propublica.org" rel="dns-prefetch">
        <link href="https://img.assets-c3.propublica.org" rel="dns-prefetch">
    <link href="https://img.assets-d.propublica.org" rel="dns-prefetch">

    <!-- STYLES -->
    <link rel="stylesheet" href="https://assets.propublica.org/static/prod/v5/css/main.6d666a76.css">

    <!-- OTHER -->
            
        <link rel="icon" href="https://assets.propublica.org/static/prod/v5/images/favicon.ico">
    <link rel="icon" href="https://assets.propublica.org/static/prod/v5/images/icon.min.svg" type="image/svg+xml">
    <link rel="apple-touch-icon" href="https://assets.propublica.org/static/prod/v5/images/apple-touch-icon-180x180.png">
    
    

    <!--mastodon-->
    <link rel="me" href="https://newsie.social/@ProPublica" />
    <meta name="fediverse:creator" content="@propublica@newsie.social" />

<title>Zolgensma Creation Story Reveals Truths About Drug Pricing — ProPublica</title><meta name="description" content="Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the widely held conception that high prices reflect huge industry investments in innovation.">
<meta name="referrer" content="no-referrer-when-downgrade">
<meta name="robots" content="all">
<meta content="Robin Fields" property="author">
<meta content="Zolgensma Creation Story Reveals Truths About Drug Pricing" property="headline">
<meta content="13320939444" property="fb:profile_id">
<meta content="229862657130557" property="fb:app_id">
<meta content="en_US" property="og:locale">
<meta content="ProPublica" property="og:site_name">
<meta content="article" property="og:type">
<meta content="https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis" property="og:url">
<meta content="What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing" property="og:title">
<meta content="Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the widely held conception that high prices reflect huge industry investments in innovation." property="og:description">
<meta content="https://img.assets-c3.propublica.org/images/articles/20250131-ProPublica_Owen_Gent_Zolgensma_Final_Artwork_1200x630.jpg?crop=focalpoint&amp;fit=crop&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=630&amp;imgixProfile=propublicaAssets&amp;q=90&amp;w=1200&amp;s=91e4137e84071d14a021a6c5b48bb2ca" property="og:image">
<meta content="https://vimeo.com/propublica" property="og:see_also">
<meta content="https://www.pinterest.com/propublica" property="og:see_also">
<meta content="https://www.instagram.com/propublica" property="og:see_also">
<meta content="https://www.linkedin.com/company/propublica/" property="og:see_also">
<meta content="https://github.com/propublica" property="og:see_also">
<meta content="https://www.youtube.com/user/propublica" property="og:see_also">
<meta content="https://en.wikipedia.org/wiki/ProPublica" property="og:see_also">
<meta content="https://www.facebook.com/propublica/" property="og:see_also">
<meta content="https://twitter.com/propublica" property="og:see_also">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@propublica">
<meta name="twitter:creator" content="@propublica">
<meta name="twitter:title" content="What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing">
<meta name="twitter:description" content="Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the widely held conception that high prices reflect huge industry investments in innovation.">
<meta name="twitter:image" content="https://img.assets-c3.propublica.org/images/articles/20250131-ProPublica_Owen_Gent_Zolgensma_Final_Artwork_1200x630.jpg?crop=focalpoint&amp;fit=crop&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=630&amp;imgixProfile=propublicaAssets&amp;q=90&amp;w=1200&amp;s=91e4137e84071d14a021a6c5b48bb2ca">
<link href="https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis" rel="canonical">
<link href="https://www.propublica.org" rel="home">
<link type="text/plain" href="https://www.propublica.org/humans.txt" rel="author"></head>

<body id="www-propublica-org" class="entry-type-article bg-white text-dark neutral-cool user-level--0 accent-blue contains-highlights" data-pp-location="v5 body">
    
            
    
<style>
    .site-header__banner {
        font-family: Graphik, sans-serif;
        font-size: 13px;
        line-height: 1.2;
        position: relative;
        z-index: 100;
    }
    @media screen and (min-width: 40em) {
        .site-header__banner {
            font-size: 15px;
        }
    }
    a.site-header__banner-link {
        align-items: center;
        background: linear-gradient(
            to right,
            #e98406,
            #cf176d,
            #2074df
        );
        color: white;
        display: flex;
        justify-content: center;
        overflow: hidden;
        padding: 0.5em 1em;
        text-decoration: none;
        transition: unset;
    }
    .site-header__banner-link > * + * {
        margin-left: 8px;
    }
    .site-header__banner-cta {
        background: #da352b;
        border-radius: 0.2em;
        color: white;
        display: inline;
        font-size: 0.85em;
        font-weight: 700;
        padding: 0.5em 1em;
        text-transform: uppercase;
        text-align: center;
        /* see here for smooth box-shadow calculation: https://shadows.brumm.af */
        /*
        box-shadow:
            0 1.3px 1.3px rgba(0, 0, 0, 0.07),
            0 4.5px 4.5px rgba(0, 0, 0, 0.042),
            0 20px 20px rgba(0, 0, 0, 0.028)
        ;
        */
    }
    /*
    .site-header__banner-copy {
        display: none;
    }
    @media screen and (min-width: 50em) {
        .site-header__banner-copy {
            display: block;
        }
    }
    */
    /*
    .site-header__banner-link:focus .site-header__banner-cta,
    .site-header__banner-link:hover .site-header__banner-cta {
        background: #9b0000;
        color: white;
    }
    */

    .site-header__banner-title {
        padding-right: 0.25em;
    }

    @media screen and (min-width: 60em) {
        .opener--grid {
            /* Tweak full height to account for promo bar height */
            grid-template-rows: minmax(calc(100vh - 2.25rem), auto) auto auto;
        }
    }
    @media screen and (min-width: 60em) {
        .opener--grid .opener__art.opener__art--inset,
        .opener--grid .opener__art.opener__art--inset > img,
        .opener--grid .opener__art.opener__art--inset > video {
            /* Tweak full height to account for promo bar height */
            max-height: calc( 100vh - 2.25rem - 2 * var(--opener-page-margins));
        }
    }
</style>


    <!-- Load SiteHeader variant based on variable -->

<script type="application/json" class="svelte-config">
                            {"componentName":"SiteHeader","props":{"type":"compact","fixedNavScrollStart":".opener"},"contextArray":[]}
                        </script>
                        <a class="site-header-skip-link a11y a11y-focusable--absolute svelte-5qrmpy" href="#main" data-svelte-h="svelte-19fmzuu">Skip to content</a>   <div class="site-header--compact svelte-5qrmpy" data-pp-location="svelte-siteheader"><div class="variant-compact__inner-wrap svelte-5qrmpy variant-compact__inner-wrap--has-border"><div class="variant-compact__section-menu svelte-5qrmpy"> <button class="button shape--round-rect  button-is-icon-only  svelte-1qpwxqa" data-link="Menu" data-pp-skip="false" data-testid="compact-menu-button" style="--button-bg-color: transparent; --button-border: none; --button-color: var(--site-header-color-button-text, var(--color-neutral-80)); --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: 1em;"><span class="icon-before svelte-1qpwxqa"><svg role="img" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><title>Menu</title><path fill-rule="evenodd" clip-rule="evenodd" d="M2 12C2 11.4477 2.44772 11 3 11H21C21.5523 11 22 11.4477 22 12C22 12.5523 21.5523 13 21 13H3C2.44772 13 2 12.5523 2 12Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M2 6C2 5.44772 2.44772 5 3 5H21C21.5523 5 22 5.44772 22 6C22 6.55228 21.5523 7 21 7H3C2.44772 7 2 6.55228 2 6Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M2 18C2 17.4477 2.44772 17 3 17H21C21.5523 17 22 17.4477 22 18C22 18.5523 21.5523 19 21 19H3C2.44772 19 2 18.5523 2 18Z" fill="currentColor"></path></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">Menu</span>  </button></div> <a class="variant-compact__wordmark svelte-5qrmpy" href="https://www.propublica.org"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 574.24 75" fill="currentColor"><title>ProPublica</title><path d="M66.4,13.48,66,14.91l6.23,11.45,1.15.47L75,26.29V75H50.95A41.2,41.2,0,0,0,62.13,46.88a40.61,40.61,0,0,0-3.39-16.26,45.17,45.17,0,0,1,7.79-4.95l1.69-.2.14-.41L65,18.83H64.5l-.88,1.29c-2.91,1.9-4.67,2.3-8.54,3.79A41.35,41.35,0,0,0,20.46,5.42,39.87,39.87,0,0,0,0,10.91V0H75V8.81ZM57.32,47A37.54,37.54,0,0,1,44.65,75H0V16A37,37,0,0,1,57.32,47ZM43.7,37.06c0-8.13-6-12-17.75-12H7.18v3.66l4.2.95V62.2l-4.2.95v3.73H27.85V63.14l-7.18-.95V50.14h5.15C37.26,50.14,43.7,45.53,43.7,37.06Zm-9.76.27c0,5.15-2.78,8.33-7.25,8.33h-6V29.47H27C31.37,29.47,33.94,32.32,33.94,37.33Z"></path><path d="M116.53,60.07l9.15,1.08v4.2H99.39v-4.2l5.28-1.36v-44l-5.28-1.36V10.41H123c15.31,0,22.9,5.28,22.9,16.13,0,11.18-8.33,17.41-23.1,17.41h-6.3Zm0-21.14h6.84c6.44,0,10.5-4.61,10.5-12.06,0-7.18-3.73-11.45-10.09-11.45h-7.25Z"></path><path d="M200.74,61.15v4.2H185.9l-16-20.6h-2.51v15l5.28,1.36v4.2H150.27v-4.2l5.28-1.36V23.35l-5-1.36V17.93H175.2c10.5,0,17.55,5.08,17.55,12.67,0,8.4-5.76,12.2-11,13.55l13.48,15.79ZM167.41,39.74h4.47c5.76,0,8.81-3.18,8.81-8.88,0-5.35-2.85-7.93-8.81-7.93h-4.47Z"></path><path d="M199.59,41.64c0-14.77,9.82-24.73,25.68-24.73s25.68,10,25.68,24.73-9.82,24.73-25.68,24.73S199.59,56.48,199.59,41.64Zm38.89,0c0-9.69-3.25-19.17-13.21-19.17S212.05,32,212.05,41.64s3.25,19.17,13.21,19.17S238.48,51.33,238.48,41.64Z"></path><path d="M270.79,60.07l9.15,1.08v4.2H253.31v-4.2l5.62-1.36v-44l-5.62-1.36V10.41h24c15.31,0,22.9,5.28,22.9,16.13,0,11.18-8.33,17.41-23.1,17.41h-6.3Zm0-21.14h6.84c6.44,0,10.5-4.61,10.5-12.06,0-7.18-3.73-11.45-10.1-11.45h-7.25Z"></path><path d="M354.26,22l-4.95,1.36V47c0,12.87-7.79,19.38-20.05,19.38-13.62,0-20.73-7.86-20.73-20v-23L303.58,22V17.93h22V22l-5.08,1.36V47.74c0,7.25,4.34,12.06,11.45,12.06,6.84,0,11.25-4.47,11.25-11.31V23.35L338.14,22V17.93h16.12Z"></path><path d="M403.85,52.21c0,8.88-7.11,13.14-22,13.14H357.58v-4.2l5.56-1.36V23.35L358.26,22V17.93h23.92c12.6,0,19.51,3.79,19.51,11.72,0,6.17-4.06,9.08-10.91,9.89v.27C399.31,40.76,403.85,45.1,403.85,52.21ZM375,38.32h5.76c6.1,0,9-2.78,9-7.79,0-5.22-3.12-7.59-9-7.59H375Zm16.8,13.41c0-5.62-3.79-8.67-11.25-8.67H375V60.34h6.64C388.07,60.34,391.79,57.29,391.79,51.74Z"></path><path d="M451.07,48.62l-4.4,16.73H408v-4.2l5.28-1.36V23.35L407.65,22V17.93h22.76V22l-5.28,1.36v37l14.16-.81L447,47.26Z"></path><path d="M475.4,61.15v4.2H453v-4.2l5.28-1.36V23.35L453,22V17.93H475.4V22l-5.28,1.36V59.8Z"></path><path d="M478,41.78c0-15.85,12.13-24.86,27-24.86a35.6,35.6,0,0,1,18.29,5.15l-2,13.21h-4.2l-1.69-9.08a13.23,13.23,0,0,0-10.09-4.13c-9.15,0-14.7,6.57-14.7,18.22,0,13.21,6.84,19.31,15.24,19.31,6.17,0,10.23-3.39,13.41-9.55l4.27,2c-4.27,10-11.65,14.36-21.07,14.36C488.4,66.37,478,56.48,478,41.78Z"></path><path d="M574.24,61.15v4.2H551.48v-4.2L557,60l-2.85-8.13h-16.6l-3.12,8.2,5.42,1.15-.07,4.2-16.53-.07v-4.2l4.27-1.08,14.9-37.33-4-1.29V17.93h13.69L569.3,60Zm-27.57-31-.47-1.56-.47,1.56-6.23,16.73h12.94Z"></path></svg></a>  <a data-pp-view="" href="https://give.propublica.org/give/346423/#!/donation/checkout?c_src=UpRed" class="button shape--round-rect    svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--red-50); --button-border: none; --button-color: var(--white); --button-font-size: var(--scale-2); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale2); --icon-size: 1em;"> <span class="text font--serif svelte-1qpwxqa">Donate</span>  </a></div></div>  <div class="site-header-overlay svelte-5qrmpy" data-testid="overlay" data-pp-location="svelte-siteheader-overlay" style="opacity: 0; pointer-events: none;"><div class="variant-overlay__top-inner-wrap svelte-5qrmpy"><div class="variant-overlay__section-menu svelte-5qrmpy"> <button class="button shape--round-rect  button-is-icon-only  svelte-1qpwxqa" data-link="Menu" data-pp-skip="false" data-testid="close-overlay-button" style="--button-bg-color: transparent; --button-border: none; --button-color: white; --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: var(--scale0);"><span class="icon-before svelte-1qpwxqa"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><title>Close</title><line x1="18" y1="6" x2="6" y2="18"></line><line x1="6" y1="6" x2="18" y2="18"></line></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">Close</span>  </button></div> <a class="variant-overlay__wordmark svelte-5qrmpy" href="https://www.propublica.org"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 574.24 75" fill="currentColor"><title>ProPublica</title><path d="M66.4,13.48,66,14.91l6.23,11.45,1.15.47L75,26.29V75H50.95A41.2,41.2,0,0,0,62.13,46.88a40.61,40.61,0,0,0-3.39-16.26,45.17,45.17,0,0,1,7.79-4.95l1.69-.2.14-.41L65,18.83H64.5l-.88,1.29c-2.91,1.9-4.67,2.3-8.54,3.79A41.35,41.35,0,0,0,20.46,5.42,39.87,39.87,0,0,0,0,10.91V0H75V8.81ZM57.32,47A37.54,37.54,0,0,1,44.65,75H0V16A37,37,0,0,1,57.32,47ZM43.7,37.06c0-8.13-6-12-17.75-12H7.18v3.66l4.2.95V62.2l-4.2.95v3.73H27.85V63.14l-7.18-.95V50.14h5.15C37.26,50.14,43.7,45.53,43.7,37.06Zm-9.76.27c0,5.15-2.78,8.33-7.25,8.33h-6V29.47H27C31.37,29.47,33.94,32.32,33.94,37.33Z"></path><path d="M116.53,60.07l9.15,1.08v4.2H99.39v-4.2l5.28-1.36v-44l-5.28-1.36V10.41H123c15.31,0,22.9,5.28,22.9,16.13,0,11.18-8.33,17.41-23.1,17.41h-6.3Zm0-21.14h6.84c6.44,0,10.5-4.61,10.5-12.06,0-7.18-3.73-11.45-10.09-11.45h-7.25Z"></path><path d="M200.74,61.15v4.2H185.9l-16-20.6h-2.51v15l5.28,1.36v4.2H150.27v-4.2l5.28-1.36V23.35l-5-1.36V17.93H175.2c10.5,0,17.55,5.08,17.55,12.67,0,8.4-5.76,12.2-11,13.55l13.48,15.79ZM167.41,39.74h4.47c5.76,0,8.81-3.18,8.81-8.88,0-5.35-2.85-7.93-8.81-7.93h-4.47Z"></path><path d="M199.59,41.64c0-14.77,9.82-24.73,25.68-24.73s25.68,10,25.68,24.73-9.82,24.73-25.68,24.73S199.59,56.48,199.59,41.64Zm38.89,0c0-9.69-3.25-19.17-13.21-19.17S212.05,32,212.05,41.64s3.25,19.17,13.21,19.17S238.48,51.33,238.48,41.64Z"></path><path d="M270.79,60.07l9.15,1.08v4.2H253.31v-4.2l5.62-1.36v-44l-5.62-1.36V10.41h24c15.31,0,22.9,5.28,22.9,16.13,0,11.18-8.33,17.41-23.1,17.41h-6.3Zm0-21.14h6.84c6.44,0,10.5-4.61,10.5-12.06,0-7.18-3.73-11.45-10.1-11.45h-7.25Z"></path><path d="M354.26,22l-4.95,1.36V47c0,12.87-7.79,19.38-20.05,19.38-13.62,0-20.73-7.86-20.73-20v-23L303.58,22V17.93h22V22l-5.08,1.36V47.74c0,7.25,4.34,12.06,11.45,12.06,6.84,0,11.25-4.47,11.25-11.31V23.35L338.14,22V17.93h16.12Z"></path><path d="M403.85,52.21c0,8.88-7.11,13.14-22,13.14H357.58v-4.2l5.56-1.36V23.35L358.26,22V17.93h23.92c12.6,0,19.51,3.79,19.51,11.72,0,6.17-4.06,9.08-10.91,9.89v.27C399.31,40.76,403.85,45.1,403.85,52.21ZM375,38.32h5.76c6.1,0,9-2.78,9-7.79,0-5.22-3.12-7.59-9-7.59H375Zm16.8,13.41c0-5.62-3.79-8.67-11.25-8.67H375V60.34h6.64C388.07,60.34,391.79,57.29,391.79,51.74Z"></path><path d="M451.07,48.62l-4.4,16.73H408v-4.2l5.28-1.36V23.35L407.65,22V17.93h22.76V22l-5.28,1.36v37l14.16-.81L447,47.26Z"></path><path d="M475.4,61.15v4.2H453v-4.2l5.28-1.36V23.35L453,22V17.93H475.4V22l-5.28,1.36V59.8Z"></path><path d="M478,41.78c0-15.85,12.13-24.86,27-24.86a35.6,35.6,0,0,1,18.29,5.15l-2,13.21h-4.2l-1.69-9.08a13.23,13.23,0,0,0-10.09-4.13c-9.15,0-14.7,6.57-14.7,18.22,0,13.21,6.84,19.31,15.24,19.31,6.17,0,10.23-3.39,13.41-9.55l4.27,2c-4.27,10-11.65,14.36-21.07,14.36C488.4,66.37,478,56.48,478,41.78Z"></path><path d="M574.24,61.15v4.2H551.48v-4.2L557,60l-2.85-8.13h-16.6l-3.12,8.2,5.42,1.15-.07,4.2-16.53-.07v-4.2l4.27-1.08,14.9-37.33-4-1.29V17.93h13.69L569.3,60Zm-27.57-31-.47-1.56-.47,1.56-6.23,16.73h12.94Z"></path></svg></a>  <a data-pp-view="" href="https://give.propublica.org/give/346423/#!/donation/checkout?c_src=UpRed" class="button shape--round-rect    svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--red-50); --button-border: none; --button-color: var(--white); --button-font-size: var(--scale-2); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale2); --icon-size: 1em;"> <span class="text font--serif svelte-1qpwxqa">Donate</span>  </a></div> <div class="site-header-overlay__wrap-expanded svelte-5qrmpy" data-pp-location="masthead wrap-expanded"> <div class="site-header__section-search svelte-5qrmpy"><form class="search-form svelte-5qrmpy" role="search" action="https://propublica.org/search" method="get"><label class="a11y hed-form hed-site-search" for="search-form__input-text" data-svelte-h="svelte-zdbb25">Search ProPublica:</label> <div class="search-form__input-wrap svelte-5qrmpy"><input placeholder="Search" id="search-form__input-text" class="search-form__input-text svelte-5qrmpy" type="search" value="" name="qss">  <button class="button shape--circle  button-is-icon-only  svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--cool-70); --button-border: none; --button-color: white; --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale4); --icon-size: var(--scale0);"><span class="icon-before svelte-1qpwxqa"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><title>Search</title><circle cx="11" cy="11" r="8"></circle><line x1="21" y1="21" x2="16.65" y2="16.65"></line></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">Search</span>  </button></div></form></div>   <nav class="site-header__section-links-expanded svelte-5qrmpy" aria-label="Expanded Links" hidden><div class="site-header__links site-header__links-topics svelte-5qrmpy"><strong class="site-header__links-heading svelte-5qrmpy">Topics </strong> <ul class="site-header__links-list svelte-5qrmpy"><li class="svelte-5qrmpy"><span class="icon svelte-5qrmpy"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 15 15" fill="currentColor"><title>Racial Justice</title><path d="M15,12.23v0L14,4.55l.24.06.11,0a.38.38,0,0,0,.36-.27.38.38,0,0,0-.25-.47c-.19-.06-.39-.1-.59-.15a.38.38,0,0,0-.29-.26.37.37,0,0,0-.28.11c-.6-.15-1.21-.28-1.82-.39V1.29A1.29,1.29,0,0,0,10.17,0,1.32,1.32,0,0,0,9.11.57a1.37,1.37,0,0,0-2,.26A1.3,1.3,0,0,0,6.23.51a1.32,1.32,0,0,0-1.12.66A1.13,1.13,0,0,0,4.46,1,1.19,1.19,0,0,0,3.27,2.14V3.25c-.53.1-1,.21-1.57.34a.37.37,0,0,0-.28-.11.38.38,0,0,0-.29.26c-.19,0-.39.09-.58.15a.38.38,0,0,0-.25.47.38.38,0,0,0,.36.27l.11,0L1,4.55,0,12.21v0A2.67,2.67,0,0,0,2.6,15a2.67,2.67,0,0,0,2.57-2.73h0a.19.19,0,0,0,0-.07.13.13,0,0,0,0-.06h0L2,4.27c.41-.1.82-.18,1.24-.25v.37a4,4,0,0,0-.12,1A3.93,3.93,0,0,0,5.21,8.81v1.77a.38.38,0,1,0,.75,0v-2a.39.39,0,0,0-.21-.34A3.19,3.19,0,0,1,3.9,5.39a1.18,1.18,0,0,0,.56.16,1.2,1.2,0,0,0,.8-.32,1.35,1.35,0,0,0,1,.43,1.29,1.29,0,0,0,1-.44,1.29,1.29,0,0,0,.6.32,3.58,3.58,0,0,0-.89.85.37.37,0,0,0,.3.59.39.39,0,0,0,.31-.15A2.81,2.81,0,0,1,9.76,5.61a.38.38,0,0,0,0-.75H8.14a.59.59,0,0,1-.58-.59v-.5h2.82a.73.73,0,0,1,.75.71v.89A3.19,3.19,0,0,1,9.28,8.24a.39.39,0,0,0-.21.34v2a.38.38,0,1,0,.75,0V8.81a3.93,3.93,0,0,0,2.06-3.44V4.48A1.33,1.33,0,0,0,11.8,4c.4.07.79.15,1.18.24L9.87,12.11h0a.13.13,0,0,0,0,.06.25.25,0,0,0,0,.07h0A2.67,2.67,0,0,0,12.41,15,2.67,2.67,0,0,0,15,12.25ZM1.65,5.35l2.59,6.53H.83Zm1,8.9A1.88,1.88,0,0,1,.81,12.63H4.39A1.88,1.88,0,0,1,2.6,14.25ZM4.9,4.36a.44.44,0,0,1-.44.44A.44.44,0,0,1,4,4.36V2.14a.44.44,0,0,1,.44-.44.44.44,0,0,1,.44.44Zm1.91,0a.58.58,0,1,1-1.16,0V2.14a.7.7,0,0,0,0-.14.4.4,0,0,0,0-.15.58.58,0,1,1,1.16,0Zm.73-2.58a.43.43,0,0,0,0-.11.65.65,0,1,1,1.29,0V3H7.56V1.85S7.54,1.78,7.54,1.74ZM9.6,3V1.63s0,0,0-.06,0,0,0,0V1.29a.57.57,0,0,1,1.14,0V3.07a1.49,1.49,0,0,0-.36,0Zm4.58,8.86H10.77l2.59-6.53Zm-1.77,2.37a1.89,1.89,0,0,1-1.79-1.62H14.2A1.88,1.88,0,0,1,12.41,14.25Z"></path></svg> </span> <a class="site-header__link svelte-5qrmpy" data-link="Racial Justice" href="https://www.propublica.org/topics/racial-justice">Racial Justice</a> </li><li class="svelte-5qrmpy"><span class="icon svelte-5qrmpy"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 15 15" fill="currentColor"><title>Healthcare</title><path d="M6.77,4.81H6.28a10,10,0,0,1-4.19-.92L.44,3a.67.67,0,0,1-.36-.67.7.7,0,0,1,.49-.6L4.38.65a1.14,1.14,0,0,1,1,.19,1.08,1.08,0,0,1,.42.86.56.56,0,0,0,.54.56h.48a.37.37,0,0,1,.37.37A.38.38,0,0,1,6.77,3H6.29A1.3,1.3,0,0,1,5,1.7a.31.31,0,0,0-.13-.26.31.31,0,0,0-.29-.06L.92,2.43l1.5.79a9.35,9.35,0,0,0,3.86.84h.49a.38.38,0,0,1,0,.75Z"></path><path d="M8.76,4.81H8.29a.38.38,0,1,1,0-.75h.47a9.24,9.24,0,0,0,3.87-.85l1.5-.78L10.45,1.38a.3.3,0,0,0-.27.05.35.35,0,0,0-.13.27A1.3,1.3,0,0,1,8.77,3H8.29a.38.38,0,0,1-.38-.38.37.37,0,0,1,.38-.37h.47A.56.56,0,0,0,9.3,1.7,1.1,1.1,0,0,1,9.72.84a1.08,1.08,0,0,1,.93-.19l3.82,1.1A.7.7,0,0,1,14.61,3L13,3.88A9.92,9.92,0,0,1,8.76,4.81Z"></path><path d="M7.52,13.82a.34.34,0,0,1-.23-.08L6,12.76a1.72,1.72,0,0,1-.61-1.52,1.63,1.63,0,0,1,.77-1.33L9.61,8A.88.88,0,0,0,10,7.33a1.11,1.11,0,0,0-.28-.91l-.33-.29a.38.38,0,1,1,.51-.55l.32.29a1.8,1.8,0,0,1,.52,1.55A1.59,1.59,0,0,1,10,8.65L6.56,10.56a.89.89,0,0,0-.39.74,1,1,0,0,0,.32.87l1.26,1a.39.39,0,0,1,.07.53A.41.41,0,0,1,7.52,13.82Z"></path><path d="M7.53,13.82a.41.41,0,0,1-.3-.14.39.39,0,0,1,.07-.53l1.26-1a1,1,0,0,0,.32-.87.89.89,0,0,0-.39-.74L5.07,8.65a1.62,1.62,0,0,1-.76-1.24,1.82,1.82,0,0,1,.51-1.54l.32-.29a.38.38,0,0,1,.51.55l-.33.3a1.08,1.08,0,0,0-.27.89A.92.92,0,0,0,5.44,8L8.86,9.91a1.63,1.63,0,0,1,.77,1.33A1.72,1.72,0,0,1,9,12.76l-1.26,1A.34.34,0,0,1,7.53,13.82Z"></path><path d="M7.52,15a.37.37,0,0,1-.37-.38V.44A.37.37,0,0,1,7.52.06.38.38,0,0,1,7.9.44V14.57A.38.38,0,0,1,7.52,15Z"></path></svg> </span> <a class="site-header__link svelte-5qrmpy" data-link="Health Care" href="https://www.propublica.org/topics/health-care">Health Care</a> </li><li class="svelte-5qrmpy"><span class="icon svelte-5qrmpy"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 15 15" fill="currentColor"><title>Politics</title><path d="M12.54,14.89h-10a.38.38,0,0,1-.38-.37V11a.38.38,0,0,1,.38-.38h10a.38.38,0,0,1,.38.38v3.55A.38.38,0,0,1,12.54,14.89Zm-9.66-.75h9.29v-2.8H2.88Z"></path><path d="M14.52,14.89H.53a.38.38,0,0,1,0-.75h14a.38.38,0,0,1,0,.75Z"></path><path d="M11.71,11.35H3.34A.37.37,0,0,1,3,11V8.7a.38.38,0,0,1,.37-.38h8.37a.37.37,0,0,1,.37.38V11A.36.36,0,0,1,11.71,11.35Zm-8-.75h7.61V9.07H3.72Z"></path><path d="M8.36,5.11A.38.38,0,0,1,8,4.73V3.42H7.07V4.73a.38.38,0,1,1-.75,0V3a.37.37,0,0,1,.37-.37H8.36A.37.37,0,0,1,8.73,3V4.73A.38.38,0,0,1,8.36,5.11Z"></path><path d="M3.84,13.79a.38.38,0,0,1-.38-.37V12.25a.38.38,0,0,1,.75,0v1.17A.38.38,0,0,1,3.84,13.79Z"></path><path d="M5.31,13.79a.38.38,0,0,1-.37-.37V12.25a.38.38,0,0,1,.75,0v1.17A.38.38,0,0,1,5.31,13.79Z"></path><path d="M6.79,13.79a.37.37,0,0,1-.37-.37V12.25a.36.36,0,0,1,.37-.37.37.37,0,0,1,.38.37v1.17A.38.38,0,0,1,6.79,13.79Z"></path><path d="M8.27,13.79a.38.38,0,0,1-.38-.37V12.25a.37.37,0,0,1,.38-.37.36.36,0,0,1,.37.37v1.17A.37.37,0,0,1,8.27,13.79Z"></path><path d="M9.75,13.79a.38.38,0,0,1-.38-.37V12.25a.38.38,0,0,1,.75,0v1.17A.38.38,0,0,1,9.75,13.79Z"></path><path d="M11.22,13.79a.38.38,0,0,1-.37-.37V12.25a.38.38,0,0,1,.75,0v1.17A.38.38,0,0,1,11.22,13.79Z"></path><path d="M7.53,3.42A.37.37,0,0,1,7.16,3V.48A.37.37,0,0,1,7.53.11a.38.38,0,0,1,.38.37V3A.38.38,0,0,1,7.53,3.42Z"></path><path d="M11.72,9.06a.38.38,0,0,1-.38-.37A3.74,3.74,0,0,0,7.53,5,3.74,3.74,0,0,0,3.72,8.69a.38.38,0,0,1-.75,0A4.49,4.49,0,0,1,7.53,4.28a4.49,4.49,0,0,1,4.56,4.41A.37.37,0,0,1,11.72,9.06Z"></path></svg> </span> <a class="site-header__link svelte-5qrmpy" data-link="Politics" href="https://www.propublica.org/topics/politics">Politics</a> </li><li class="svelte-5qrmpy"><span class="icon svelte-5qrmpy"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 15 15" fill="currentColor"><title>Criminal Justice</title><path d="M13.48,4h-.11A20.22,20.22,0,0,0,1.76,4a.38.38,0,0,1-.47-.26.37.37,0,0,1,.25-.46,21,21,0,0,1,12.05,0,.37.37,0,0,1-.11.73Z"></path><path d="M10.53,15h-6a.38.38,0,1,1,0-.75h6a.38.38,0,0,1,0,.75Z"></path><path d="M7.5,15a.37.37,0,0,1-.37-.38V.42A.37.37,0,0,1,7.5,0a.38.38,0,0,1,.38.38V14.6A.38.38,0,0,1,7.5,15Z"></path><path d="M5.39,9.89H.46a.37.37,0,0,1-.31-.16.36.36,0,0,1,0-.35L2.57,3.16a.38.38,0,0,1,.35-.24h0a.38.38,0,0,1,.35.23L5.74,9.38a.36.36,0,0,1,0,.35A.37.37,0,0,1,5.39,9.89ZM1,9.14H4.84L2.92,4.31Z"></path><path d="M14.6,9.89H9.67a.37.37,0,0,1-.31-.16.36.36,0,0,1,0-.35l2.46-6.22a.38.38,0,0,1,.35-.24h0a.37.37,0,0,1,.35.23L15,9.38a.36.36,0,0,1,0,.35A.37.37,0,0,1,14.6,9.89Zm-4.38-.75h3.83L12.13,4.31Z"></path><path d="M2.92,11.75A3,3,0,0,1,.1,9.62a.36.36,0,0,1,.06-.33.38.38,0,0,1,.3-.15H5.39a.38.38,0,0,1,.3.15.39.39,0,0,1,.06.33A3,3,0,0,1,2.92,11.75ZM1,9.89A2.21,2.21,0,0,0,2.92,11,2.22,2.22,0,0,0,4.83,9.89Z"></path><path d="M12.13,11.75A3,3,0,0,1,9.3,9.62a.39.39,0,0,1,.06-.33.38.38,0,0,1,.3-.15h4.93a.38.38,0,0,1,.3.15.36.36,0,0,1,.06.33A3,3,0,0,1,12.13,11.75ZM10.22,9.89a2.19,2.19,0,0,0,3.81,0Z"></path></svg> </span> <a class="site-header__link svelte-5qrmpy" data-link="Criminal Justice" href="https://www.propublica.org/topics/criminal-justice">Criminal Justice</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="more…" href="https://www.propublica.org/topics/">more…</a> </li></ul> </div><div class="site-header__links site-header__links-region svelte-5qrmpy"><strong class="site-header__links-heading svelte-5qrmpy">Browse by Place </strong> <ul class="site-header__links-list svelte-5qrmpy"><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Midwest" href="https://www.propublica.org/midwest/">Midwest</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Northwest" href="https://www.propublica.org/northwest/">Northwest</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="South" href="https://www.propublica.org/south/">South</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Southwest" href="https://www.propublica.org/southwest/">Southwest</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Texas" href="https://www.propublica.org/texas/">Texas</a> </li></ul> </div><div class="site-header__links site-header__links-type svelte-5qrmpy"><strong class="site-header__links-heading svelte-5qrmpy">Type </strong> <ul class="site-header__links-list svelte-5qrmpy"><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Graphics &amp; Data" href="https://www.propublica.org/newsapps/">Graphics &amp; Data</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Newsletters" href="https://www.propublica.org/newsletters/">Newsletters</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Series" href="https://www.propublica.org/series/">Series</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Videos" href="https://www.propublica.org/video/">Videos</a> </li></ul> </div><div class="site-header__links site-header__links-special svelte-5qrmpy"> <ul class="site-header__links-list svelte-5qrmpy"><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Local Reporting Network" href="https://www.propublica.org/local-reporting-network/">Local Reporting Network</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Electionland" href="https://www.propublica.org/electionland/">Electionland</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Data Store" href="https://www.propublica.org/datastore/">Data Store</a> </li></ul> </div><div class="site-header__links site-header__links-info svelte-5qrmpy"><strong class="site-header__links-heading svelte-5qrmpy">Info </strong> <ul class="site-header__links-list svelte-5qrmpy"><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="About Us" href="https://www.propublica.org/about/">About Us</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Impact" href="https://www.propublica.org/impact/">Impact</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Jobs &amp; Fellowships" href="https://www.propublica.org/jobs/">Jobs &amp; Fellowships</a> </li><li class="svelte-5qrmpy"> <a class="site-header__link svelte-5qrmpy" data-link="Contact Us" href="https://www.propublica.org/contact/">Contact Us</a> </li></ul> </div>  <div class="site-header__links site-header__links-follow svelte-5qrmpy"><strong class="site-header__links-heading svelte-5qrmpy" data-svelte-h="svelte-19sje8q">Follow ProPublica</strong> <ul class="site-header__links-list site-header__links-list-follow svelte-5qrmpy"><li data-link="Bluesky" class="svelte-5qrmpy"> <a href="https://bsky.app/profile/propublica.org" class="button shape--circle  button-is-icon-only  svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--cool-70); --button-border: none; --button-color: white; --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: 1em;"><span class="icon-before svelte-1qpwxqa"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="currentColor"><title>Bluesky</title><path d="M5.20079 2.42542C7.95442 4.48593 10.9155 8.67296 12 10.9221C13.0845 8.67768 16.0456 4.49064 18.7992 2.42542C20.7843 0.935439 24 -0.215052 24 3.45332C24 4.18416 23.5804 9.60656 23.3352 10.4883C22.477 13.5437 19.3556 14.3264 16.5784 13.8502C21.4303 14.6753 22.6656 17.4101 19.9969 20.1449C14.9328 25.3409 12.7214 18.8435 12.1556 17.179C12.0754 16.948 12.033 16.8113 12 16.8113C11.967 16.8113 11.9246 16.9527 11.8444 17.179C11.2786 18.8435 9.06248 25.3409 4.00314 20.1449C1.3391 17.4101 2.56974 14.6753 7.42161 13.8502C4.6444 14.3264 1.52299 13.5437 0.669548 10.4836C0.419646 9.60184 0 4.17945 0 3.4486C0 -0.219767 3.21572 0.930724 5.20079 2.4207V2.42542Z"></path></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">Bluesky</span>  </a></li> <li data-link="Instagram" class="svelte-5qrmpy"> <a href="https://www.instagram.com/propublica" class="button shape--circle  button-is-icon-only  svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--cool-70); --button-border: none; --button-color: white; --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: 1em;"><span class="icon-before svelte-1qpwxqa"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="currentColor"><title>Instagram</title><path d="M12,2.32c3.15,0,3.53,0,4.77.07a6.51,6.51,0,0,1,2.19.4,3.58,3.58,0,0,1,1.36.89A3.58,3.58,0,0,1,21.21,5a6.51,6.51,0,0,1,.4,2.19c.06,1.24.07,1.62.07,4.77s0,3.53-.07,4.77a6.51,6.51,0,0,1-.4,2.19A4,4,0,0,1,19,21.21a6.51,6.51,0,0,1-2.19.4c-1.24.06-1.62.07-4.77.07s-3.53,0-4.77-.07A6.51,6.51,0,0,1,5,21.21a3.58,3.58,0,0,1-1.36-.89A3.58,3.58,0,0,1,2.79,19a6.51,6.51,0,0,1-.4-2.19c-.06-1.24-.07-1.62-.07-4.77s0-3.53.07-4.77A6.51,6.51,0,0,1,2.79,5a3.58,3.58,0,0,1,.89-1.36A3.58,3.58,0,0,1,5,2.79a6.51,6.51,0,0,1,2.19-.4c1.24-.06,1.62-.07,4.77-.07M12,.19C8.79.19,8.39.2,7.13.26A8.84,8.84,0,0,0,4.26.81,6,6,0,0,0,.81,4.26,8.84,8.84,0,0,0,.26,7.13C.2,8.39.19,8.79.19,12s0,3.61.07,4.87a8.84,8.84,0,0,0,.55,2.87,6,6,0,0,0,3.45,3.45,8.84,8.84,0,0,0,2.87.55c1.26.06,1.66.07,4.87.07s3.61,0,4.87-.07a8.84,8.84,0,0,0,2.87-.55,6,6,0,0,0,3.45-3.45,8.84,8.84,0,0,0,.55-2.87c.06-1.26.07-1.66.07-4.87s0-3.61-.07-4.87a8.84,8.84,0,0,0-.55-2.87A6,6,0,0,0,19.74.81,8.84,8.84,0,0,0,16.87.26C15.61.2,15.21.19,12,.19Z"></path><path d="M12,5.94A6.06,6.06,0,1,0,18.06,12,6.06,6.06,0,0,0,12,5.94Zm0,10A3.94,3.94,0,1,1,15.94,12,3.95,3.95,0,0,1,12,15.94Z"></path><circle cx="18.3" cy="5.7" r="1.42"></circle></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">Instagram</span>  </a></li> <li data-link="Facebook" class="svelte-5qrmpy"> <a href="https://www.facebook.com/propublica/" class="button shape--circle  button-is-icon-only  svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--cool-70); --button-border: none; --button-color: white; --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: 1em;"><span class="icon-before svelte-1qpwxqa"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="currentColor"><title>Facebook</title><path d="M8.25 14.0297V24H13.6875V14.0297H17.7422L18.5859 9.44531H13.6875V7.82344C13.6875 5.4 14.6391 4.47188 17.0953 4.47188C17.8594 4.47188 18.4734 4.49062 18.8297 4.52812V0.370313C18.1594 0.1875 16.5187 0 15.5719 0C10.5609 0 8.25 2.36719 8.25 7.47187V9.44531H5.15625V14.0297H8.25Z"></path></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">Facebook</span>  </a></li> <li data-link="Twitter" class="svelte-5qrmpy"> <a href="https://x.com/propublica" class="button shape--circle  button-is-icon-only  svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--cool-70); --button-border: none; --button-color: white; --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: 1em;"><span class="icon-before svelte-1qpwxqa"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="currentColor"><title>X</title><path d="M18.2439 2.25H21.5532L14.3251 10.5094L22.8282 21.75H16.172L10.9548 14.9344L4.99229 21.75H1.67822L9.40791 12.9141L1.25635 2.25H8.08135L12.7923 8.47969L18.2439 2.25ZM17.0813 19.7719H18.9142L7.08291 4.125H5.11416L17.0813 19.7719Z"></path></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">(Twitter)</span>  </a></li> <li data-link="YouTube" class="svelte-5qrmpy"> <a href="https://www.youtube.com/user/propublica" class="button shape--circle  button-is-icon-only  svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--cool-70); --button-border: none; --button-color: white; --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: 1em;"><span class="icon-before svelte-1qpwxqa"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="currentColor"><title>YouTube</title><path d="M24 12C24 20 24 20 12 20C0 20 0 20 0 12C0 4 0 4 12 4C24 4 24 4 24 12ZM16.5 12L9 7.76471V16.2353L16.5 12Z"></path></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">YouTube</span>  </a></li> <li data-link="Threads" class="svelte-5qrmpy"> <a href="https://www.threads.net/@propublica" class="button shape--circle  button-is-icon-only  svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--cool-70); --button-border: none; --button-color: white; --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: 1em;"><span class="icon-before svelte-1qpwxqa"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="currentColor"><title>Threads</title><path d="M17.0391 11.0484C17.1422 11.0906 17.2359 11.1375 17.3344 11.1797C18.7031 11.8406 19.7063 12.8297 20.2313 14.0578C20.9672 15.7687 21.0375 18.5484 18.8109 20.7703C17.1141 22.4672 15.0469 23.2313 12.1266 23.2547H12.1125C8.82187 23.2313 6.29531 22.125 4.59375 19.9641C3.07969 18.0422 2.30156 15.3656 2.27344 12.0141V12V11.9906C2.29688 8.63906 3.075 5.9625 4.58906 4.04062C6.29063 1.87969 8.82187 0.773438 12.1125 0.75H12.1266C15.4219 0.773438 17.9812 1.875 19.7344 4.02656C20.5969 5.09063 21.2344 6.37031 21.6375 7.85625L19.7438 8.3625C19.4109 7.15312 18.9094 6.12188 18.2344 5.29688C16.8656 3.61875 14.8125 2.75625 12.1172 2.7375C9.44531 2.76094 7.425 3.61875 6.10781 5.2875C4.87969 6.84844 4.24219 9.10781 4.21875 12C4.24219 14.8922 4.87969 17.1516 6.10781 18.7172C7.42031 20.3859 9.44531 21.2438 12.1172 21.2672C14.5266 21.2484 16.1203 20.6766 17.4469 19.35C18.9609 17.8406 18.9328 15.9844 18.45 14.8547C18.1641 14.1891 17.6484 13.6359 16.9547 13.2188C16.7813 14.4797 16.4016 15.4828 15.7969 16.2562C14.9953 17.2781 13.8563 17.8313 12.3891 17.9109C11.2828 17.9719 10.2187 17.7047 9.39375 17.1609C8.41875 16.5141 7.84688 15.5297 7.78594 14.3812C7.66875 12.1172 9.45938 10.4906 12.2484 10.3312C13.2375 10.275 14.1656 10.3172 15.0234 10.4625C14.9109 9.76875 14.6812 9.21563 14.3391 8.8125C13.8703 8.26406 13.1391 7.98281 12.1734 7.97812H12.1406C11.3625 7.97812 10.3125 8.19375 9.64219 9.21094L8.02969 8.10469C8.92969 6.74062 10.3875 5.99063 12.1453 5.99063H12.1828C15.1172 6.00938 16.8656 7.84219 17.0438 11.0391L17.0344 11.0484H17.0391ZM9.72656 14.2734C9.7875 15.45 11.0578 15.9984 12.2859 15.9281C13.4859 15.8625 14.8453 15.3938 15.075 12.4969C14.4563 12.3609 13.7719 12.2906 13.0406 12.2906C12.8156 12.2906 12.5906 12.2953 12.3656 12.3094C10.3547 12.4219 9.68438 13.3969 9.73125 14.2687L9.72656 14.2734Z"></path></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">Threads</span>  </a></li> <li data-link="LinkedIn" class="svelte-5qrmpy"> <a href="https://www.linkedin.com/company/propublica/posts/" class="button shape--circle  button-is-icon-only  svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--cool-70); --button-border: none; --button-color: white; --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: 1em;"><span class="icon-before svelte-1qpwxqa"><svg viewBox="0 0 24 24" fill="currentColor" xmlns="http://www.w3.org/2000/svg"><title>LinkedIn</title><path d="M6.65548 8.41229H2.64045C2.46226 8.41229 2.31787 8.55674 2.31787 8.73487V21.6335C2.31787 21.8116 2.46226 21.956 2.64045 21.956H6.65548C6.83368 21.956 6.97806 21.8116 6.97806 21.6335V8.73487C6.97806 8.55674 6.83368 8.41229 6.65548 8.41229Z"></path><path d="M4.64942 2C3.18852 2 2 3.18723 2 4.64652C2 6.10645 3.18852 7.29413 4.64942 7.29413C6.10916 7.29413 7.29671 6.10639 7.29671 4.64652C7.29677 3.18723 6.10916 2 4.64942 2Z"></path><path d="M16.868 8.09167C15.2554 8.09167 14.0634 8.7849 13.3403 9.57258V8.73484C13.3403 8.55671 13.1959 8.41226 13.0177 8.41226H9.17265C8.99445 8.41226 8.85007 8.55671 8.85007 8.73484V21.6334C8.85007 21.8116 8.99445 21.956 9.17265 21.956H13.1789C13.3571 21.956 13.5015 21.8116 13.5015 21.6334V15.2516C13.5015 13.1011 14.0856 12.2633 15.5847 12.2633C17.2174 12.2633 17.3471 13.6064 17.3471 15.3623V21.6335C17.3471 21.8117 17.4915 21.9561 17.6697 21.9561H21.6774C21.8556 21.9561 22 21.8117 22 21.6335V14.5584C22 11.3606 21.3903 8.09167 16.868 8.09167Z"></path></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">LinkedIn</span>  </a></li> <li data-link="RSS" class="svelte-5qrmpy"> <a href="https://www.propublica.org/feeds/propublica/main" class="button shape--circle  button-is-icon-only  svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--cool-70); --button-border: none; --button-color: white; --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: 1em;"><span class="icon-before svelte-1qpwxqa"><svg role="img" width="24" height="24" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><title>RSS</title><path d="M20 19.6598C20 19.75 19.9642 19.8365 19.9004 19.9002C19.8367 19.964 19.7502 19.9998 19.66 19.9998H17.3401C17.2499 19.9998 17.1635 19.964 17.0997 19.9002C17.0359 19.8365 17.0001 19.75 17.0001 19.6598C17.0022 18.5247 16.8508 17.3945 16.5501 16.3C16.2604 15.2486 15.8334 14.2399 15.2802 13.3001C14.7244 12.3657 14.0524 11.5055 13.2803 10.7402C12.5149 9.96799 11.6548 9.29599 10.7204 8.74024C9.77847 8.19108 8.77037 7.76432 7.72047 7.47029C6.62038 7.16109 5.48333 7.00298 4.3406 7.00031C4.29566 7.00271 4.25076 6.99497 4.20921 6.97766C4.16767 6.96035 4.13055 6.93392 4.10061 6.90032C4.06701 6.87038 4.04058 6.83326 4.02327 6.79172C4.00596 6.75017 3.99822 6.70527 4.00062 6.66033V4.34041C3.99822 4.29547 4.00596 4.25057 4.02327 4.20902C4.04058 4.16748 4.06701 4.13036 4.10061 4.10042C4.13055 4.06682 4.16767 4.04039 4.20921 4.02308C4.25076 4.00577 4.29566 3.99803 4.3406 4.00043C5.746 4.00053 7.14505 4.18886 8.50044 4.56041C9.81129 4.91981 11.0688 5.45106 12.2403 6.14035C13.3965 6.81934 14.4616 7.64258 15.4102 8.59025C16.3578 9.53878 17.1811 10.6039 17.8601 11.7601C18.5494 12.9316 19.0806 14.1891 19.44 15.5C19.8116 16.8554 19.9999 18.2544 20 19.6598ZM15.0002 19.6598C15.0002 19.75 14.9644 19.8365 14.9006 19.9002C14.8369 19.964 14.7504 19.9998 14.6602 19.9998H12.3403C12.2501 19.9998 12.1636 19.964 12.0999 19.9002C12.0361 19.8365 12.0003 19.75 12.0003 19.6598C12.0074 18.6284 11.7997 17.6067 11.3903 16.6599C10.6228 14.8248 9.15935 13.3686 7.32049 12.6101C6.37989 12.2034 5.36534 11.9958 4.3406 12.0001C4.29566 12.0025 4.25076 11.9948 4.20921 11.9775C4.16767 11.9602 4.13055 11.9337 4.10061 11.9001C4.06701 11.8702 4.04058 11.8331 4.02327 11.7915C4.00596 11.75 3.99822 11.7051 4.00062 11.6601V9.34022C3.99822 9.29528 4.00596 9.25037 4.02327 9.20883C4.04058 9.16729 4.06701 9.13017 4.10061 9.10023C4.13055 9.06663 4.16767 9.04019 4.20921 9.02288C4.25076 9.00557 4.29566 8.99783 4.3406 9.00023C5.29329 9.00091 6.24162 9.1287 7.1605 9.38022C8.05554 9.62739 8.91568 9.98691 9.7204 10.4502C10.5061 10.9162 11.2315 11.4771 11.8803 12.1201C12.5233 12.769 13.0842 13.4944 13.5502 14.28C14.0135 15.0847 14.373 15.9449 14.6202 16.8399C14.8717 17.7588 14.9995 18.7071 15.0002 19.6598ZM9.00042 17.4999C9.0038 17.8288 8.94091 18.155 8.81549 18.4591C8.69008 18.7632 8.50471 19.0389 8.27045 19.2698C8.04096 19.506 7.7655 19.6926 7.46109 19.8181C7.15667 19.9437 6.82976 20.0055 6.50052 19.9998C6.17104 20.0073 5.84359 19.9463 5.53891 19.8207C5.23424 19.695 4.95899 19.5074 4.73059 19.2698C4.493 19.0414 4.30543 18.7662 4.17977 18.4615C4.05412 18.1568 3.99311 17.8294 4.00062 17.4999C3.99492 17.1707 4.05675 16.8438 4.1823 16.5393C4.30785 16.2349 4.49445 15.9595 4.73059 15.73C4.9615 15.4957 5.23721 15.3103 5.5413 15.1849C5.84538 15.0595 6.17161 14.9966 6.50052 15C6.82881 14.997 7.15425 15.061 7.45689 15.1883C7.75953 15.3155 8.03297 15.5033 8.26045 15.74C8.49717 15.9675 8.68491 16.2409 8.81215 16.5435C8.9394 16.8462 9.00346 17.1716 9.00042 17.4999Z" fill="currentColor"></path></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">RSS</span>  </a></li></ul></div> </nav> </div>  </div>
                        <!--svelte-component-end-->
                            
    
<main class="content" id="main">

        <article class="article center">

        
            <!-- Class assignment -->





                
    
<div class="opener  opener--large opener--center opener--order-hed-art-dek" data-pp-location="article opener">

            
                <figure class="opener__art-wrapper">
            
    


    <img
        class="opener__art"
        alt=""
        width="3000"
        height="2000"
                src="https://img.assets-d.propublica.org/v5/images/ProPublica_Owen_Gent_Zolgensma_Final_Artwork-3x2web.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=533&amp;q=75&amp;w=800&amp;s=c67ead55b5aa66d325b31e27c96b87da"
        srcset="https://img.assets-d.propublica.org/v5/images/ProPublica_Owen_Gent_Zolgensma_Final_Artwork-3x2web.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=267&amp;q=75&amp;w=400&amp;s=3fe3b1e2cd11dee9e7652f96994380d5 400w, https://img.assets-d.propublica.org/v5/images/ProPublica_Owen_Gent_Zolgensma_Final_Artwork-3x2web.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=533&amp;q=75&amp;w=800&amp;s=c67ead55b5aa66d325b31e27c96b87da 800w, https://img.assets-d.propublica.org/v5/images/ProPublica_Owen_Gent_Zolgensma_Final_Artwork-3x2web.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=1200&amp;s=9fa2baf31549fdc4954e8b0aa9f8bb04 1200w, https://img.assets-d.propublica.org/v5/images/ProPublica_Owen_Gent_Zolgensma_Final_Artwork-3x2web.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=867&amp;q=75&amp;w=1300&amp;s=8a9055bf6d9c7d1618060feecf747a8e 1300w, https://img.assets-d.propublica.org/v5/images/ProPublica_Owen_Gent_Zolgensma_Final_Artwork-3x2web.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=967&amp;q=75&amp;w=1450&amp;s=048ac3955a2b25b8047eadf899a93eb6 1450w, https://img.assets-d.propublica.org/v5/images/ProPublica_Owen_Gent_Zolgensma_Final_Artwork-3x2web.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1067&amp;q=75&amp;w=1600&amp;s=2cb591027141f21b359cdf663a712706 1600w, https://img.assets-d.propublica.org/v5/images/ProPublica_Owen_Gent_Zolgensma_Final_Artwork-3x2web.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1333&amp;q=75&amp;w=2000&amp;s=904dc4bc71290bdd56161368bc8c55b7 2000w"
                fetchpriority="high"    />


            
            
<figcaption class="attribution">
    
        <span class="attribution__credit">
        <span class="a11y">Credit: </span>
        Owen Gent, special to ProPublica
    </span>
    
    
    </figcaption>

        </figure>
            <div class="opener__topic-title-dek-wrapper ">

                    <span class="opener__topics  opener__topics--vertical-rule">
            <a class="opener__topics-link " href="https://www.propublica.org/topics/health-care">Health Care</a>
        </span>
    
    <h1 class="opener__hed " >        What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing
    </h1>

    <h2 class="opener__dek " style="display: none" >        Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the widely held conception that high prices reflect huge industry investments in innovation.
    </h2>
    </div> <!-- Close .opener__topic-title-dek-wrapper -->

</div>
        
<div class="article-meta-1
     article-meta-1--center     " data-pp-location="article meta">

    <span class="article-meta-1__byline" data-pp-location="article byine">
        by <a class="name" href="https://www.propublica.org/people/robin-fields">Robin Fields</a>    </span>
    <time class="article-meta-1__pubdate">
        <time class="timestamp" datetime="2025-02-12EST08:00">Feb. 12, 2025, 8 a.m. EST</time>
    </time>

    <div class="article-meta-1__section-actions
         article-meta-1__section-actions--center     " data-pp-location="article story-tools">
        <script type="application/json" class="svelte-config">
                            {"componentName":"ShareTools","props":{"pageTitle":"Zolgensma Creation Story Reveals Truths About Drug Pricing","pageUrl":"https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis"},"contextArray":[]}
                        </script>
                        <div class="share-tools" data-pp-click data-pp-location="share tools"> <button class="button shape--pill    svelte-1qpwxqa" data-pp-skip="false" role="button" aria-haspopup="dialog" aria-expanded="false" data-state="closed" id="XCaCf_cCzp" data-melt-popover-trigger="" data-popover-trigger="" style="--button-bg-color: var(--color-neutral-10); --button-border: none; --button-color: var(--color-neutral-70); --button-font-size: var(--scale-2); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: 1em;"><span class="icon-before svelte-1qpwxqa"><svg viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><g clip-path="url(#clip0_149_321)"><path fill-rule="evenodd" clip-rule="evenodd" d="M4 11C4.55228 11 5 11.4477 5 12V20C5 20.2652 5.10536 20.5196 5.29289 20.7071C5.48043 20.8946 5.73478 21 6 21H18C18.2652 21 18.5196 20.8946 18.7071 20.7071C18.8946 20.5196 19 20.2652 19 20V12C19 11.4477 19.4477 11 20 11C20.5523 11 21 11.4477 21 12V20C21 20.7957 20.6839 21.5587 20.1213 22.1213C19.5587 22.6839 18.7957 23 18 23H6C5.20435 23 4.44129 22.6839 3.87868 22.1213C3.31607 21.5587 3 20.7956 3 20V12C3 11.4477 3.44772 11 4 11Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M11.2929 1.29289C11.6834 0.902369 12.3166 0.902369 12.7071 1.29289L16.7071 5.29289C17.0976 5.68342 17.0976 6.31658 16.7071 6.70711C16.3166 7.09763 15.6834 7.09763 15.2929 6.70711L12 3.41421L8.70711 6.70711C8.31658 7.09763 7.68342 7.09763 7.29289 6.70711C6.90237 6.31658 6.90237 5.68342 7.29289 5.29289L11.2929 1.29289Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M12 1C12.5523 1 13 1.44772 13 2V15C13 15.5523 12.5523 16 12 16C11.4477 16 11 15.5523 11 15V2C11 1.44772 11.4477 1 12 1Z" fill="currentColor"></path></g><defs><clipPath id="clip0_149_321"><rect width="24" height="24" fill="white"></rect></clipPath></defs></svg></span> <span class="text font--sans svelte-1qpwxqa">Share</span>  </button> </div>
                        <!--svelte-component-end-->
                                <script type="application/json" class="svelte-config">
                            {"componentName":"DarkModeToggle","props":{},"contextArray":[]}
                        </script>
                        <div class="dark-mode-toggle svelte-1x7qxk6"> <button aria-hidden class="button shape--circle  button-is-icon-only  svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: var(--color-bg); --button-border: 1px solid var(--color-neutral-10); --button-color: var(--color-text-supp); --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: 1.7rem; --icon-size: 1em;"><span class="icon-before svelte-1qpwxqa"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><title>Contrast</title><circle cx="12" cy="12" r="10"></circle><path fill="currentColor" d="M12 18a6 6 0 000-12v12z"></path></svg> </span> <span class="text font--sans svelte-1qpwxqa a11y">Change Appearance</span>  </button> <label class="a11y" for="dark-mode-toggle__select" data-svelte-h="svelte-ku6aby">Change Appearance</label> <select class="dark-mode-toggle__select svelte-1x7qxk6" id="dark-mode-toggle__select" data-pp-change data-pp-category="change-mode"><option value="auto">Auto</option><option value="light">Light</option><option value="dark">Dark</option></select> </div>
                        <!--svelte-component-end-->
                                        <a class="article-meta-1__republish btn btn--outline" style="--button-color: var(--color-neutral-10); color: var(--color-neutral-70)" href="#" data-pp-action="republish open">Republish</a>
            </div>

    </div>
    

    
    <div class="article-body" data-pp-location="article body" >

        
                    <div class="article-body__top-notes" data-pp-location="top-note">
                

                                                
            <div class="article-body__note article-body__note--newsletter" id="newsletter-txt-note">
                <p>ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive <a href="https://www.propublica.org/newsletters/the-big-story?source=www.propublica.org&amp;placement=top-note&amp;region=national">our biggest stories</a> as soon as they’re published.</p>

            </div>

                

            </div><!-- end .article-body__top-notes -->
        
                    

<div class="highlights">
    <h3 class="highlights__heading">Reporting Highlights</h3>
    <ul class="highlights__list">
                    <li class="highlights__highlight"><span class="highlights__subheading">A Record Price: </span> The gene therapy Zolgensma helped children born with a fatal disease, spinal muscular atrophy, grow up to run and play. But the cost was stunning: $2 million per dose.</li>
            <li class="highlights__highlight"><span class="highlights__subheading">Cashing In: </span> While taxpayers and small charities funded the drug’s early development, executives, venture-capital backers and a pharma giant have reaped the profits.</li>
            <li class="highlights__highlight"><span class="highlights__subheading">Priced Out: </span> The drug’s cost adds to the nation’s ballooning bill for prescription drugs and puts Zolgensma out of reach for kids in many low- and middle-income countries.</li>
            </ul>
    <p class="highlights__disclaimer">
        These highlights were written by the reporters and editors who worked on this story. <span id="survey-placeholder"></span>
    </p>
</div>

<script>
    // When Iterate loads, add a "Give Feedback" button to the page that, when clicked, opens a survey. Since Iterate is commonly blocked by ad blockers, we want to avoid displaying a feedback button that won't trigger a survey and will appear broken.
    document.addEventListener("DOMContentLoaded", (event) => {
        Iterate('onLoad', (survey) => {
            var elSurveyPlaceholder = document.getElementById("survey-placeholder");
            elSurveyPlaceholder.innerHTML = "<button onclick='window.launchSurvey()'>Were they helpful?</button>";

            window.launchSurvey = function() {
              Iterate('install', '65c3aced2f5ee000017661d6');
            }
        })
    });

    // Set JS variable when page contains highlights. Used by Convert to know when to run highlight-specific A/B tests.
    window.hasHighlights = true;
</script>

<style>
    #survey-placeholder button {
      display: inline;
      font-size: inherit;
      background: transparent;
      color: inherit;
      padding: 0;
      margin: 0;
      text-decoration: underline;
    }
</style>

        
        




                    

<figure
    data-pp-id="1"
    data-pp-blocktype="embed"
    class="bb-embed size04 right out02 wide-sm wrap
                hide-print
        ">

    


                        <iframe class="lazyload" id="noa-web-audio-player" style="border: none" src="https://embed-player.newsoveraudio.com/v4?key=pp03n4&id=https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis&bgColor=2B3136&color=04AEE0&playColor=04AEE0&progressBgColor=E0E0E2&progressBorderColor=2B3136&titleColor=E0E0E2&timeColor=E0E0E2&speedColor=E0E0E2&noaLinkColor=E0E0E2&noaLinkHighlightColor=04AEE0" width="100%" height="110px"></iframe>
            
    
<figcaption class="attribution">
    
    
    
    </figcaption>


</figure>

        
    
                    
<p data-pp-blocktype="copy" data-pp-id="2.0">Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma had ended and the forces that turned it into the world’s most expensive drug had taken over.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="3.0">It was May 2014. He and his wife were sitting in the cafeteria at Nationwide Children’s Hospital in Columbus, Ohio.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="4.0">Elsewhere in the hospital, an infant — patient No. 1 in a landmark clinical trial — was receiving an IV infusion that, if it worked, would fix the genetic mutation that caused spinal muscular atrophy, a rare, incurable disease. At the time, children born with the most severe form of SMA swiftly lost their ability to move, to swallow, to breathe. Depending on the disease’s progression, most didn’t live to their second birthdays.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="5.0">The Gaynors’ daughter Sophia had been diagnosed with SMA five years earlier. Since then, they’d raced to fund research to save her. Their charity, Sophia’s Cure, was covering a substantial portion of the costs of the trial.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="6.0">They’d helped raise about $2 million for a program at Nationwide run by Brian Kaspar, a leading researcher. Gaynor, a New York City construction worker, had forged a tight bond with Kaspar, speaking frequently with him by phone, sometimes deep into the night.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="7.0">But their relationship had started to fray when — with success in sight — Kaspar became part owner of AveXis, a biotech startup that had snapped up the rights to his SMA drug. Billions of dollars were at stake.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="8.0">When Kaspar walked into the cafeteria that day, Gaynor said, the scientist didn’t acknowledge him or his wife before sitting down a short distance away. Neither did the man with him, the startup’s CEO.</p>
        
    
                    
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="10.0">“It was like they didn’t know us,” Gaynor recalled.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="11.0">When Zolgensma hit the market five years later, it was hailed as a miracle drug. Some babies treated with it grew up able to run and play. It helped reduce U.S. death rates from SMA, long the leading genetic cause of infant mortality, by <a href="https://www.curesma.org/wp-content/uploads/2024/06/9042024_State-of-SMA_vWeb.pdf">two-thirds</a>.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="12.0">That leap forward came at a sky-high price: more than $2 million per dose, making Zolgensma then the costliest one-time treatment ever.</p>

<p data-pp-blocktype="copy" data-pp-id="12.1">How did a drug rooted, like many, in seed money from the U.S. government — that is, American taxpayers — and spurred by the grassroots fundraising of desperate parents, end up with such a price tag?</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="13.0">The story of Zolgensma lays bare a confounding reality about modern drug development, in which revolutionary new treatments are becoming available only to be priced out of reach for many. It’s a story that upends commonly held conceptions that high drug prices reflect huge industry investments in innovation. Most of all, it’s a story that prompts, again and again, an increasingly urgent question: Do medical advances really have to be this expensive?</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="14.0">ProPublica traced Zolgensma’s journey from lab to market, from the supporters there at the beginning to the hired guns brought in at the end to construct a rationale for its unprecedented price.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="15.0">We found that taxpayers and private charities like Sophia’s Cure subsidized much of the science that yielded Zolgensma, providing research grants and opening the door to federal tax credits and other benefits that sped its path to approval.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="16.0">Yet that support came with no conditions — financial or otherwise — for the for-profit companies that brought the drug over the finish line, particularly when it came to pricing.</p>
        
    
                    

<figure
    data-pp-id="17"
    data-pp-blocktype="image"
    class="bb-image size08 center  wide-sm wrap 
                ">

    


                    
    


    <img
        class=""
        alt=""
        width="1024"
        height="768"
        loading="lazy" js-autosizes        src="https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_2914_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=600&amp;q=75&amp;w=800&amp;s=04ca8174677267d7060a13ccc5ff026f"
        srcset="https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_2914_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=300&amp;q=75&amp;w=400&amp;s=48c6bc29bd171ffed47446d6a3c3b2fd 400w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_2914_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=600&amp;q=75&amp;w=800&amp;s=04ca8174677267d7060a13ccc5ff026f 800w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_2914_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=900&amp;q=75&amp;w=1200&amp;s=bcc12807b9d1484e2810f574ddc51f72 1200w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_2914_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=975&amp;q=75&amp;w=1300&amp;s=e81e9925f4c68bd59c7676a64315569f 1300w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_2914_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1088&amp;q=75&amp;w=1450&amp;s=9b181b4214ee0406b3ff4b425aa3e606 1450w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_2914_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1200&amp;q=75&amp;w=1600&amp;s=8690a3ec407f4fea2e0fd32685fb362c 1600w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_2914_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1500&amp;q=75&amp;w=2000&amp;s=74a9a4911c21491c1ba77b975b34a9e2 2000w"
                    />

            
    
<figcaption class="attribution">
        <span class="attribution__caption">Vincent Gaynor with his daughter Sophia</span>
    
        <span class="attribution__credit">
        <span class="a11y">Credit: </span>
        Photo courtesy of Vincent Gaynor
    </span>
    
    
    </figcaption>

</figure>

        
    
                    
<p data-pp-blocktype="copy" data-pp-id="18.0">Once Zolgensma’s potential was clear, early champions like the Gaynors were left behind as the private sector rushed in. AveXis’ top executives and venture-capital backers made tens or hundreds of millions of dollars apiece when the startup was swallowed by the pharmaceutical giant Novartis AG in 2018.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="19.0">Wall Street analysts predicted Novartis’ new prize drug would be the first therapy to smash the million-dollar-a-dose mark. The Swiss colossus crafted a sophisticated campaign to justify more than double that amount, enlisting a team of respected academics, data-modelers and pricing strategists to help make its case.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="20.0">“This was a case where the charities and the government did everything to get this thing commercialized, and then it just became an opportunity for a bunch of people to make transformative, generational wealth,” said James Love, director of the public advocacy group Knowledge Ecology International.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="21.0">In a statement to ProPublica, Novartis said Zolgensma’s price reflects its benefits to children with SMA and to society more broadly.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="22.0">“Zolgensma is consistently priced based on the value it provides to patients, caregivers and health systems,” the company said, adding that the drug may reduce the burden of SMA by replacing “repeat, lifelong therapies with a single treatment.”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="23.0">Zolgensma’s price quickly became the standard for gene therapies. Nine of them cost more than $2 million. A tenth, approved in November, is predicted to run about $3.8 million, just shy of the most expensive, also approved last year, which costs $4.25 million a dose.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="24.0">“Drug companies charge whatever they think they can get away with,” said David Mitchell, the founder of Patients For Affordable Drugs. “And every time the benchmark moves up, they think, ‘Well, we can get away with more.’”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="25.0">Parents of children with SMA say their concerns about costs pale in comparison to the hope offered by such cutting-edge therapies. “I mean, it’s a child’s life,” said Hailey Weihs, who battled her health plan to get Zolgensma for her daughter. “Anybody would want that for their own child.”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="26.0">The seven-figure costs of Zolgensma and other gene therapies add to the nation’s ballooning bill for prescription drugs, absorbed by all Americans in the form of rising insurance premiums and taxes for public programs like Medicaid.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="27.0">Breakthroughs like Zolgensma are often framed as wins for all: Patients get life-saving new therapies. Drug companies and biotech investors make enough money to incentivize even more breakthroughs.</p>

<p data-pp-blocktype="copy" data-pp-id="27.1">But not everyone’s a winner, Gaynor noted.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="28.0">No one wanted Zolgensma to succeed more than he did, or understands better what it has meant for families like his. Yet his years behind the scenes of the drug’s development left him and his family disillusioned.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="29.0">“I learned it’s all about money,” Gaynor said. “It’s not about saving people.”</p>

<hr>
</p>
        
    
                    
        <figure
    data-pp-id="31"
    data-pp-blocktype="intro-module"
    class="bb-intro-module
            size03 out03 wrap right bb-intro-module--on-article-page
            wide-md
        ">
    <h4>
        What We’re Watching
    </h4>
    <div class="bb-intro-module__dek">
        <p>During Donald Trump’s second presidency, ProPublica will focus on the areas most in need of scrutiny. Here are some of the issues our reporters will be watching — and how to get in touch with them securely.</p>

    </div>
    <div class="bb-intro-module__container">

        
<div class="bb-intro-module__card bb-intro-module__card--current">
            
    


    <img
        class="bb-intro-module__art"
        alt=""
        width="400"
        height="400"
        loading="lazy" js-autosizes        src="https://img.assets-d.propublica.org/v5/images/ProPublica-Reporters-Trump_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=800&amp;s=4ded2e639bc7a5ceafbc0e26fede28fb"
        srcset="https://img.assets-d.propublica.org/v5/images/ProPublica-Reporters-Trump_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=400&amp;q=75&amp;w=400&amp;s=41ee031e0b19bd7a9b593023cb32ec74 400w, https://img.assets-d.propublica.org/v5/images/ProPublica-Reporters-Trump_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=800&amp;s=4ded2e639bc7a5ceafbc0e26fede28fb 800w, https://img.assets-d.propublica.org/v5/images/ProPublica-Reporters-Trump_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1200&amp;q=75&amp;w=1200&amp;s=6813e35a3f61a4d65aeace96046d9d5c 1200w, https://img.assets-d.propublica.org/v5/images/ProPublica-Reporters-Trump_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1300&amp;q=75&amp;w=1300&amp;s=c156d8b6c175da431c7838bd97a86dbe 1300w, https://img.assets-d.propublica.org/v5/images/ProPublica-Reporters-Trump_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1450&amp;q=75&amp;w=1450&amp;s=0c8bab7c2608527a42a03775bed40d7e 1450w, https://img.assets-d.propublica.org/v5/images/ProPublica-Reporters-Trump_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1600&amp;q=75&amp;w=1600&amp;s=68b4f93ce5534506098073b8b35df69b 1600w, https://img.assets-d.propublica.org/v5/images/ProPublica-Reporters-Trump_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=2000&amp;q=75&amp;w=2000&amp;s=3df23fd68e3b45483b727b2c381e6a98 2000w"
                    />

        <div class="bb-intro-module__card-description">
                    <p><a href="https://www.propublica.org/article/second-trump-presidency-issues-contact">Learn more about our reporting team.</a> We will continue to share our areas of interest as the news develops.</p>

            </div>
</div>



                
                    
<div class="bb-intro-module__card bb-intro-module__card--reporter ">
            <img class='bb-intro-module__art bb-intro-module__art--headshot' alt='Portrait of Sharon Lerner' src='https://assets-c3.propublica.org/images/bio/_oneOne75w/Sharon-Lerner-1x1_2024-01-03-204306_ifac.jpg' width='75' height='75' srcset='https://assets-c3.propublica.org/images/bio/_oneOne75w/Sharon-Lerner-1x1_2024-01-03-204306_ifac.jpg 75w, https://assets-c3.propublica.org/images/bio/_oneOne150w/Sharon-Lerner-1x1_2024-01-03-204306_ifac.jpg 150w' loading='lazy'>
        <div class="bb-intro-module__card-description">
                    <h5>Sharon Lerner</h5>
<p>I cover health and the environment and the agencies that govern them, including the Environmental Protection Agency.</p>

                <ul class="stack stack--row stack--wrap stack--spacing-1">
                            <li><a class="btn" href="https://signal.me/#p/+17188775236">Signal</a></li>
                            <li><a class="btn" href="/cdn-cgi/l/email-protection#92e1faf3e0fdfcbcfef7e0fcf7e0d2e2e0fde2e7f0fefbf1f3bcfde0f5">Email</a></li>
                            <li><a class="btn" href="tel:17188775236">Phone</a></li>
                    </ul>
    </div>
</div>
                    
<div class="bb-intro-module__card bb-intro-module__card--reporter ">
            <img class='bb-intro-module__art bb-intro-module__art--headshot' alt='Photo of Maryam Jameel' width='400' height='400' src='https://img.assets-c3.propublica.org/images/bio/maryam-jameel-sized.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=800&amp;s=f76107a3ce87b74ecea00f3151342016' srcset='https://img.assets-c3.propublica.org/images/bio/maryam-jameel-sized.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=400&amp;q=75&amp;w=400&amp;s=0799731aedffff4b6f9e9e5543561d5f 400w, https://img.assets-c3.propublica.org/images/bio/maryam-jameel-sized.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=800&amp;s=f76107a3ce87b74ecea00f3151342016 800w, https://img.assets-c3.propublica.org/images/bio/maryam-jameel-sized.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1200&amp;q=75&amp;w=1200&amp;s=3f0b20c9c263cbd501f8266d3d2dc80e 1200w, https://img.assets-c3.propublica.org/images/bio/maryam-jameel-sized.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1300&amp;q=75&amp;w=1300&amp;s=31e273e5b9d3d5bfdb0bd6b173e0ae50 1300w, https://img.assets-c3.propublica.org/images/bio/maryam-jameel-sized.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1450&amp;q=75&amp;w=1450&amp;s=4dc206dffedfd6773ef2357841158031 1450w, https://img.assets-c3.propublica.org/images/bio/maryam-jameel-sized.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1600&amp;q=75&amp;w=1600&amp;s=ea238008565d2cdcc2e1a5eb5202e617 1600w, https://img.assets-c3.propublica.org/images/bio/maryam-jameel-sized.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=2000&amp;q=75&amp;w=2000&amp;s=25e432eca8ec6ce956e791bd8edbdc81 2000w'>
        <div class="bb-intro-module__card-description">
                    <h5>Maryam Jameel</h5>
<p>I’m an engagement reporter interested in immigration, labor and the federal workforce.</p>

                <ul class="stack stack--row stack--wrap stack--spacing-1">
                            <li><a class="btn" href="tel:12028869548">Phone</a></li>
                            <li><a class="btn" href="https://signal.me/#p/+12028869548">Signal</a></li>
                            <li><a class="btn" href="/cdn-cgi/l/email-protection#422f23303b232f6c28232f27272e0232302d3237202e2b21236c2d3025">Email</a></li>
                    </ul>
    </div>
</div>
                    
<div class="bb-intro-module__card bb-intro-module__card--reporter ">
            <img class='bb-intro-module__art bb-intro-module__art--headshot' alt='Portrait of Mark Olalde' src='https://assets-c3.propublica.org/images/bio/_oneOne75w/mark-olalde.jpg' width='75' height='75' srcset='https://assets-c3.propublica.org/images/bio/_oneOne75w/mark-olalde.jpg 75w, https://assets-c3.propublica.org/images/bio/_oneOne150w/mark-olalde.jpg 150w' loading='lazy'>
        <div class="bb-intro-module__card-description">
                    <h5>Mark Olalde</h5>
<p>I’m interested in Trump’s and his allies’ promises to dismantle the federal bureaucracy and laws that protect the environment.</p>

                <ul class="stack stack--row stack--wrap stack--spacing-1">
                            <li><a class="btn" href="/cdn-cgi/l/email-protection#0b666a79602564676a676f6e4b7b79647b7e696762686a2564796c">Email</a></li>
                            <li><a class="btn" href="https://signal.me/#p/+16306054470">Signal</a></li>
                    </ul>
    </div>
</div>
                    
<div class="bb-intro-module__card bb-intro-module__card--reporter ">
            <img class='bb-intro-module__art bb-intro-module__art--headshot' alt='Photo of Jesse Coburn' width='400' height='400' src='https://img.assets-c3.propublica.org/images/bio/Jesse-Coburn-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=800&amp;s=10f6ed75833d0c1965211df2b79660e7' srcset='https://img.assets-c3.propublica.org/images/bio/Jesse-Coburn-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=400&amp;q=75&amp;w=400&amp;s=60beeb4d6f81e4c09ac4c15512adbd97 400w, https://img.assets-c3.propublica.org/images/bio/Jesse-Coburn-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=800&amp;s=10f6ed75833d0c1965211df2b79660e7 800w, https://img.assets-c3.propublica.org/images/bio/Jesse-Coburn-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1200&amp;q=75&amp;w=1200&amp;s=099f2b4e7684e137bb19100524a961c0 1200w, https://img.assets-c3.propublica.org/images/bio/Jesse-Coburn-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1300&amp;q=75&amp;w=1300&amp;s=f9c56c686d6881eb42dc122f55459f33 1300w, https://img.assets-c3.propublica.org/images/bio/Jesse-Coburn-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1450&amp;q=75&amp;w=1450&amp;s=63b2a160afcbbe699afb2bbf30d2fbd6 1450w, https://img.assets-c3.propublica.org/images/bio/Jesse-Coburn-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1600&amp;q=75&amp;w=1600&amp;s=e9d7e6cc061cda74eaf398ee03a64c07 1600w, https://img.assets-c3.propublica.org/images/bio/Jesse-Coburn-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=2000&amp;q=75&amp;w=2000&amp;s=7a3afc11e47aafbee2095d35a7a6beaf 2000w'>
        <div class="bb-intro-module__card-description">
                    <h5>Jesse Coburn</h5>
<p>I’m tracking how the Trump administration reshapes policy at the Department of Housing and Urban Development and the Department of Transportation.</p>

                <ul class="stack stack--row stack--wrap stack--spacing-1">
                            <li><a class="btn" href="/cdn-cgi/l/email-protection#7e141b0d0d1b501d111c0b0c103e0e0c110e0b1c12171d1f50110c19">Email</a></li>
                            <li><a class="btn" href="https://signal.me/#p/+19172396642">Signal</a></li>
                            <li><a class="btn" href="https://wa.me/19172396642">WhatsApp</a></li>
                            <li><a class="btn" href="tel:19172396642">Phone</a></li>
                    </ul>
    </div>
</div>
        
        
<div class="bb-intro-module__card ">
            
    


    <img
        class="bb-intro-module__art"
        alt=""
        width="400"
        height="400"
        loading="lazy" js-autosizes        src="https://img.assets-c3.propublica.org/images/externals/20191029-federal-govt-callout-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=800&amp;s=d53f4f2e61169b796ae4d7a314ae618d"
        srcset="https://img.assets-c3.propublica.org/images/externals/20191029-federal-govt-callout-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=400&amp;q=75&amp;w=400&amp;s=be2589eb833e6e7b11c9bf797a166799 400w, https://img.assets-c3.propublica.org/images/externals/20191029-federal-govt-callout-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=800&amp;s=d53f4f2e61169b796ae4d7a314ae618d 800w, https://img.assets-c3.propublica.org/images/externals/20191029-federal-govt-callout-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1200&amp;q=75&amp;w=1200&amp;s=0a9cdcc42005c4310a5b181a4bfa3188 1200w, https://img.assets-c3.propublica.org/images/externals/20191029-federal-govt-callout-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1300&amp;q=75&amp;w=1300&amp;s=5f97bad407ac7a14f1e3ba65fb0bd577 1300w, https://img.assets-c3.propublica.org/images/externals/20191029-federal-govt-callout-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1450&amp;q=75&amp;w=1450&amp;s=36bce00446cce8166beb952e5d24ba7b 1450w, https://img.assets-c3.propublica.org/images/externals/20191029-federal-govt-callout-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1600&amp;q=75&amp;w=1600&amp;s=949b62d97e21f05e775e9b41780df347 1600w, https://img.assets-c3.propublica.org/images/externals/20191029-federal-govt-callout-1x1.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=2000&amp;q=75&amp;w=2000&amp;s=d7655549311bc7c97ce7e5d98f70ff20 2000w"
                    />

        <div class="bb-intro-module__card-description">
                    <p>If you don’t have a specific tip or story in mind, we could still use your help. Sign up to be a member of our <a href="https://www.propublica.org/tips/federal-workers/">federal worker source network</a> to stay in touch.</p>

            </div>
</div>

            </div>
    <nav class="bb-intro-module__nav">
        <a href="#" class="bb_intro-module__nav--current"><span></span>&nbsp;</a>
        <a href="#"><span></span>&nbsp;</a>
        <a href="#"><span></span>&nbsp;</a>
        <a href="#"><span></span>&nbsp;</a>
        <a href="#"><span></span>&nbsp;</a>
        <a href="#"><span></span>&nbsp;</a>
            </nav>
    <p class="bb-intro-module__survey">We’re trying something new. <a href="https://iteratehq.com/propublica/670eabefffb484af7dc7db86">Was it helpful?</a></p>
</figure>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="32.0">When Vincent and Catherine Gaynor started their married life in 2006, they knew one thing for certain: They wanted children.</p>

<p data-pp-blocktype="copy" data-pp-id="32.1">They learned well into Catherine’s 2008 pregnancy that they were both carriers for SMA, meaning there was a 25% chance their child would be born with the muscle-wasting disorder.</p>

<p data-pp-blocktype="copy" data-pp-id="32.2">They were concerned but clung to the larger chance the baby would be born healthy.</p>

<p data-pp-blocktype="copy" data-pp-id="32.3">When Sophia was born in late February 2009, at first they just marveled at her sweet disposition and bright, expressive eyes. How she loved being snuggled. How she sighed after she burped.</p>

<p data-pp-blocktype="copy" data-pp-id="32.4">But it didn’t take long for Vincent, who’d grown up with younger siblings, to sense something was off. Sophia didn’t lift her legs. They flopped outward like a frog’s when he changed her diaper.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="33.0">Their pediatrician assured them Sophia was fine. Then a different doctor suggested testing her for SMA. While they waited for the results, the family went to a nearby park, and Catherine pushed Sophia’s stroller around a pond. “I remember walking behind her with the video camera and knowing in my heart this was the last day we were all going to be happy,” Vincent recalled.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="34.0">After Sophia’s diagnosis, Catherine quit her office job to care for the baby full time. Vincent started gulping down studies and going to conferences, desperate to find a way to save his daughter.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="35.0">At the time, there were no treatments to slow or stop SMA. By the time Sophia was 4 months old, she needed a machine to help her breathe overnight. At 6 months, she could no longer take a bottle and needed a feeding tube. Each time she lost ground, their urgency to find a treatment grew.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="36.0">The Gaynors didn’t have deep pockets or wealthy friends. He was a steamfitter with Local 638, from a family of steamfitters. They began raising small amounts of money by hosting golf tournaments and throwing Zumba parties. As the volume of donations grew, they founded Sophia’s Cure, emerging as serious players in the small world of SMA charities.</p>
        
    
                    <figure
    data-pp-id="37"
    data-pp-blocktype="pull-quote"
    class="bb-pull-quote bb--border-top
        size04 left out02 wide-sm wrap">

    <blockquote class="bb-pull-quote__text">
        <p>I learned it’s all about money. It’s not about saving people.</p>

    </blockquote>
        <figcaption class="bb-pull-quote__source">
        —Vincent Gaynor, who raised funds for medical research to help his daughter with spinal muscular atrophy

    </figcaption>
    
</figure>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="38.0">Vincent met Brian Kaspar at a cocktail hour for high-yield fundraisers. Kaspar was among the small group of top researchers working to find treatments for SMA, competing fiercely for recognition and funds. (Kaspar declined an interview request from ProPublica and didn’t respond to written questions.)</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="39.0">Because his drug was a gene therapy, public grant money and private philanthropy played an especially central role, with the National Institutes of Health alone <a href="https://www.yahoo.com/news/opinion-why-didn-t-nonprofits-084025378.html">putting over $450 million into science related to SMA</a>. Drug companies at the time approached these treatments with more skepticism, waiting longer to invest and letting universities and academic hospitals do the heavy lifting, said Ameet Sarpatwari, an assistant professor at Harvard Medical School who studies the pharmaceutical industry.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="40.0">Drug companies sponsored only 40% of the U.S. gene therapy trials active in January 2019, <a href="https://jamanetwork.com/journals/jama/fullarticle/2762298">according to a study</a> Sarpatwari co-authored.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="41.0">“The narrative of industry is, ‘We’re doing the hard, expensive part of drug development,’ and, at least for cell and gene therapies, the most risky part is actually being done by public or federally supported labs,” Sarpatwari said, calling Zolgensma a “poster child” for the study’s findings.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="42.0">By the time of the cocktail party, Kaspar had turned early research into a promising drug therapy that he was beginning to test on animals — the precursor to a human trial. Gaynor remembered him as humble and almost classically nerdy, happy to spend hours on the phone explaining how motor neurons work.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="43.0">More established SMA charities tended to hedge their bets, spreading money around to multiple programs. But Sophia was already around 18 months old, and Gaynor had no time for that. In September 2010, when Sophia’s Cure won a $250,000 grant from the Pepsi Refresh Project by amassing votes online, he steered the money to Kaspar’s program. The following June, the charity signed an agreement promising Kaspar up to $1 million more, for which it had launched a drive to recruit 200 people to raise $5,000 apiece.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="44.0">As the money flowed in, Gaynor and Kaspar became close friends. The Gaynors stayed overnight at Kaspar’s house on their drive to an annual charity event. Kaspar did a Q&amp;A for the Sophia’s Cure YouTube channel from the Gaynors’ dining room and proofread posts Vincent wrote for the charity’s website.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="45.0">Gaynor said they often talked about how getting the drug through the development process would require way more money and muscle than the various SMA charities could muster. Kaspar shared his conversations with venture capital firms and even asked Gaynor to talk to a potential investor.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="46.0">Yet Gaynor said he was blindsided when Kaspar told him he’d formed a relationship with a Dallas startup called BioLife Cell Bank that had been focused on stem cell research.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="47.0">The CEO, John Carbona, then 54, had run medical device and equipment companies, but he had no background in drug development. In an interview, Carbona told ProPublica that he took the reins at BioLife in the aftermath of his mother’s death, determined to do something “significant” to fulfill her hopes for him. After an associate’s twins were born with SMA, he said he became convinced that Kaspar’s gene therapy was the answer.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="48.0">Carbona remade BioLife into AveXis: Av for adeno-associated virus serotype 9, the engine of Kaspar’s drug; ve for vector; X for the DNA helix; and Is for Isis, the goddess of children, nature and magic.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="49.0">Still, for much of the next year and a half, money from charities and more than $2.5 million from the National Institutes of Health remained Kaspar’s bread and butter. In late 2012, Sophia’s Cure agreed to provide another $550,000 for a Phase 1 clinical trial. The Nationwide Children’s Hospital Foundation, an affiliate of the hospital, agreed to match it.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="50.0">Kaspar singled out Sophia’s Cure for the extent of its support in a <a href="https://www.nationwidechildrens.org/newsroom/news-releases/2013/01/sophias-cure-foundation-donates-650000-in-2012-to-nationwide-childrens-hospital">Nationwide press release</a>.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="51.0">“Sophia’s Cure Foundation has been the lead funder of this program and their incredible investment in this lab has accelerated our program by many years,” he said.</p>
        
    
                        <aside class="bb-ad full | hide-print">
        <div class="htlad-inline-2"></div>
    </aside>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="53.0">The trial protocol called for Kaspar’s therapy to be tested on infants up to 9 months old. It was a pragmatic decision: The company had limited funds and capacity to produce the test doses, which would be smaller for children who weighed less. Plus, the youngest children were likely to show the most dramatic results since they’d be treated before SMA inflicted its worst damage.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="54.0">That left out Sophia, as well as most of the kids whose parents made up Gaynor’s fundraising network.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="55.0">Gaynor’s dream of saving his daughter had tapered into determination to stop the disease’s progression and preserve the strength she had left. Sophia could no longer move her whole hand, but she could still tap with her right pointer finger. She could use an eye-gaze computer to click open screens and attend school remotely. She could communicate a bit, blinking once for yes and twice for no.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="56.0">Early on, Gaynor said, Kaspar had promised a trial for older kids. But Gaynor felt Kaspar’s commitment wavered as his ties to AveXis grew and his reliance on funding from Sophia’s Cure diminished.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="57.0">Carbona struck a deal with Nationwide Children’s in late 2013, getting AveXis the exclusive right to develop an SMA treatment using the hospital’s inventions, including Kaspar’s, in exchange for stock. A few months later, Kaspar signed a contract that granted him an even larger stake in the company. The company also landed its first major investor, Paul Manning of PBM Capital.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="58.0">Over this period, Gaynor said, the phone calls and updates from Kaspar slowed. The Gaynors were invited to Nationwide Children’s for the start of the clinical trial by the family of the child receiving the first dose.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="59.0">After the initial awkwardness in the cafeteria, the Gaynors said, Kaspar and Carbona eventually came over and sat with them. Carbona remembers it differently, saying that he recalled seeing the Gaynors that day and the mood was friendly, even celebratory.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="60.0">Tension surfaced two months later when they all converged in Lancaster, Wisconsin, for Avery’s Race, an annual SMA fundraiser benefiting Sophia’s Cure.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="61.0">The event brought together dozens of families from across the country for an awareness walk, an auction and a rubber ducky race in a nearby creek. In the finale, parents posed questions to Kaspar, Gaynor and Carbona, almost all of them about the clinical trial.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="62.0">In video footage captured by a documentary filmmaker, Catherine Gaynor asked bluntly whether testing the drug only on infants meant the FDA would approve the treatment only for the youngest patients while “everyone else is left hanging out to dry.”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="63.0">Kaspar acknowledged this was possible. He described expanding the treatment to older children as “step two” but made clear that funds for testing would have to come from Sophia’s Cure.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="64.0">That’s what the money raised at Avery’s Race would support, Vincent Gaynor said, adding pointedly that his nonprofit would focus on the work others would avoid “because it’s not going to push stock prices up.”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="65.0">Neither Kaspar nor Carbona responded directly to the dig. Carbona, noting the company had other funding needs, said they would expand testing when they had proof the drug worked.</p>
        
    
                    <figure
    data-pp-id="66"
    data-pp-blocktype="pull-quote"
    class="bb-pull-quote bb--border-top
        size04 left out02 wide-sm wrap">

    <blockquote class="bb-pull-quote__text">
        <p>I mean, they all have their hearts in the right place, but they’re being run by people who are looking for a return on investment.</p>

    </blockquote>
        <figcaption class="bb-pull-quote__source">
        —John Carbona, former CEO of AveXis

    </figcaption>
    
</figure>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="67.0">By early 2015, AveXis had raised millions from deep-pocketed biotech investors, adding members of several venture-capital funds to its board. Their participation would be critical in bringing the drug to market, paying for licenses to patented technology needed to make and administer it, for example. It also meant that Zolgensma had to do more than save lives — its promise had to make AveXis’ investors a profit.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="68.0">Almost immediately, Carbona said, the board pushed to take the company public.</p>

<p data-pp-blocktype="copy" data-pp-id="68.1">“I mean, they all have their hearts in the right place, but they’re being run by people who are looking for a return on investment,” he said.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="69.0">As AveXis moved toward an initial public offering, some on the board questioned whether Carbona should continue running it, he said. He’d been accused years earlier of fraud and breach of fiduciary duty by a former employer, who won a $2.2 million court judgment against him. Carbona had denied any wrongdoing and the judgment was reversed in part and reduced on appeal, but the case left lasting damage. “It hurt me immensely,” he said.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="70.0">Later that year, the board replaced Carbona with a new chief executive, Sean P. Nolan, who had a decadeslong record at pharmaceutical and biotech companies.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="71.0">In September, a company representative offered the Gaynors a meeting with Nolan, saying Kaspar had stressed how instrumental Sophia’s Cure had been to the work on the drug. The Gaynors traveled into Manhattan for the meeting at a hotel bar. They told Nolan about their concerns, including that older kids wouldn’t have access to Kaspar’s drug since it hadn’t been tested on them. They said Nolan was cordial but never followed up. (Nolan didn’t respond to emailed questions from ProPublica.)</p>
        
    
                    

<figure
    data-pp-id="72"
    data-pp-blocktype="video-self-hosted"
    class="bb-video-self-hosted size04 right out03 wide-sm wrap
                hide-print
    ">

    


            <video class="lazyload"
            preload="none"
            playsinline
             poster="https://assets-c3.propublica.org/images/20250205-zolgensma-avexis-still-smaller.jpg"              muted data-autoplay loop data-expand="500"
                        >
            <source type="video/mp4" src="https://assets-d.propublica.org/v5/video/zolgensma-smaller.mp4">
        </video>
    
    
<figcaption class="attribution">
        <span class="attribution__caption">Nasdaq posted a video to Facebook with the caption, “Getting ready to ring the #Nasdaq opening bell with AveXis, Inc!”</span>
    
        <span class="attribution__credit">
        <span class="a11y">Credit: </span>
        Excerpt from archived live video clip obtained from Nasdaq/Facebook
    </span>
    
    
    </figcaption>


</figure>

        
    
                    
<p data-pp-blocktype="copy" data-pp-id="73.0">Early the following year, AveXis went public. Nolan celebrated by <a href="https://www.facebook.com/share/v/18MSbEm1HC/">ringing the NASDAQ opening bell</a> as Kaspar, other company executives and members of the board whooped and clapped.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="74.0">The IPO and subsequent stock sales raised hundreds of millions of dollars, but little of the money went toward additional trials on Zolgensma, an analysis by KEI, the public advocacy group, concluded.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="75.0">The drug’s trials were small, often involving two dozen patients or fewer. AveXis, and later Novartis, spent less than $12 million up to the point of the drug’s approval — surprisingly little — to prove the therapy was safe and effective, the group estimated, based on information obtained through Freedom of Information Act requests, from studies and in Securities and Exchange Commission filings. (Novartis did not respond to questions from ProPublica about trial costs.)</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="76.0">The companies spent more than 10 times that amount to license intellectual property from others, KEI found. It’s not the clinical trials, Love, the director, said, that “makes developing gene therapies more expensive than it has to be.”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="77.0">By the time of AveXis’ IPO, the Gaynors had decided to wind down Sophia’s Cure and step back from the SMA community. In 2015, Sophia began having seizures that became more frequent over time. She was 6 years old and growing weaker. Her SMA had progressed too far for Kaspar’s drug to help her.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="78.0">Vincent’s sense of failure was crushing. In September 2016, after years of pent-up anger, he took a last stab at getting Kaspar and AveXis to acknowledge that the charity and its donors had essentially been a partner in developing Zolgensma.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="79.0">Sophia’s Cure sued Kaspar, Carbona, Nolan, AveXis, Nationwide Children’s Hospital and its affiliated research institute and foundation for breach of contract. They’d relied on the charity’s money to advance the treatment, the lawsuit alleged, then violated the terms of donation agreements by cutting it out of credit and ownership rights once the drug was headed for success. The suit sought damages of $500 million.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="80.0">Many larger disease foundations have launched <a href="https://www.nytimes.com/2014/11/19/business/for-cystic-fibrosis-foundation-venture-yields-windfall-in-hope-and-cash.html">venture philanthropy</a> programs that <a href="https://llsorg.widen.net/s/vqgztg59sl/lls-tap-external-presentation">invest in biotech companies and projects</a>, getting royalties and other financial considerations if their gifts help fund new treatments. In court filings, Nationwide Children’s called the notion that the tiny Sophia’s Cure had any right to the drug “simply not true, or even plausible,” and AveXis called it “wholly unsupported.”</p>
        
    
                        <aside class="bb-ad full | hide-print">
        <div class="htlad-inline-2"></div>
    </aside>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="82.0">Carbona said he was “disappointed and surprised” by the lawsuit. Nationwide didn’t respond to questions about the matter.</p>

<p data-pp-blocktype="copy" data-pp-id="82.1">In November 2017, as the litigation went on, the results of the clinical trial that the charity helped fund were published.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="83.0">They were remarkable. At 20 months, all 15 children who’d been treated remained alive, and none relied on a ventilator to breathe. Eleven of 12 infants who received a higher dose of the therapy were able to sit unassisted, speak and be fed orally. Two could walk on their own.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="84.0">Based on preliminary trial data, the FDA had designated Zolgensma a <a href="https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy">breakthrough therapy</a>, one of three <a href="https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review">special designations</a> that helped it <a href="https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track">race from human trials</a> to regulatory approval in five years. Once the full trial results came out, AveXis became a red-hot acquisition target.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="85.0">In April 2018, Novartis beat out another bidder, agreeing to buy the company for $8.7 billion.</p>

<p data-pp-blocktype="copy" data-pp-id="85.1">The sale delivered massive windfalls to those with the biggest stakes in AveXis.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="86.0">Kaspar alone took in more than $400 million. He swapped his longtime family home in New Albany, Ohio, for a 9-acre estate in San Diego County, California, that had been listed for just over $8 million. It featured a dine-in stone wine cellar, a horse ring and stables.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="87.0">Nolan, who’d led AveXis for less than three years, walked away with over $190 million; according to a financial filing, his payout included a golden parachute worth almost $65 million. Manning, the startup’s first big investor, made more than $315 million, multiplying his original investment by about 60. (Manning didn’t respond to calls or emailed questions from ProPublica.)</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="88.0">Carbona, too, made a bundle — he declined to say how much. Since he’d already left the company, his payout wasn’t disclosed in SEC filings. “It didn’t matter,” he said of the money. The 20-hour days he’d put into AveXis had helped advance a lifesaving drug. “This was a significant impact on humanity.”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="89.0">After watching AveXis’ executives and investors cash in, the Gaynors were dealt another painful setback. In early 2019, a U.S. district court judge in Ohio dismissed Sophia’s Cure’s lawsuit against all parties, concluding there had been no breach of contract.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="90.0">Their last hope for recognition of the charity’s role in bringing Zolgensma to the world was extinguished.</p>

<hr>
<p data-pp-blocktype="copy" data-pp-id="90.1">Once Novartis acquired AveXis, it turned to setting a price for its much-anticipated gene therapy.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="91.0">Unlike other nations, the United States allows companies to charge whatever they want for new drugs. This often means <a href="https://aspe.hhs.gov/reports/comparing-prescription-drugs">Americans pay the world’s highest prices</a>, particularly during the period when only the original manufacturer can market a drug. Research by PhRMA, the trade group for drug companies, <a href="https://phrma.org/resources/global-access-to-new-medicines-report">suggests</a> unfettered pricing buys Americans faster access, as long as insurers will pay: New medicines most often launch first in the U.S.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="92.0">Novartis’ deliberations took place at the end of a decade in which launch prices of new drugs had risen exponentially, <a href="https://www.latimes.com/business/la-fi-agenda-specialty-drugs-20150921-story.html">drawing ire from patient advocacy groups</a> and <a href="https://www.finance.senate.gov/ranking-members-news/wyden-grassley-sovaldi-investigation-finds-revenue-driven-pricing-strategy-behind-84-000-hepatitis-drug">Congress</a>. The median annual launch price for a new drug <a href="https://jamanetwork.com/journals/jama/fullarticle/2792986#:~:text=Median%20launch%20prices%20increased%20from%20$2115%20per,in%202008%2D2013%20and%2047%%20(42/89)%20in%202020%2D2021.">jumped from about $2,000 in 2008 to about $180,000 in 2021</a>, one study found.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="93.0">In part, the increase reflected that a growing proportion of new drugs treated rare diseases. Drug companies have argued these therapies should cost more because their markets are smaller, making it harder to recoup expenses.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="94.0">Cell and gene therapies also drove prices higher. The first three such treatments were approved in 2017, launching at prices of $370,000 or more. Luxturna, a gene therapy for a rare disorder that causes vision loss, costs $425,000 per eye.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="95.0">Industry insiders assumed Zolgensma would cost more than Luxturna. But how much?</p>
        
    
                    <figure
    data-pp-id="96"
    data-pp-blocktype="pull-quote"
    class="bb-pull-quote bb--border-top
        size04 left out02 wide-sm wrap">

    <blockquote class="bb-pull-quote__text">
        <p>There was what I would call pressure from Wall Street. This was going to set a precedent. Investors wanted to see a high price here.</p>

    </blockquote>
        <figcaption class="bb-pull-quote__source">
        —Dr. Steven D. Pearson, founder of a nonprofit that assesses drug prices

    </figcaption>
    
</figure>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="97.0">How drug companies pick prices for their products is among their most closely held secrets.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="98.0">Beyond its statement, Novartis didn’t respond to questions from ProPublica about how it set or justified Zolgensma’s price. We reached out to more than three dozen people who were at the company or consulted for it at the time; most didn’t respond or declined to comment. A couple said they were bound by nondisclosure agreements.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="99.0">The most visible portion of Novartis’ work was an effort to put a dollar value on how much Zolgensma would extend and improve SMA patients’ lives and offset the costs of caring for them.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="100.0">This approach, known as value-based pricing, was originally championed by insurers and consumer watchdogs hoping to rein in drug prices. Other nations use economic assessments to decide whether to cover drugs and at what price, often paying far less than the U.S. for the same treatments.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="101.0">But pharmaceutical companies have learned to <a href="https://www.propublica.org/article/big-pharma-quietly-enlists-leading-professors-to-justify-1000-per-day-drugs">use these techniques to their advantage</a>.</p>

<p data-pp-blocktype="copy" data-pp-id="101.1">Novartis brought together experts from academia and top consulting firms to work with its internal health economics team to publish research framing Zolgensma as a good value even at a high price.</p>

<p data-pp-blocktype="copy" data-pp-id="101.2">One of the academics was Daniel Malone, then a professor at the University of Arizona’s College of Pharmacy. The target audience was mainly insurers, he said in an interview.</p>

<p data-pp-blocktype="copy" data-pp-id="101.3">“We’re trying to influence the thousands of pharmacy and therapeutics committees around the country that are going to be looking at this therapy and whether they are going to provide it,” he said.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="102.0">At the company’s direction, Malone said, their model mainly compared Zolgensma to the only other SMA treatment then on the market, a chronic treatment called Spinraza. It, too, was pricey, costing $750,000 in the first year and $375,000 every year after; over a decade, the tally would come to more than $4 million. (This was hypothetical; the FDA had approved Spinraza in December 2016, so no one had ever taken it for that long.)</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="103.0">A <a href="https://www.mdpi.com/2001-6689/7/1/1601484">paper Malone co-authored concluded</a> that Zolgensma, at prices up to $5 million, was a better buy than its rival, delivering more therapeutic benefit at a similar cost.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="104.0">Company executives publicly floated multimillion-dollar prices for Zolgensma using data points from Malone and others.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="105.0">“Four million dollars is a significant amount of money,” Dave Lennon, then president of Novartis’ AveXis unit, told Wall Street analysts on a call in November 2018. But “we’ve shown through other studies that we are cost-effective in the range of $4 million to $5 million.”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="106.0">Such talk normalized “prices that would’ve been inconceivable a generation ago,” said Peter Maybarduk, director of access to medicines at the nonprofit consumer advocacy group Public Citizen. “It has a desensitizing effect.”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="107.0">Novartis’ team of experts also helped the company prepare for Zolgensma’s evaluation by the Institute for Clinical and Economic Review, a nonprofit that assesses whether drugs are priced fairly.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="108.0">Unlike agencies in Europe that do similar evaluations to set drug prices for national health systems, ICER’s recommendations aren’t binding, but they’ve become increasingly influential among public and private payers when it comes to coverage decisions.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="109.0">Dr. Steven D. Pearson, the nonprofit’s founder, said that as ICER began its review, he was aware that investors were pushing for a big number.</p>

<p data-pp-blocktype="copy" data-pp-id="109.1">“There was what I would call pressure from Wall Street,” he said. “This was going to set a precedent. Investors wanted to see a high price here.”</p>

<p data-pp-blocktype="copy" data-pp-id="109.2">At first, it looked like ICER would resist. Its December 2018 draft report said Zolgensma would be overpriced at $2 million.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="110.0">Novartis pushed back. Another consultant, University of Washington professor emeritus Louis Garrison, submitted public comments echoing a forthcoming AveXis-sponsored journal article he’d co-authored. It argued that drugs like Zolgensma, which treat rare, catastrophic conditions, <a href="https://www.jmcp.org/doi/10.18553/jmcp.2019.18378">deserved higher prices</a>, in part to “incentivize appropriate risk taking and investments” by their developers.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="111.0">Garrison said AveXis reviewed the article prior to publication, but he had the final say on its content. “I thought I could make a value-based argument that they would welcome and that I believe in,” he said. He said he was not directly involved in the company’s pricing decision.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="112.0">Nonetheless, ICER’s final report in April 2019 concluded Zolgensma would need to be priced under $900,000 to be cost-effective, though it acknowledged the drug was still being tested on infants who hadn’t yet shown symptoms of SMA. If they also benefited, the report suggested the drug’s value might increase.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="113.0">On May 24, the FDA approved Zolgensma to treat children under 2 with all forms of SMA.</p>

<p data-pp-blocktype="copy" data-pp-id="113.1">Novartis finally revealed the treatment’s U.S. launch price, $2.125 million, framing this as a 50% discount on Spinraza and what the company’s research showed the gene therapy was worth.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="114.0">It also pocketed yet another taxpayer-funded benefit: a voucher from the Food and Drug Administration redeemable for accelerated review of another drug. Such vouchers — designed to encourage companies to invest in pediatric rare-disease treatments — can be sold, typically bringing prices of <a href="https://www.fiercepharma.com/pharma/sarepta-sells-prv-102m-mystery-buyer-another-example-declining-prices-fda-vouchers">around $100 million</a> apiece.</p>
        
    
                        <aside class="bb-ad full | hide-print">
        <div class="htlad-inline-2"></div>
    </aside>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="116.0">That same day, ICER released an update. New data showing Zolgensma’s substantial benefits for presymptomatic children made the drug cost-effective at prices up to $1.9 million by one benchmark and up to $2.1 million by another, it said.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="117.0">Pearson acknowledged the scale and timing of the switch were unusual, but said it was driven by the data, not outside pressure. “We weren’t trying to fit into somebody’s preexpectation of where the number would be, believe me,” he said.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="118.0">He immediately caught flak from insurers.</p>

<p data-pp-blocktype="copy" data-pp-id="118.1">“I got a lot of phone calls saying, ‘Why on earth did you say $2.1 million was a fair price? How could that possibly be the case? We’re going to get swamped with this,’” he recalled.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="119.0">The Gaynors, linking to news coverage on Zolgensma’s launch, wrote on the Sophia’s Cure Facebook page that they were “ecstatic” for children newly born with SMA, but that helping create the world’s most expensive drug “is certainly not what we had in mind.”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="120.0">Malone said he thought it was mostly the potential for blowback that had prevented Novartis from demanding even more for Zolgensma. He’d recommended charging the full $5 million.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="121.0">“Obviously it didn’t stick,” he said. “They decided not to price the product there, I think, because of the political backlash they would’ve gotten being the first out of the gate at that price point.”</p>
        
    
                    
<hr>
<p data-pp-blocktype="copy" data-pp-id="122.0">In the months after Zolgensma hit the market in the U.S., parents of children with SMA frequently ran into resistance from health insurers that refused to pay for it.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="123.0">Between late 2019 and mid-2022, Chicago attorney Eamon Kelly represented at least seven parents battling health plans across the country, helping them appeal denied claims or representing them at state Medicaid hearings.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="124.0">Hailey Weihs came to Kelly when her insurer, a Medicaid-managed care plan in Texas, wouldn’t pay for Zolgensma for her infant daughter Aniya. As the coverage dispute dragged on, Aniya developed tongue tremors and lost the ability to bear weight on her legs.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="125.0">Kelly won the case, as he had all the others, but Aniya’s five-month wait to get the drug was terrifying. “Every day kids with this disease lose motor neurons,” Weihs said. “When you lose them, you cannot get them back.”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="126.0">Now state Medicaid programs and most employer health plans cover Zolgensma, but they often limit which patients get access. Some require doctors to get approval in advance before providing the treatment or impose restrictions on who’s eligible that go beyond what’s on the drug’s label, such as requiring an SMA specialist to prescribe it.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="127.0">Though fewer than 300 American children are born each year with SMA, treatments for the disease annually rank <a href="https://issuu.com/primetherapeutics/docs/2024-medicaid-pharmacy-trend-report?fr=sYTI0Nzc5NDY1NDA">among the top 20 drug classes</a> for Medicaid spending. From 2019 through 2022, Medicaid spent $309 million on 208 Zolgensma claims, an average of almost $1.5 million per claim. (Under federal law, Medicaid doesn’t pay list price for drugs, getting substantial rebates; other payers also negotiate discounts.)</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="128.0">Globally, more than 4,000 children have been treated with Zolgensma, Novartis said. The drug topped $1 billion in annual sales in its second full year on the market. Through 2024, the company had reported over $6.4 billion in revenue from Zolgensma sales.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="129.0">Novartis is working to expand use of the drug in older children, in part by seeking approval for a second version of the drug, administered by spinal injection, for children with less severe SMA.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="130.0">“We are unwavering in our commitment to the SMA community and will continue to advance efforts to ensure access to Zolgensma for SMA patients who may benefit from this transformative, one-time gene therapy,” the company said in its statement.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="131.0">Still, more than five years after Zolgensma’s approval in the U.S., the drug remains out of reach for children in many low- and middle-income countries.</p>

<p data-pp-blocktype="copy" data-pp-id="131.1">Love, KEI’s director, said he’s heard from families in countries like India and South Africa, where it’s a struggle to obtain not only Zolgensma, but also other SMA treatments available in the U.S.</p>

<p data-pp-blocktype="copy" data-pp-id="131.2">“It’s maddening to me,” he said.</p>

<p data-pp-blocktype="copy" data-pp-id="131.3">After setting aside their charity work, the Gaynors refocused their energy on Sophia and her two younger siblings, who don’t have SMA.</p>
        
    
                    

<figure
    data-pp-id="132"
    data-pp-blocktype="image"
    class="bb-image size08 center  wide-sm wrap 
                ">

    


                    
    


    <img
        class=""
        alt=""
        width="2784"
        height="1856"
        loading="lazy" js-autosizes        src="https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_0771_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=533&amp;q=75&amp;w=800&amp;s=6f880f1a931aeea341363c137d02dadc"
        srcset="https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_0771_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=267&amp;q=75&amp;w=400&amp;s=e5c13e7b426e24992660bb7e54d3515a 400w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_0771_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=533&amp;q=75&amp;w=800&amp;s=6f880f1a931aeea341363c137d02dadc 800w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_0771_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=1200&amp;s=024cfd24a3d0d8954e26b8975a641030 1200w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_0771_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=867&amp;q=75&amp;w=1300&amp;s=48c08fb7809228fcc42a94298ba3d492 1300w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_0771_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=967&amp;q=75&amp;w=1450&amp;s=f1a75f543306d7cf52b307efebbe1294 1450w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_0771_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1067&amp;q=75&amp;w=1600&amp;s=1139d84b7e454401c7b8a528e818b580 1600w, https://img.assets-d.propublica.org/v5/images/Gaynor-Zolgensma-IMG_0771_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1333&amp;q=75&amp;w=2000&amp;s=a8caffc8417ba4b7482c18d9ca4ef8cb 2000w"
                    />

            
    
<figcaption class="attribution">
        <span class="attribution__caption">The Gaynor family</span>
    
        <span class="attribution__credit">
        <span class="a11y">Credit: </span>
        Photo courtesy Vincent Gaynor
    </span>
    
    
    </figcaption>

</figure>

        
    
                    
<p data-pp-blocktype="copy" data-pp-id="133.0">They’ve taken the clan to Disney World and to the Bahamas to swim with dolphins. Their youngest, who’s 8, lies beside Sophia on her bed and watches movies with her.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="134.0">Now 15, Sophia had her longest-ever hospitalization in early 2024 when a virus caused her blood sugar to plummet and triggered frequent seizures. She didn’t wake up for two weeks. Since then, she’s been weaker, her affect flatter.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="135.0">Her parents say they don’t think about the future. “Our focus is that she’s happy, that there’s love all around her,” Catherine said. “It’s just day to day.”</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="136.0">The Gaynors have taken solace in the idea that, through Sophia’s Cure, their daughter has made a difference for all the children with SMA who came after her. “That was kind of our consolation prize,” Catherine said.</p>
        
    
                                  <aside
    data-pp-id="137"
    data-pp-blocktype="promo"
    data-pp-location="story promo"
    dir="ltr"
    class="bb-promo-story story-promo-group size04 right out02 wide-sm wrap | hide-print" >

    <div class="story-promo-group__logo user-level--0__show user-level--1__show">
        
<svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 574.24 75" fill="currentColor">
    <title>ProPublica</title>
    <path d="M66.4,13.48,66,14.91l6.23,11.45,1.15.47L75,26.29V75H50.95A41.2,41.2,0,0,0,62.13,46.88a40.61,40.61,0,0,0-3.39-16.26,45.17,45.17,0,0,1,7.79-4.95l1.69-.2.14-.41L65,18.83H64.5l-.88,1.29c-2.91,1.9-4.67,2.3-8.54,3.79A41.35,41.35,0,0,0,20.46,5.42,39.87,39.87,0,0,0,0,10.91V0H75V8.81ZM57.32,47A37.54,37.54,0,0,1,44.65,75H0V16A37,37,0,0,1,57.32,47ZM43.7,37.06c0-8.13-6-12-17.75-12H7.18v3.66l4.2.95V62.2l-4.2.95v3.73H27.85V63.14l-7.18-.95V50.14h5.15C37.26,50.14,43.7,45.53,43.7,37.06Zm-9.76.27c0,5.15-2.78,8.33-7.25,8.33h-6V29.47H27C31.37,29.47,33.94,32.32,33.94,37.33Z"/><path d="M116.53,60.07l9.15,1.08v4.2H99.39v-4.2l5.28-1.36v-44l-5.28-1.36V10.41H123c15.31,0,22.9,5.28,22.9,16.13,0,11.18-8.33,17.41-23.1,17.41h-6.3Zm0-21.14h6.84c6.44,0,10.5-4.61,10.5-12.06,0-7.18-3.73-11.45-10.09-11.45h-7.25Z"/><path d="M200.74,61.15v4.2H185.9l-16-20.6h-2.51v15l5.28,1.36v4.2H150.27v-4.2l5.28-1.36V23.35l-5-1.36V17.93H175.2c10.5,0,17.55,5.08,17.55,12.67,0,8.4-5.76,12.2-11,13.55l13.48,15.79ZM167.41,39.74h4.47c5.76,0,8.81-3.18,8.81-8.88,0-5.35-2.85-7.93-8.81-7.93h-4.47Z"/><path d="M199.59,41.64c0-14.77,9.82-24.73,25.68-24.73s25.68,10,25.68,24.73-9.82,24.73-25.68,24.73S199.59,56.48,199.59,41.64Zm38.89,0c0-9.69-3.25-19.17-13.21-19.17S212.05,32,212.05,41.64s3.25,19.17,13.21,19.17S238.48,51.33,238.48,41.64Z"/><path d="M270.79,60.07l9.15,1.08v4.2H253.31v-4.2l5.62-1.36v-44l-5.62-1.36V10.41h24c15.31,0,22.9,5.28,22.9,16.13,0,11.18-8.33,17.41-23.1,17.41h-6.3Zm0-21.14h6.84c6.44,0,10.5-4.61,10.5-12.06,0-7.18-3.73-11.45-10.1-11.45h-7.25Z"/><path d="M354.26,22l-4.95,1.36V47c0,12.87-7.79,19.38-20.05,19.38-13.62,0-20.73-7.86-20.73-20v-23L303.58,22V17.93h22V22l-5.08,1.36V47.74c0,7.25,4.34,12.06,11.45,12.06,6.84,0,11.25-4.47,11.25-11.31V23.35L338.14,22V17.93h16.12Z"/><path d="M403.85,52.21c0,8.88-7.11,13.14-22,13.14H357.58v-4.2l5.56-1.36V23.35L358.26,22V17.93h23.92c12.6,0,19.51,3.79,19.51,11.72,0,6.17-4.06,9.08-10.91,9.89v.27C399.31,40.76,403.85,45.1,403.85,52.21ZM375,38.32h5.76c6.1,0,9-2.78,9-7.79,0-5.22-3.12-7.59-9-7.59H375Zm16.8,13.41c0-5.62-3.79-8.67-11.25-8.67H375V60.34h6.64C388.07,60.34,391.79,57.29,391.79,51.74Z"/><path d="M451.07,48.62l-4.4,16.73H408v-4.2l5.28-1.36V23.35L407.65,22V17.93h22.76V22l-5.28,1.36v37l14.16-.81L447,47.26Z"/><path d="M475.4,61.15v4.2H453v-4.2l5.28-1.36V23.35L453,22V17.93H475.4V22l-5.28,1.36V59.8Z"/><path d="M478,41.78c0-15.85,12.13-24.86,27-24.86a35.6,35.6,0,0,1,18.29,5.15l-2,13.21h-4.2l-1.69-9.08a13.23,13.23,0,0,0-10.09-4.13c-9.15,0-14.7,6.57-14.7,18.22,0,13.21,6.84,19.31,15.24,19.31,6.17,0,10.23-3.39,13.41-9.55l4.27,2c-4.27,10-11.65,14.36-21.07,14.36C488.4,66.37,478,56.48,478,41.78Z"/><path d="M574.24,61.15v4.2H551.48v-4.2L557,60l-2.85-8.13h-16.6l-3.12,8.2,5.42,1.15-.07,4.2-16.53-.07v-4.2l4.27-1.08,14.9-37.33-4-1.29V17.93h13.69L569.3,60Zm-27.57-31-.47-1.56-.47,1.56-6.23,16.73h12.94Z"/>
</svg>
    </div>

    
    <div class="user-level--2__show user-level--3__show">
        
<div class="lead-in">
            <p class="lead-in__title" id="read-more">Read More</p>
        </div>

    </div>

    
                    
    
        
        <a href="https://www.propublica.org/article/trump-funding-freeze-wildfire-season" class="story-promo section-articles" >

            
                                                                                                                                
                                    
                    <div class="story-promo__art">
                        <img
                            class="lazyload"
                            alt=""
                            src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271%27%20height%3D%271%27%20style%3D%27background%3Atransparent%27%2F%3E"
                            width="75"
                            height="75"
                            data-sizes="auto"
                            data-srcset="https://img.assets-d.propublica.org/v5/images/6c9bcda3-3706-40ca-b7dc-220c7c6ef13aOriginal_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=75&amp;q=70&amp;w=75&amp;s=ac79512b8d92b95ac502ba835bb037ba 75w, https://img.assets-d.propublica.org/v5/images/6c9bcda3-3706-40ca-b7dc-220c7c6ef13aOriginal_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=150&amp;q=70&amp;w=150&amp;s=aeaf4f1e724a7f42f978937b72181069 150w, https://img.assets-d.propublica.org/v5/images/6c9bcda3-3706-40ca-b7dc-220c7c6ef13aOriginal_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=400&amp;q=70&amp;w=400&amp;s=81a67daf806dca285ae2604a1ffb05b5 400w"
                            />
                    </div>
                
            
            <div class="story-promo__info" dir="auto">
                <strong class="story-promo__hed">How Trump’s Federal Funding and Hiring Freezes Are Leaving America Vulnerable to Catastrophic Wildfire</strong>
                            </div>
        </a>

    
</aside>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="138.0">One of those kids turned out to be her cousin, Vincent’s sister’s son, who was diagnosed with SMA in 2023 and then treated with Zolgensma. He walked at 10 months and now races around. “That helped me, in part, feel better about what we did,” Vincent said.</p>
        
    
                    
<p data-pp-blocktype="copy" data-pp-id="139.0">He still bristles at the drug’s price, which he blames on the payouts hauled in by those at AveXis and now Novartis.</p>

<p data-pp-blocktype="copy" data-pp-id="139.1">“All those people, they all came in at the 12th hour once the trial was funded and you had the breakthrough,” he said. “Once it was taken from us, it was all about greed.”</p>
        
    
                    
    
    
    <figure
        data-pp-id="140"
        data-pp-blocktype="callout"
        data-pp-location="callout"
        callout-slug="do-you-have-a-tip-for-propublica-help-us-do-journalism"
        class="bb-callout size08 center  wide-sm wrap | hide-print">

        
<div class="lead-in">
            <p class="lead-in__title" id="do-you-have-a-tip-for-propublica-help-us-do-journalism">Do You Have a Tip for ProPublica? Help Us Do Journalism.</p>
                <div class="lead-in__intro">
            <p>Got a story we should hear? Are you down to be a background source on a story about your community, your schools or your workplace? Get in touch.</p>

        </div>
    </div>


        <div class="bb-callout__wrapper">
            <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" src=https://propublica.jotform.com/jsform/232846680914969></script>
        </div>

        <div class="bb-callout__overlay | -js-hide"></div>
        <a href="#"
            class="bb-callout__expand-button | btn size02 center -js-hide"
            style="--button-color: var(--color-accent-70)"
            data-pp-view data-pp-category="get involved" data-pp-action="expand"
        >Expand</a>

    </figure>

    
            
    
                    <div class="article-body__bottom-notes" data-pp-location="bottom-note">
                                    

                                    
        <div class="article-body__note article-body__note--contributor-line" data-pp-location="bottom-note" >
                        <p><a href="https://www.propublica.org/people/kirsten-berg">Kirsten Berg</a> contributed research.</p>

        </div>

    
            </div><!-- end .article-body__bottom-notes -->
        
    </div>

    <footer class="article-footer" data-pp-location="article footer">
        
    
    <div class="topics-list  size02 out02 wrap left wide-md | hide-print">
        <p class="topics-list__label"><strong>Filed under —</strong></p>
        <ul class="topics-list__group">
                            <li class="topics-list__topic">
                    <a class="topics-list__topic-link" href="https://www.propublica.org/topics/health-care">Health Care</a>
                </li>
                    </ul>
    </div>
        
        <div class="rich-byline-group">






    <div class="rich-byline">

                                            <a class="rich-byline__headshot" href="https://www.propublica.org/people/robin-fields"><img alt="Portrait of Robin Fields" src="https://assets-c3.propublica.org/images/bio/_oneOne75w/20180409_portraits0181-robin-fields-sized.jpg" width="75" height="75" srcset="https://assets-c3.propublica.org/images/bio/_oneOne75w/20180409_portraits0181-robin-fields-sized.jpg 75w, https://assets-c3.propublica.org/images/bio/_oneOne150w/20180409_portraits0181-robin-fields-sized.jpg 150w" loading="lazy"/></a>
            
            <div class="rich-byline__info">
                <div class="stack stack--row">
                    <a class="rich-byline__name" href="https://www.propublica.org/people/robin-fields">Robin Fields</a>
                    <ul class="rich-byline__social-list | stack stack--row stack--spacing-2">
                                                                        <li>
                            <a
                                class="btn btn--icon-only btn--circular"
                                style="--button-color: var(--color-neutral-10); --button-text-color: var(--color-neutral-full); --button-size: 1.2rem;"
                                title="X (Twitter)" href="https://twitter.com/fieldsrobin"
                            >
                                <span class="icon" style="--icon-size: 1em">
                                    
<svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="currentColor">
    <title>X</title>
    <path d="M18.2439 2.25H21.5532L14.3251 10.5094L22.8282 21.75H16.172L10.9548 14.9344L4.99229 21.75H1.67822L9.40791 12.9141L1.25635 2.25H8.08135L12.7923 8.47969L18.2439 2.25ZM17.0813 19.7719H18.9142L7.08291 4.125H5.11416L17.0813 19.7719Z"/>
</svg>
                                </span>
                            </a>
                        </li>
                                                                                                                                            </ul> <!-- end .rich-byline__social-list -->
                </div>

                                    <p class="rich-byline__bio-short">Robin Fields is a reporter with ProPublica. She joined ProPublica as a reporter in 2008, became a senior editor in 2010 and served as managing editor from 2013 to 2022 prior to returning to the reporter role.</p>

                
                <ul class="rich-byline__more">
                    <li class="rich-byline__more-item">
                        <a href="https://www.propublica.org/people/robin-fields">More Stories</a>
                    </li>
                                        <li class="rich-byline__more-item" style="anchor-name: --contactAnchor146401;">
                                                

                
    


<script type="application/json" class="svelte-config">
                            {
            "componentName": "ContactTools",
            "props": {
                "emailAddress": "robin.fields@propublica.org",
                "signalNumber": "",
                "signalUsername": "",
                "phoneNumber": "",
                "buttonText": "Need to Get in Touch?",
                "buttonProps": {"bgColor":"var(--color-text-hed)","shape":"round-rect","textColor":"var(--color-bg)","textSize":"var(--scale-2)"}
            },
            "contextArray": []
        }
                        </script>
                        <div class="contact-tools" data-pp-click data-pp-location="contact tools"> <button class="button shape--pill    svelte-1qpwxqa" data-pp-skip="false" role="button" aria-haspopup="dialog" aria-expanded="false" data-state="closed" id="mQaVOOSzyP" data-melt-popover-trigger="" data-popover-trigger="" style="--button-bg-color: var(--color-neutral-10); --button-border: none; --button-color: var(--color-neutral-70); --button-font-size: var(--scale-2); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: 1em;"> <span class="text font--sans svelte-1qpwxqa">Contact Me</span>  </button>  </div>
                        <!--svelte-component-end-->
                                            </li>
                                    </ul> <!-- end .rich-byline__contact-list -->

                
            </div> <!-- end .rich-byline__info -->

        
    </div> <!-- end .rich-byline -->


</div> <!-- end .rich-byline-group -->
    </footer>

    </article>
    
    <div class="post-article" data-pp-location="post-article">

    </div><!-- end .post-article -->

</main><!-- end .content -->

        

<div class="topics-band | hide-print" data-pp-location="recirc more in topic">
    <strong class="topics-band__heading">
        <a href="https://www.propublica.org/topics/health-care" class="link-style--no-decoration link-style--hover-underline">More in Health Care</a>
        <div class="icon">
            

<svg role="img" xmlns="http://www.w3.org/2000/svg" fill="none" height="16" viewBox="0 0 16 16" width="16">
    <title>Caret</title>
    <path clip-rule="evenodd" d="m9.5858 8.00008-5.29289-5.2929 1.41421-1.41421 6.70708 6.70711-6.70708 6.70712-1.41421-1.4142z" fill="currentColor" fill-rule="evenodd"/>
</svg>
        </div>
    </strong>

    <ul class="topics-band-group | stack stack--row stack--spacing-gutter | scrollable-overflow scrollable-overflow--snap scrollable-overflow--full-below-xl">
                    

        
                    
<div class="story-card story-card--standard">
    
    

                    
                    
    
        <div class="lead-art">
            <a class="aspect-3-2" href="https://www.propublica.org/article/missouri-abortion-ban-amendment-planned-parenthood-lawsuit">
                <img
                    alt=""
                    src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%273%27%20height%3D%272%27%20style%3D%27background%3Atransparent%27%2F%3E"
                    srcset="https://img.assets-d.propublica.org/v5/images/MOAbortion2-2_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=267&amp;q=75&amp;w=400&amp;s=1336da1d61e7b293bc4f9dac9ec26b28 400w, https://img.assets-d.propublica.org/v5/images/MOAbortion2-2_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=533&amp;q=75&amp;w=800&amp;s=a072ef557dafc3c796027a34a9c11786 800w, https://img.assets-d.propublica.org/v5/images/MOAbortion2-2_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=1200&amp;s=6a759efe39a7c84ad57397bf9f0b8909 1200w, https://img.assets-d.propublica.org/v5/images/MOAbortion2-2_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1067&amp;q=75&amp;w=1600&amp;s=940693d162adf39526e174870bcf3e1d 1600w"
                    width="400"
                    height="267"
                    loading="lazy"
                    js-autosizes
                />
            </a>
        </div>
    
    <div class="story-card__description">
                
        <h3 class="story-card__hed" >
            <a href="https://www.propublica.org/article/missouri-abortion-ban-amendment-planned-parenthood-lawsuit">
                                    Three Months After Missouri Voted to Make Abortion Legal, Access Is Still Being Blocked
                            </a>
        </h3>

        <p class="story-card__dek" >
                            Reproductive rights are now enshrined in the state constitution, but Missouri’s main abortion provider is fighting legal hurdles to resume offering the procedure. Meanwhile, anti-abortion lawmakers strategize to prevent a return of abortion services.
                    </p>

        <p class="story-card__byline">
            by <a class="name" href="https://www.propublica.org/people/jeremy-kohler">Jeremy Kohler</a>,             <time class="timestamp" datetime="2025-02-05EST16:40">Feb. 5, 2025, 4:40 p.m. EST</time>
        </p>

            </div>
</div>
                    

        
                    
<div class="story-card story-card--standard">
    
    


                    
    
        <div class="lead-art">
            <a class="aspect-3-2" href="https://www.propublica.org/article/arizona-sober-homes-deaths-medicaid-fraud">
                <img
                    alt=""
                    src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%273%27%20height%3D%272%27%20style%3D%27background%3Atransparent%27%2F%3E"
                    srcset="https://img.assets-d.propublica.org/v5/images/20241213-Zehbrauskas-Sober-Homes019_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=267&amp;q=75&amp;w=400&amp;s=7e2c8a896a7bc772ef8ac8b59097eb3f 400w, https://img.assets-d.propublica.org/v5/images/20241213-Zehbrauskas-Sober-Homes019_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=533&amp;q=75&amp;w=800&amp;s=6ca5116e0968ba6962feb0fd5adac380 800w, https://img.assets-d.propublica.org/v5/images/20241213-Zehbrauskas-Sober-Homes019_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=1200&amp;s=e8f307b0af8a20a5070f81a7ad4f7138 1200w, https://img.assets-d.propublica.org/v5/images/20241213-Zehbrauskas-Sober-Homes019_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1067&amp;q=75&amp;w=1600&amp;s=118933a42ef6ef5176a5695777a53eae 1600w"
                    width="400"
                    height="267"
                    loading="lazy"
                    js-autosizes
                />
            </a>
        </div>
    
    <div class="story-card__description">
                
        <h3 class="story-card__hed" >
            <a href="https://www.propublica.org/article/arizona-sober-homes-deaths-medicaid-fraud">
                                    Dozens of People Died in Arizona Sober Living Homes as State Officials Fumbled Medicaid Fraud Response
                            </a>
        </h3>

        <p class="story-card__dek" >
                            Arizona officials acknowledged that a fraud scheme targeting Indigenous people with addictions cost taxpayers $2.5 billion. But they haven’t accounted publicly for the number of deaths tied to the scheme.
                    </p>

        <p class="story-card__byline">
            by <a class="name" href="https://www.propublica.org/people/mary-hudetz">Mary Hudetz</a>, ProPublica, and <a class="name" href="https://azcir.org/news/author/hbassett/">Hannah Bassett</a>, <a href="http://azcir.org">Arizona Center for Investigative Reporting</a>,             <time class="timestamp" datetime="2025-01-27EST07:00">Jan. 27, 2025, 7 a.m. EST</time>
        </p>

            </div>
</div>
                    

        
                    
<div class="story-card story-card--standard">
    
    

                    
                    
    
        <div class="lead-art">
            <a class="aspect-3-2" href="https://www.propublica.org/article/mississippi-law-mental-health-jailings-data">
                <img
                    alt=""
                    src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%273%27%20height%3D%272%27%20style%3D%27background%3Atransparent%27%2F%3E"
                    srcset="https://img.assets-d.propublica.org/v5/images/3X0A0297_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true_2025-01-22-185237_addh.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=267&amp;q=75&amp;w=400&amp;s=b0fa9118ca9ae9bca05d8dfe0a701634 400w, https://img.assets-d.propublica.org/v5/images/3X0A0297_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true_2025-01-22-185237_addh.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=533&amp;q=75&amp;w=800&amp;s=57785d03a1a25699faf68fa4bf153d99 800w, https://img.assets-d.propublica.org/v5/images/3X0A0297_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true_2025-01-22-185237_addh.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=1200&amp;s=36009ed7902e482c69644f5936a17a29 1200w, https://img.assets-d.propublica.org/v5/images/3X0A0297_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true_2025-01-22-185237_addh.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1067&amp;q=75&amp;w=1600&amp;s=49234e627a8a0ccc1468ea466e2d13bf 1600w"
                    width="400"
                    height="267"
                    loading="lazy"
                    js-autosizes
                />
            </a>
        </div>
    
    <div class="story-card__description">
                        <a class="story-card__series" href="https://www.propublica.org/series/committed-to-jail">Committed to Jail</a>
        
        <h3 class="story-card__hed" >
            <a href="https://www.propublica.org/article/mississippi-law-mental-health-jailings-data">
                                    Is a New Mississippi Law Decreasing Jailings of People Awaiting Mental Health Treatment? The State Doesn’t Know.
                            </a>
        </h3>

        <p class="story-card__dek" >
                            Community mental health centers, counties and a state agency have reported vastly different numbers of people who spent time in jail while waiting to be treated for serious mental illness.
                    </p>

        <p class="story-card__byline">
            by <span class="name">Gwen Dilworth</span>, <a href="https://mississippitoday.org/">Mississippi Today</a>,             <time class="timestamp" datetime="2025-01-23EST05:00">Jan. 23, 2025, 5 a.m. EST</time>
        </p>

                <p class="story-card__unit">Local Reporting Network</p>
            </div>
</div>
                    

        
                    
<div class="story-card story-card--standard">
    
    

                    
                    
    
        <div class="lead-art">
            <a class="aspect-3-2" href="https://www.propublica.org/article/mental-health-insurance-denials-patient-progress">
                <img
                    alt=""
                    src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%273%27%20height%3D%272%27%20style%3D%27background%3Atransparent%27%2F%3E"
                    srcset="https://img.assets-d.propublica.org/v5/images/20241028-PanichLinsman-Mental-Health-Sequence_0037_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.4211&amp;fp-y=0.1896&amp;h=267&amp;q=75&amp;w=400&amp;s=cb833261e36b0c45bf243f8b866149be 400w, https://img.assets-d.propublica.org/v5/images/20241028-PanichLinsman-Mental-Health-Sequence_0037_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.4211&amp;fp-y=0.1896&amp;h=533&amp;q=75&amp;w=800&amp;s=a8a67cd93ac2fe7f22f91acecc8c696d 800w, https://img.assets-d.propublica.org/v5/images/20241028-PanichLinsman-Mental-Health-Sequence_0037_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.4211&amp;fp-y=0.1896&amp;h=800&amp;q=75&amp;w=1200&amp;s=8618bbea6667fd7ee4c528d7e8ca2827 1200w, https://img.assets-d.propublica.org/v5/images/20241028-PanichLinsman-Mental-Health-Sequence_0037_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.4211&amp;fp-y=0.1896&amp;h=1067&amp;q=75&amp;w=1600&amp;s=e144ec129e5940afbd9acc7aa340dcc0 1600w"
                    width="400"
                    height="267"
                    loading="lazy"
                    js-autosizes
                />
            </a>
        </div>
    
    <div class="story-card__description">
                        <a class="story-card__series" href="https://www.propublica.org/series/americas-mental-barrier">America’s Mental Barrier</a>
        
        <h3 class="story-card__hed" >
            <a href="https://www.propublica.org/article/mental-health-insurance-denials-patient-progress">
                                    Her Mental Health Treatment Was Helping. That’s Why Insurance Cut Off Her Coverage.
                            </a>
        </h3>

        <p class="story-card__dek" >
                            Providers, patients and even some federal judges say progress-based insurance denials harm patients at key moments of mental health treatment.
                    </p>

        <p class="story-card__byline">
            by <a class="name" href="https://www.propublica.org/people/maya-miller">Maya Miller</a> and <a class="name" href="https://www.propublica.org/people/duaa-eldeib">Duaa Eldeib</a>,             <time class="timestamp" datetime="2024-12-31EST05:00">Dec. 31, 2024, 5 a.m. EST</time>
        </p>

            </div>
</div>
                    

        
                    
<div class="story-card story-card--standard">
    
    

                    
                    
    
        <div class="lead-art">
            <a class="aspect-3-2" href="https://www.propublica.org/article/mental-health-insurance-denials-unitedhealthcare-cigna-doctors">
                <img
                    alt=""
                    src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%273%27%20height%3D%272%27%20style%3D%27background%3Atransparent%27%2F%3E"
                    srcset="https://img.assets-d.propublica.org/v5/images/20241028-PanichLinsman-Mental-Health-Sequence_0102.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5079&amp;fp-y=0.2291&amp;h=267&amp;q=75&amp;w=400&amp;s=4bba3272384b08e58fac6ad0d998ca3e 400w, https://img.assets-d.propublica.org/v5/images/20241028-PanichLinsman-Mental-Health-Sequence_0102.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5079&amp;fp-y=0.2291&amp;h=533&amp;q=75&amp;w=800&amp;s=098a717d2b2c73c1d58d311d6c2e4a2c 800w, https://img.assets-d.propublica.org/v5/images/20241028-PanichLinsman-Mental-Health-Sequence_0102.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5079&amp;fp-y=0.2291&amp;h=800&amp;q=75&amp;w=1200&amp;s=89385b540dad844680703cf439929d7a 1200w, https://img.assets-d.propublica.org/v5/images/20241028-PanichLinsman-Mental-Health-Sequence_0102.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5079&amp;fp-y=0.2291&amp;h=1067&amp;q=75&amp;w=1600&amp;s=e80ca7cb4fab73b39cd56589ffefebba 1600w"
                    width="400"
                    height="267"
                    loading="lazy"
                    js-autosizes
                />
            </a>
        </div>
    
    <div class="story-card__description">
                        <a class="story-card__series" href="https://www.propublica.org/series/americas-mental-barrier">America’s Mental Barrier</a>
        
        <h3 class="story-card__hed" >
            <a href="https://www.propublica.org/article/mental-health-insurance-denials-unitedhealthcare-cigna-doctors">
                                    Insurers Continue to Rely on Doctors Whose Judgments Have Been Criticized by Courts
                            </a>
        </h3>

        <p class="story-card__dek" >
                            In dozens of cases ProPublica reviewed, judges found that some doctors working for these companies engaged in “selective readings” of medical evidence and “shut their eyes” to medical opinions opposing their conclusions.
                    </p>

        <p class="story-card__byline">
            by <a class="name" href="https://www.propublica.org/people/duaa-eldeib">Duaa Eldeib</a> and <a class="name" href="https://www.propublica.org/people/maya-miller">Maya Miller</a>, with research by <a class="name" href="https://www.propublica.org/people/kirsten-berg">Kirsten Berg</a>,             <time class="timestamp" datetime="2024-12-30EST06:00">Dec. 30, 2024, 6 a.m. EST</time>
        </p>

            </div>
</div>
                    

        
                    
<div class="story-card story-card--standard">
    
    

                    
                    
    
        <div class="lead-art">
            <a class="aspect-3-2" href="https://www.propublica.org/article/abortion-ban-deaths-cdc-maternal-health-care">
                <img
                    alt=""
                    src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%273%27%20height%3D%272%27%20style%3D%27background%3Atransparent%27%2F%3E"
                    srcset="https://img.assets-d.propublica.org/v5/images/SABA_ProPublica_AbortionDeaths_CDC_Final_preview_maxWidth_3000_maxHeight_3000_ppi_72_embedColorProfile_true_quality_95.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=267&amp;q=75&amp;w=400&amp;s=d1073a0036c73b0e5f185700508f19d4 400w, https://img.assets-d.propublica.org/v5/images/SABA_ProPublica_AbortionDeaths_CDC_Final_preview_maxWidth_3000_maxHeight_3000_ppi_72_embedColorProfile_true_quality_95.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=533&amp;q=75&amp;w=800&amp;s=07238eb95b0a2e6c9891bbb20bdefe05 800w, https://img.assets-d.propublica.org/v5/images/SABA_ProPublica_AbortionDeaths_CDC_Final_preview_maxWidth_3000_maxHeight_3000_ppi_72_embedColorProfile_true_quality_95.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=1200&amp;s=546fe7da12adef64bb78da84b8c8b61d 1200w, https://img.assets-d.propublica.org/v5/images/SABA_ProPublica_AbortionDeaths_CDC_Final_preview_maxWidth_3000_maxHeight_3000_ppi_72_embedColorProfile_true_quality_95.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1067&amp;q=75&amp;w=1600&amp;s=814ba78a1b7fb902d2325711564b4cbf 1600w"
                    width="400"
                    height="267"
                    loading="lazy"
                    js-autosizes
                />
            </a>
        </div>
    
    <div class="story-card__description">
                        <a class="story-card__series" href="https://www.propublica.org/series/life-of-the-mother">Life of the Mother</a>
        
        <h3 class="story-card__hed" >
            <a href="https://www.propublica.org/article/abortion-ban-deaths-cdc-maternal-health-care">
                                    The CDC Hasn’t Asked States to Track Deaths Linked to Abortion Bans
                            </a>
        </h3>

        <p class="story-card__dek" >
                            The Biden administration hasn’t delivered on its goals of measuring the public health impact of abortion bans. Experts say it’s a missed opportunity to study how the laws may lead to deaths and long-term injuries.
                    </p>

        <p class="story-card__byline">
            by <a class="name" href="https://www.propublica.org/people/kavitha-surana">Kavitha Surana</a>, <a class="name" href="https://www.propublica.org/people/robin-fields">Robin Fields</a> and <a class="name" href="https://www.propublica.org/people/ziva-branstetter">Ziva Branstetter</a>,             <time class="timestamp" datetime="2024-12-20EST05:00">Dec. 20, 2024, 5 a.m. EST</time>
        </p>

            </div>
</div>
            </ul>
</div>



    
<div class="most-read | hide-print" data-pp-location="most read">

    <strong class="most-read__heading">Most Read</strong>

    <ol class="most-read-group">
                    <div class="most-read-story">
                                    

        
                    
<div class="story-card story-card--standard">
    
    


                    
    
        <div class="lead-art">
            <a class="aspect-3-2" href="https://www.propublica.org/article/usaid-peter-marocco-state-department-bosnia-serbia-diplomacy-trump-foreign-policy">
                <img
                    alt=""
                    src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%273%27%20height%3D%272%27%20style%3D%27background%3Atransparent%27%2F%3E"
                    srcset="https://img.assets-d.propublica.org/v5/images/20250215-marocco-3x2-GettyImages-1148910129.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=267&amp;q=75&amp;w=400&amp;s=8f4a18a9f5cb7043801b1b9f20b9583c 400w, https://img.assets-d.propublica.org/v5/images/20250215-marocco-3x2-GettyImages-1148910129.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=533&amp;q=75&amp;w=800&amp;s=b1a5c7120d0eb23f263419f8d703ead8 800w, https://img.assets-d.propublica.org/v5/images/20250215-marocco-3x2-GettyImages-1148910129.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=800&amp;q=75&amp;w=1200&amp;s=7ab3c98f4b0b0066484bf64a5985da42 1200w, https://img.assets-d.propublica.org/v5/images/20250215-marocco-3x2-GettyImages-1148910129.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=1067&amp;q=75&amp;w=1600&amp;s=ecbb3a5c2a036b032cc52fd9b4f65202 1600w"
                    width="400"
                    height="267"
                    loading="lazy"
                    js-autosizes
                />
            </a>
        </div>
    
    <div class="story-card__description">
                
        <h3 class="story-card__hed" >
            <a href="https://www.propublica.org/article/usaid-peter-marocco-state-department-bosnia-serbia-diplomacy-trump-foreign-policy">
                                    Trump Official Destroying USAID Secretly Met With Christian Nationalists Abroad in Defiance of U.S. Policy
                            </a>
        </h3>

        <p class="story-card__dek" >
                            Now one of the most powerful people in the U.S. government, Peter Marocco’s turbulent tenure during the first Trump administration sheds light on his current efforts to dismantle the American foreign aid system from the inside out.
                    </p>

        <p class="story-card__byline">
            by <a class="name" href="https://www.propublica.org/people/brett-murphy">Brett Murphy</a> and <a class="name" href="https://www.propublica.org/people/anna-maria-barry-jester">Anna Maria Barry-Jester</a>,             <time class="timestamp" datetime="2025-02-15EST21:00">Feb. 15, 2025, 9 p.m. EST</time>
        </p>

            </div>
</div>
                            </div>
                    <div class="most-read-story">
                                    

        
                    
<div class="story-card story-card--standard">
    
    

                    
                    
    
        <div class="lead-art">
            <a class="aspect-3-2" href="https://www.propublica.org/article/elon-musk-doge-staffers-additional-names">
                <img
                    alt=""
                    src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%273%27%20height%3D%272%27%20style%3D%27background%3Atransparent%27%2F%3E"
                    srcset="https://img.assets-d.propublica.org/v5/images/DOGE-Tracker-Update_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.3674&amp;fp-y=0.3396&amp;h=267&amp;q=75&amp;w=400&amp;s=1c7be9da7f2ccc17e2959073a67afb70 400w, https://img.assets-d.propublica.org/v5/images/DOGE-Tracker-Update_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.3674&amp;fp-y=0.3396&amp;h=533&amp;q=75&amp;w=800&amp;s=df52c3f171797a1b98e90018a3249afa 800w, https://img.assets-d.propublica.org/v5/images/DOGE-Tracker-Update_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.3674&amp;fp-y=0.3396&amp;h=800&amp;q=75&amp;w=1200&amp;s=d668fbc562f5ff4e9d29fca8a68eb966 1200w, https://img.assets-d.propublica.org/v5/images/DOGE-Tracker-Update_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.3674&amp;fp-y=0.3396&amp;h=1067&amp;q=75&amp;w=1600&amp;s=07683b81a2bae501ab8bbe5b85947aba 1600w"
                    width="400"
                    height="267"
                    loading="lazy"
                    js-autosizes
                />
            </a>
        </div>
    
    <div class="story-card__description">
                
        <h3 class="story-card__hed" >
            <a href="https://www.propublica.org/article/elon-musk-doge-staffers-additional-names">
                                    The Staffers Helping Elon Musk Dismantle and Downsize the U.S. Government, One Agency at a Time
                            </a>
        </h3>

        <p class="story-card__dek" >
                            Musk and his lieutenants are reshaping the government and its mission with the blessing of President Trump. ProPublica has confirmed the names and roles of more than 30 staffers affiliated with the billionaire.
                    </p>

        <p class="story-card__byline">
            by <a class="name" href="https://www.propublica.org/people/christopher-bing">Christopher Bing</a> and <a class="name" href="https://www.propublica.org/people/annie-waldman">Annie Waldman</a>,             <time class="timestamp" datetime="2025-02-11EST18:25">Feb. 11, 2025, 6:25 p.m. EST</time>
        </p>

            </div>
</div>
                            </div>
                    <div class="most-read-story">
                                    

        
                    
<div class="story-card story-card--standard">
    
    

                    
                    
    
        <div class="lead-art thumbnail">
            <a class="aspect-1-1" href="https://www.propublica.org/article/whats-a-pig-butchering-scam-heres-how-to-avoid-falling-victim-to-one">
                <img
                    alt=""
                    src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271%27%20height%3D%271%27%20style%3D%27background%3Atransparent%27%2F%3E"
                    srcset="https://img.assets-d.propublica.org/v5/images/20220919-pig-butchering-scam.jpeg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=105&amp;q=75&amp;w=105&amp;s=eaf5dc5893e9e235b92548e847c00f41 105w, https://img.assets-d.propublica.org/v5/images/20220919-pig-butchering-scam.jpeg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=210&amp;q=75&amp;w=210&amp;s=8014404eb75e6553fc48b41ae65e0962 210w"
                    width="105"
                    height="105"
                    loading="lazy"
                    js-autosizes
                />
            </a>
        </div>
    
    <div class="story-card__description">
                
        <h3 class="story-card__hed" >
            <a href="https://www.propublica.org/article/whats-a-pig-butchering-scam-heres-how-to-avoid-falling-victim-to-one">
                                    What’s a Pig Butchering Scam? Here’s How to Avoid Falling Victim to One.
                            </a>
        </h3>

        <p class="story-card__dek" >
                            Thousands have lost huge sums after being lured into fraudulent online investment schemes by seemingly attractive strangers who strike up online conversations with them. Here’s a guide to spotting the telltale signs.
                    </p>

        <p class="story-card__byline">
            by <a class="name" href="https://www.propublica.org/people/cezary-podkul">Cezary Podkul</a>,             <time class="timestamp" datetime="2022-09-19EDT15:50">Sept. 19, 2022, 3:50 p.m. EDT</time>
        </p>

            </div>
</div>
                            </div>
                    <div class="most-read-story">
                                    

        
                    
<div class="story-card story-card--standard">
    
    

                    
                    
    
        <div class="lead-art thumbnail">
            <a class="aspect-1-1" href="https://www.propublica.org/article/department-of-education-civil-rights-office-investigations">
                <img
                    alt=""
                    src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271%27%20height%3D%271%27%20style%3D%27background%3Atransparent%27%2F%3E"
                    srcset="https://img.assets-d.propublica.org/v5/images/ProPublica-EmilyScherer-TrumpDOE-Final-1_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=105&amp;q=75&amp;w=105&amp;s=2c9b05b549623b15a993e17e8190fd77 105w, https://img.assets-d.propublica.org/v5/images/ProPublica-EmilyScherer-TrumpDOE-Final-1_maxWidth_3000_maxHeight_3000_ppi_72_quality_95_embedColorProfile_true.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=210&amp;q=75&amp;w=210&amp;s=d7b2ac9d366654c968b9baaa123a8c74 210w"
                    width="105"
                    height="105"
                    loading="lazy"
                    js-autosizes
                />
            </a>
        </div>
    
    <div class="story-card__description">
                
        <h3 class="story-card__hed" >
            <a href="https://www.propublica.org/article/department-of-education-civil-rights-office-investigations">
                                    “We’ve Been Essentially Muzzled”: Department of Education Halts Thousands of Civil Rights Investigations Under Trump
                            </a>
        </h3>

        <p class="story-card__dek" >
                            Since Inauguration Day, the Office for Civil Rights has only opened about 20 investigations focused on Trump’s priorities, placing more than 10,000 student complaints related to disability access and sexual and racial harassment on hold.
                    </p>

        <p class="story-card__byline">
            by <a class="name" href="https://www.propublica.org/people/jennifer-smith-richards">Jennifer Smith Richards</a> and <a class="name" href="https://www.propublica.org/people/jodi-cohen">Jodi S. Cohen</a>,             <time class="timestamp" datetime="2025-02-13EST21:30">Feb. 13, 2025, 9:30 p.m. EST</time>
        </p>

            </div>
</div>
                            </div>
                    <div class="most-read-story">
                                    

        
                    
<div class="story-card story-card--standard">
    
    

                    
                    
    
        <div class="lead-art thumbnail">
            <a class="aspect-1-1" href="https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis">
                <img
                    alt=""
                    src="data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271%27%20height%3D%271%27%20style%3D%27background%3Atransparent%27%2F%3E"
                    srcset="https://img.assets-d.propublica.org/v5/images/ProPublica_Owen_Gent_Zolgensma_Final_Artwork-3x2web.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=105&amp;q=75&amp;w=105&amp;s=59ee57983a75bdbd4740c4022677a022 105w, https://img.assets-d.propublica.org/v5/images/ProPublica_Owen_Gent_Zolgensma_Final_Artwork-3x2web.jpg?crop=focalpoint&amp;fit=crop&amp;fm=webp&amp;fp-x=0.5&amp;fp-y=0.5&amp;h=210&amp;q=75&amp;w=210&amp;s=4af33d1758a64a4e821dab6ad4731131 210w"
                    width="105"
                    height="105"
                    loading="lazy"
                    js-autosizes
                />
            </a>
        </div>
    
    <div class="story-card__description">
                
        <h3 class="story-card__hed" >
            <a href="https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis">
                                    What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing
                            </a>
        </h3>

        <p class="story-card__dek" >
                            Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the widely held conception that high prices reflect huge industry investments in innovation.
                    </p>

        <p class="story-card__byline">
            by <a class="name" href="https://www.propublica.org/people/robin-fields">Robin Fields</a>,             <time class="timestamp" datetime="2025-02-12EST08:00">Feb. 12, 2025, 8 a.m. EST</time>
        </p>

            </div>
</div>
                            </div>
            </ol> <!-- end .most-read-group -->

</div> <!-- end .most-read -->



    
<style>

    /* re-assert som CSS Custom Properties from v5 */
    .admin-shortcuts {
        --fonts-sans: "Graphik", sans-serif;
        --scale0: 1rem;
        --scale-1: 13px;
        --scale-2: 11px;
        --scale-3: 9px;
        --spacing-2: 4px;
        --spacing-1: 8px;
        --spacing0: 16px;
        --spacing1: 24px;
        --spacing2: 32px;
        --spacing3: 64px;
    }

    .admin-shortcuts {
        position: fixed;
        z-index: 10000;
        bottom: 0;
        right: var(--spacing0);
        width: auto;
        display: flex;
        flex-direction: row;
        justify-content: center;
        align-content: center;
        gap: var(--spacing0);
        padding: var(--spacing-1) var(--spacing0);
        background-color: black;
        color: white;
        font-size: var(--scale-1);
        font-family: var(--fonts-sans);
        border-radius: 0.25rem 0.25rem 0 0;
    }

    .admin-shortcuts__link {
        display: inline-block;
        text-decoration: none;
        color: inherit;
        display: flex;
        gap: 0.33em;
    }

    .admin-shortcuts__user:before {
        content: "";
        width: 0.66em;
        height: 0.66em;
        border-radius: 100%;
        background-color: #14b84f; /* green 50 */
    }

    .admin-shortcuts__user {
        padding-right: calc(var(--spacing-2) * 4);
        border-right: 1px solid hsla(0, 0%, 100%, 0.2);
    }

    .admin-shortcuts__user:before,
    .admin-shortcuts__icon {
        align-self: center;
    }

    .admin-shortcuts__icon {
        width: 1.1em;
        height: 1.1em;
    }
</style>


    <script type="application/json" class="svelte-config">
                            {"componentName":"SiteFooter","props":{"newsletterSignupProps":{"source":"https://www.propublica.org/","region":"national"}},"contextArray":[]}
                        </script>
                        <footer class="site-footer hide-print svelte-m9jkvx" id="site-footer" data-pp-location="footer"><div class="site-footer__section-newsletter svelte-m9jkvx"><div class="site-footer__newsletter-wrap svelte-m9jkvx"><strong class="site-footer__newsletter-heading svelte-m9jkvx" data-svelte-h="svelte-1f8pah3">Stay informed with the Daily Digest.</strong> <div class="newsletter-signup__input-wrap svelte-m9jkvx"><form class="newsletter-signup" action="https://signup.propublica.org/newsletter/turing" method="post" name="newsletterSignup"><div role="region" aria-live="polite" class="newsletter-signup__feedback" data-svelte-h="svelte-2nawdb"><p class="newsletter-signup__error-message"></p></div> <div class="newsletter-signup__input-wrap newsletter-signup__input-wrap--null svelte-10wydf7"><span class="icon"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><title>Mail</title><path d="M4 4h16c1.1 0 2 .9 2 2v12c0 1.1-.9 2-2 2H4c-1.1 0-2-.9-2-2V6c0-1.1.9-2 2-2z"></path><polyline points="22,6 12,13 2,6"></polyline></svg></span> <label for="site-footer-signup" class="a11y">Email Address:</label>  <input class="newsletter-signup__input-text svelte-10wydf7" type="email" placeholder="Enter your email" id="site-footer-signup" name="email" onfocus="recaptchaInit()" required> <div class="newsletter-signup__submit-btn-wrapper svelte-10wydf7"> <button class="button shape--circle  button-is-icon-only  svelte-1qpwxqa" data-pp-skip="false" style="--button-bg-color: transparent; --button-border: none; --button-color: var(--color-light-none); --button-font-size: var(--scale-1); --button-horizontal-spacing: var(--scale-1); --button-size: var(--scale3); --icon-size: fill;"><span class="icon-before svelte-1qpwxqa"><svg role="img" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><title>Arrow Right</title><path fill-rule="evenodd" clip-rule="evenodd" d="M22 12C22 17.5228 17.5228 22 12 22C6.47715 22 2 17.5228 2 12C2 6.47715 6.47715 2 12 2C17.5228 2 22 6.47715 22 12ZM16.7064 11.2922L12.7071 7.29289C12.3166 6.90237 11.6834 6.90237 11.2929 7.29289C10.9024 7.68342 10.9024 8.31658 11.2929 8.70711L13.5858 11H8C7.44772 11 7 11.4477 7 12C7 12.5523 7.44772 13 8 13H13.5858L11.2929 15.2929C10.9024 15.6834 10.9024 16.3166 11.2929 16.7071C11.6834 17.0976 12.3166 17.0976 12.7071 16.7071L16.7064 12.7078L16.7136 12.7005C16.8901 12.5208 16.9992 12.2746 17 12.003L17 12L17 11.997C16.9996 11.8625 16.9727 11.7343 16.9241 11.6172C16.8764 11.502 16.8063 11.3938 16.7136 11.2995L16.7064 11.2922Z" fill="currentColor"></path></svg></span> <span class="text font--sans svelte-1qpwxqa a11y">Sign Up</span>  </button></div> <input type="hidden" name="stlist" value="The Daily Digest">  <input type="hidden" name="success_location" value="https://www.propublica.org/forms/thankyou"> <input type="hidden" name="error_location" value="https://www.propublica.org/forms/error"> <input type="hidden" name="placement" value="site-footer"> <input type="hidden" name="region" value="national"> <input type="hidden" name="source" value="https://www.propublica.org/"></div> <div class="newsletter-signup__post-signup-prompt" role="region" aria-live="polite" data-svelte-h="svelte-1uvtbcq"></div></form>  </div></div> </div>  <div class="site-footer__wrap-outer svelte-m9jkvx"><div class="site-footer__wrap-inner svelte-m9jkvx"> <div class="site-footer__section-logo svelte-m9jkvx"><a class="site-footer__wordmark svelte-m9jkvx" href="https://www.propublica.org/"><svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 574.24 75" fill="currentColor"><title>ProPublica</title><path d="M66.4,13.48,66,14.91l6.23,11.45,1.15.47L75,26.29V75H50.95A41.2,41.2,0,0,0,62.13,46.88a40.61,40.61,0,0,0-3.39-16.26,45.17,45.17,0,0,1,7.79-4.95l1.69-.2.14-.41L65,18.83H64.5l-.88,1.29c-2.91,1.9-4.67,2.3-8.54,3.79A41.35,41.35,0,0,0,20.46,5.42,39.87,39.87,0,0,0,0,10.91V0H75V8.81ZM57.32,47A37.54,37.54,0,0,1,44.65,75H0V16A37,37,0,0,1,57.32,47ZM43.7,37.06c0-8.13-6-12-17.75-12H7.18v3.66l4.2.95V62.2l-4.2.95v3.73H27.85V63.14l-7.18-.95V50.14h5.15C37.26,50.14,43.7,45.53,43.7,37.06Zm-9.76.27c0,5.15-2.78,8.33-7.25,8.33h-6V29.47H27C31.37,29.47,33.94,32.32,33.94,37.33Z"></path><path d="M116.53,60.07l9.15,1.08v4.2H99.39v-4.2l5.28-1.36v-44l-5.28-1.36V10.41H123c15.31,0,22.9,5.28,22.9,16.13,0,11.18-8.33,17.41-23.1,17.41h-6.3Zm0-21.14h6.84c6.44,0,10.5-4.61,10.5-12.06,0-7.18-3.73-11.45-10.09-11.45h-7.25Z"></path><path d="M200.74,61.15v4.2H185.9l-16-20.6h-2.51v15l5.28,1.36v4.2H150.27v-4.2l5.28-1.36V23.35l-5-1.36V17.93H175.2c10.5,0,17.55,5.08,17.55,12.67,0,8.4-5.76,12.2-11,13.55l13.48,15.79ZM167.41,39.74h4.47c5.76,0,8.81-3.18,8.81-8.88,0-5.35-2.85-7.93-8.81-7.93h-4.47Z"></path><path d="M199.59,41.64c0-14.77,9.82-24.73,25.68-24.73s25.68,10,25.68,24.73-9.82,24.73-25.68,24.73S199.59,56.48,199.59,41.64Zm38.89,0c0-9.69-3.25-19.17-13.21-19.17S212.05,32,212.05,41.64s3.25,19.17,13.21,19.17S238.48,51.33,238.48,41.64Z"></path><path d="M270.79,60.07l9.15,1.08v4.2H253.31v-4.2l5.62-1.36v-44l-5.62-1.36V10.41h24c15.31,0,22.9,5.28,22.9,16.13,0,11.18-8.33,17.41-23.1,17.41h-6.3Zm0-21.14h6.84c6.44,0,10.5-4.61,10.5-12.06,0-7.18-3.73-11.45-10.1-11.45h-7.25Z"></path><path d="M354.26,22l-4.95,1.36V47c0,12.87-7.79,19.38-20.05,19.38-13.62,0-20.73-7.86-20.73-20v-23L303.58,22V17.93h22V22l-5.08,1.36V47.74c0,7.25,4.34,12.06,11.45,12.06,6.84,0,11.25-4.47,11.25-11.31V23.35L338.14,22V17.93h16.12Z"></path><path d="M403.85,52.21c0,8.88-7.11,13.14-22,13.14H357.58v-4.2l5.56-1.36V23.35L358.26,22V17.93h23.92c12.6,0,19.51,3.79,19.51,11.72,0,6.17-4.06,9.08-10.91,9.89v.27C399.31,40.76,403.85,45.1,403.85,52.21ZM375,38.32h5.76c6.1,0,9-2.78,9-7.79,0-5.22-3.12-7.59-9-7.59H375Zm16.8,13.41c0-5.62-3.79-8.67-11.25-8.67H375V60.34h6.64C388.07,60.34,391.79,57.29,391.79,51.74Z"></path><path d="M451.07,48.62l-4.4,16.73H408v-4.2l5.28-1.36V23.35L407.65,22V17.93h22.76V22l-5.28,1.36v37l14.16-.81L447,47.26Z"></path><path d="M475.4,61.15v4.2H453v-4.2l5.28-1.36V23.35L453,22V17.93H475.4V22l-5.28,1.36V59.8Z"></path><path d="M478,41.78c0-15.85,12.13-24.86,27-24.86a35.6,35.6,0,0,1,18.29,5.15l-2,13.21h-4.2l-1.69-9.08a13.23,13.23,0,0,0-10.09-4.13c-9.15,0-14.7,6.57-14.7,18.22,0,13.21,6.84,19.31,15.24,19.31,6.17,0,10.23-3.39,13.41-9.55l4.27,2c-4.27,10-11.65,14.36-21.07,14.36C488.4,66.37,478,56.48,478,41.78Z"></path><path d="M574.24,61.15v4.2H551.48v-4.2L557,60l-2.85-8.13h-16.6l-3.12,8.2,5.42,1.15-.07,4.2-16.53-.07v-4.2l4.27-1.08,14.9-37.33-4-1.29V17.93h13.69L569.3,60Zm-27.57-31-.47-1.56-.47,1.56-6.23,16.73h12.94Z"></path></svg></a> <strong class="site-footer__tagline svelte-m9jkvx" data-svelte-h="svelte-1xxi0b1">Investigative Journalism in the Public Interest</strong> <p class="site-footer__copyright svelte-m9jkvx">© Copyright 2025 Pro Publica Inc.</p></div>   <nav class="site-footer__section-links svelte-m9jkvx">   <div class="site-footer__links-sites svelte-m9jkvx"> <strong class="site-footer__links-heading svelte-m9jkvx">Sites</strong> <ul class="site-footer__links-list svelte-m9jkvx hide-below-sm" id="site-footer__links-list-sites"><li class="site-footer__link"><a href="https://www.propublica.org/" class="svelte-m9jkvx">ProPublica</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/local-reporting-network/" class="svelte-m9jkvx">Local Reporting Network</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/texas/" class="svelte-m9jkvx">Texas Tribune Partnership</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/datastore/" class="svelte-m9jkvx">The Data Store</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/electionland/" class="svelte-m9jkvx">Electionland</a>  </li></ul> </div>   <div class="site-footer__links-sections svelte-m9jkvx"> <strong class="site-footer__links-heading svelte-m9jkvx">Sections</strong> <ul class="site-footer__links-list svelte-m9jkvx hide-below-sm" id="site-footer__links-list-sections"><li class="site-footer__link"><a href="https://www.propublica.org/topics/" class="svelte-m9jkvx">Topics</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/series/" class="svelte-m9jkvx">Series</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/video/" class="svelte-m9jkvx">Videos</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/newsapps/" class="svelte-m9jkvx">News Apps</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/getinvolved/" class="svelte-m9jkvx">Get Involved</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/nerds/" class="svelte-m9jkvx">The Nerd Blog</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/atpropublica/" class="svelte-m9jkvx">@ProPublica</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/events/" class="svelte-m9jkvx">Events</a>  </li></ul> </div>   <div class="site-footer__links-info svelte-m9jkvx"> <strong class="site-footer__links-heading svelte-m9jkvx">Info</strong> <ul class="site-footer__links-list svelte-m9jkvx hide-below-sm" id="site-footer__links-list-info"><li class="site-footer__link"><a href="https://www.propublica.org/about/" class="svelte-m9jkvx">About</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/leadership/" class="svelte-m9jkvx">Board and Advisors</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/staff/" class="svelte-m9jkvx">Officers and Staff</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/diversity/" class="svelte-m9jkvx">Diversity</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/jobs/" class="svelte-m9jkvx">Jobs</a> and <a href="https://www.propublica.org/fellowships/" class="svelte-m9jkvx">Fellowships</a> </li><li class="site-footer__link"><a href="https://www.propublica.org/media-center/" class="svelte-m9jkvx">Media Center</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/reports/" class="svelte-m9jkvx">Reports</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/impact/" class="svelte-m9jkvx">Impact</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/awards/" class="svelte-m9jkvx">Awards</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/corrections/" class="svelte-m9jkvx">Corrections</a>  </li></ul> </div>   <div class="site-footer__links-policies svelte-m9jkvx"> <strong class="site-footer__links-heading svelte-m9jkvx">Policies</strong> <ul class="site-footer__links-list svelte-m9jkvx hide-below-sm" id="site-footer__links-list-policies"><li class="site-footer__link"><a href="https://www.propublica.org/code-of-ethics/" class="svelte-m9jkvx">Code of Ethics</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/advertising/" class="svelte-m9jkvx">Advertising Policy</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/legal/" class="svelte-m9jkvx">Privacy Policy</a>  </li></ul> </div>   <div class="site-footer__links-follow svelte-m9jkvx"> <strong class="site-footer__links-heading svelte-m9jkvx">Follow</strong> <ul class="site-footer__links-list svelte-m9jkvx hide-below-sm" id="site-footer__links-list-follow"><li class="site-footer__link"><a href="https://www.propublica.org/newsletters/" data-pp-view="" data-pp-action="visit" class="svelte-m9jkvx">Newsletters</a>  </li><li class="site-footer__link"><a href="https://itunes.apple.com/us/app/propublica/id355298887?mt=8" class="svelte-m9jkvx">iOS</a> and <a href="https://play.google.com/store/apps/details?id=com.propublica&amp;amp;hl=en" class="svelte-m9jkvx">Android</a> </li><li class="site-footer__link"><a href="https://www.propublica.org/feeds/propublica/main" class="svelte-m9jkvx">RSS Feed</a>  </li></ul> </div>   <div class="site-footer__links-more svelte-m9jkvx"> <strong class="site-footer__links-heading svelte-m9jkvx">More</strong> <ul class="site-footer__links-list svelte-m9jkvx hide-below-sm" id="site-footer__links-list-more"><li class="site-footer__link"><a href="https://www.propublica.org/tips/" class="svelte-m9jkvx">Send Us Tips</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/steal-our-stories/" class="svelte-m9jkvx">Steal Our Stories</a>  </li><li class="site-footer__link"><a href="http://p53lf57qovyuvwsc6xnrppyply3vtqm7l6pcobkmyqsiofyeznfu5uqd.onion/" class="svelte-m9jkvx">Browse via Tor</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/contact/" class="svelte-m9jkvx">Contact Us</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/donate/" data-pp-view="" data-pp-action="visit classy" class="svelte-m9jkvx">Donate</a>  </li><li class="site-footer__link"><a href="https://www.propublica.org/support/other-ways-to-give/" class="svelte-m9jkvx">More Ways to Give</a>  </li></ul> </div></nav> </div> </div>  </footer>
                        <!--svelte-component-end-->
                        
    <div class="modal-republish | modal -js-hide" tabindex="-1" role="dialog" title="Republish Story" data-pp-location="republish modal">
    <div class="content">

    <div class="modal__header">
        <a class="modal__close-button btn btn--icon-only btn--transparent" style="--button-size: var(--scale3)" href="#" tabindex="0"
            role="button" aria-labelledby="modal-republish__hed" aria-describedby="modal-republish__intro" data-pp-action="republish close">
            <div class="btn__icon" aria-hidden="true">
                
<svg role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round">
    <title>Close</title>
    <line x1="18" y1="6" x2="6" y2="18"></line>
    <line x1="6" y1="6" x2="18" y2="18"></line>
</svg>
            </div>
            <span class="a11y">Close this dialogue</span>
        </a>
    </div>
    <!-- end .collapsible-header -->

    <div class="modal-republish__content-wrapper">

        <div class="modal__content modal-republish__content">

            <div class="modal-republish__instructions republish-instructions">

                <h3 id="modal-republish__hed">Republish This Story for Free</h3>

                <p class="modal-republish__license"><a rel="license" href="https://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons License (CC BY-NC-ND 3.0)</a></p>

                <hr/>

                <p id="modal-republish__intro" class="modal-republish__intro">Thank you for your interest in republishing this story. You are free to republish it so long as you do the following:</p>

                <ul>
                    <li>You have to credit <em>ProPublica and any co-reporting partners</em>. In the byline, we prefer “Author Name, Publication(s).” At the top of the text of your story, include a line that reads: “This story was originally published by ProPublica.” You must link the word “ProPublica” to the original URL of the story.</li>

                    <li>If you’re republishing online, you must link to the URL of this story on propublica.org, include all of the links from our story, including our newsletter sign up language and link, and use our <a href="/pixelping">PixelPing tag</a>.</li>

                    <li>If you use canonical metadata, please use the ProPublica URL. For more information about canonical metadata, <a href="https://support.google.com/webmasters/answer/139066?hl=en">refer to this Google SEO link</a>.</li>

                    <li>You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week,” and “Portland, Ore.” to “Portland” or “here.”)</li>

                    <li>You cannot republish our photographs or illustrations without specific permission. Please contact <a href="/cdn-cgi/l/email-protection#d2bfb7b6bbb3a0bbb5baa6a192a2a0bda2a7b0bebbb1b3fcbda0b5"><span class="__cf_email__" data-cfemail="dfb2babbb6beadb6b8b7abac9fafadb0afaabdb3b6bcbef1b0adb8">[email&#160;protected]</span></a>.</li>

                    <li>It’s okay to put our stories on pages with ads, but not ads specifically sold against our stories. You can’t state or imply that donations to your organization support ProPublica’s work.</li>

                    <li>You can’t sell our material separately or syndicate it. This includes publishing or syndicating our work on platforms or apps such as Apple News, Google News, etc.</li>

                    <li>You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually. (To inquire about syndication or licensing opportunities, contact <a href="/cdn-cgi/l/email-protection#1b7772787e756872757c5b6b69746b6e797772787a3574697c"><span class="__cf_email__" data-cfemail="c5a9aca6a0abb6acaba285b5b7aab5b0a7a9aca6a4ebaab7a2">[email&#160;protected]</span></a>.)</li>

                    <li>You can’t use our work to populate a website designed to improve rankings on search engines or solely to gain revenue from network-based advertisements.</li>

                    <li>We do not generally permit translation of our stories into another language.</li>

                    <li>Any website our stories appear on must include a prominent and effective way to contact you.</li>

                </ul>
            </div>

            <div class="modal-republish__section-copy">
                <textarea readonly class="-js-copy-textarea" aria-hidden="true" tabindex="-1"></textarea>
                <a href="#" class="btn -js-copy-btn" style="--button-color: var(--color-accent-50)" data-pp-action="republish copy">Copy HTML</a>
            </div>

        </div>

    </div>

    </div>
</div>
<!-- end #modal-republish -->

          
  
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="application/json" class="svelte-config">
                            {"componentName":"BottomPanelCta","props":{"contentUrl":"https://www.propublica.org//api_components/modal-default.json"},"contextArray":[]}
                        </script>
                         <div data-pp-location="modal" data-pp-view data-pp-category="newsletter_signup" id="cta" class="cta cta-type-panel cta-fixed cta-closed svelte-rz6ji1" aria-hidden="true"><button id="cta-close" class="cta-close svelte-rz6ji1" data-svelte-h="svelte-12f7hfy"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svelte-rz6ji1"><line x1="18" y1="6" x2="6" y2="18"></line><line x1="6" y1="6" x2="18" y2="18"></line></svg></button> <div class="cta-container cta-undefined svelte-rz6ji1"><div class="cta-message svelte-rz6ji1"><h2 class="cta-heading svelte-rz6ji1">undefined</h2> <p class="cta-text svelte-rz6ji1">undefined</p></div> </div></div> <div id="cta-toast" class="cta-toast  svelte-rz6ji1" role="alert" style="background-color: var(--blue-70);"><div id="cta-toast-text" class="cta-toast-text svelte-rz6ji1"></div> <button id="cta-toast-button" class="cta-toast-button svelte-rz6ji1" data-svelte-h="svelte-8kx5h6"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svelte-rz6ji1"><line x1="18" y1="6" x2="6" y2="18"></line><line x1="6" y1="6" x2="18" y2="18"></line></svg></button> </div>
                        <!--svelte-component-end-->
                        
    <script src="https://assets.propublica.org/static/prod/v5/js/main.ebc8c8e7.js"></script>

            <script>
        // Google Tag Manager
        (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
          new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
          j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
          'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
          })(window,document,'script','dataLayer','GTM-K8BNLGX');
        // End Google Tag Manager

        PP.utils.loadJS('https://ak.sail-horizon.com/spm/spm.v1.min.js',function() {
            while(!window.hasOwnProperty("Sailthru")) {
                setTimeout(Function.prototype(), 500);
            }
            Sailthru.init({ "customerId" : "c1d320b4976cc13366759531bf948c3a" });
        });

        // Parse.ly
                  PP.utils.loadJS('//cdn.parsely.com/keys/propublica.org/p.js');
            </script>
    <!-- GA4 (for no-JS pages) -->
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K8BNLGX"
      height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    
    <script>PP.utils.loadJS('https://www.google.com/recaptcha/api.js?onload=grecaptchaLoaded&render=6LcC1roqAAAAAK9equRCqsCagWPYzf79SKrxGFGY');</script>

        <script>
        const noAds = new URLSearchParams(window.location.search).get('__no-ads');
        let adTimeout = new URLSearchParams(window.location.search).get('__ad-timeout');
        if( noAds === null ) {
            if( adTimeout === null ) { adTimeout = 0; }
            setTimeout(function() {
                PP.utils.loadJS('https://htlbid.com/v3/propublica.org/htlbid.js',function() {
                    window.htlbid = window.htlbid || {};
                    htlbid.cmd = htlbid.cmd || [];
                    htlbid.cmd.push(function() {
                        htlbid.layout("universal"); // Leave as "universal" or add custom layout
                                                    htlbid.setTargeting("is_testing", "no");
                                                htlbid.setTargeting("is_home", "no"); // Set to "yes" on the homepage
                        htlbid.setTargeting("post_tags", "health-care");
                    });
                });
            }, adTimeout);
        }
    </script>

    <!-- Begin Convert Experiences code-->
<script>
    // This variable prevents Convert from creating an overlay that can cover the page. Because we use deferred loading, we never want this overlay.
    // https://support.convert.com/hc/en-us/articles/205160025-Disable-Body-Hiding-in-Convert-Experiences
    var _conv_prevent_bodyhide = true;
</script>
<script defer src="//cdn-4.convertexperiments.com/js/1004759-1004714.js"></script>
<!-- End Convert Experiences code -->

    <!-- Hotjar Tracking Code for ProPublica -->
<script>
    (function(h,o,t,j,a,r){
        h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
        h._hjSettings={hjid:3261149,hjsv:6};
        a=o.getElementsByTagName('head')[0];
        r=o.createElement('script');r.async=1;
        r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
        a.appendChild(r);
    })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
</script>

    <!-- Iterate Code -->

<!-- Iterate baseline styles: additional styles included in pp-v5-shared -->
<style>
.iterate__container {
    font-family: var(--fonts-sans, "graphik") !important;
}
</style>

<script>

// Iterate setup script
window.iterateSettings = {
    apiKey: 'eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJjb21wYW55X2lkIjoiNjJmM2M2ZGNjYmVhNDQwMDAxNDZmMjRjIiwiaWF0IjoxNjYwMTQzMzI1fQ.HJYYZWnRLo7nKQHPteT9eeNeXePWXpYAyhaNyFAES-Y',
};
(function(i,t,e,r,a){if(t.getElementById(r)){return}
i.IterateObjectName=a;var z=function(){z.c(arguments)};z.q=[];
z.c=function(args){z.q.push(args)};i[a]=z;
function l() {var js,fjs=t.getElementsByTagName(e)[0];js=t.createElement(e);js.id=r;js.async=1;js.src="https://platform.iteratehq.com/loader.js";fjs.parentNode.insertBefore(js,fjs)};
if(t.readyState==="complete") {l();} else if(i.attachEvent) {i.attachEvent('onload', l);} else{i.addEventListener('load', l, false);}
}(window, document,'script','iterate-js','Iterate'));

// Start Iterate: this will check the server to see if a survey should be displayed
Iterate('install')

// Pass custom properties to Iterate: the 2nd parameter is user-level data, the 3rd parameter is response-level data
var url = new URL(window.location.href);
Iterate('identify', null, {
    canonical: 'https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis',
    utm_campaign: url.searchParams.get("utm_campaign"),
    utm_medium: url.searchParams.get("utm_medium"),
    utm_source: url.searchParams.get("utm_source")
})

</script>

<!-- End Iterate Code -->

    
<script type="application/ld+json">{"@context":"http://schema.org","@graph":[{"@type":"NewsArticle","author":{"@id":"https://www.propublica.org#identity"},"copyrightHolder":{"@id":"https://www.propublica.org#identity"},"copyrightYear":"2025","creator":["Robin Fields"],"dateCreated":"2025-01-31T15:19:25-05:00","dateModified":"2025-02-11T17:49:25-05:00","datePublished":"2025-02-12T08:00:00-05:00","description":"Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the widely held conception that high prices reflect huge industry investments in innovation.","headline":"Zolgensma Creation Story Reveals Truths About Drug Pricing","image":{"@type":"ImageObject","url":"https://img.assets-c3.propublica.org/images/articles/20250131-ProPublica_Owen_Gent_Zolgensma_Final_Artwork_1200x630.jpg?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=630&imgixProfile=propublicaAssets&q=90&w=1200&s=91e4137e84071d14a021a6c5b48bb2ca"},"inLanguage":"en-us","mainEntityOfPage":"https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis","name":"Zolgensma Creation Story Reveals Truths About Drug Pricing","publisher":{"@id":"#creator"},"thumbnailUrl":"https://img.assets-c3.propublica.org/images/articles/20250131-ProPublica_Owen_Gent_Zolgensma_Final_Artwork_1200x630.jpg?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=630&imgixProfile=propublicaAssets&q=90&w=1200&s=91e4137e84071d14a021a6c5b48bb2ca","url":"https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis"},{"@id":"https://www.propublica.org#identity","@type":"NewsMediaOrganization","address":{"@type":"PostalAddress","addressCountry":"US","addressLocality":"New York","addressRegion":"NY","postalCode":"10013","streetAddress":"155 Avenue of the Americas, 13th Floor"},"description":"ProPublica is an independent, non-profit newsroom that produces investigative journalism in the public interest.","email":"info@propublica.org","name":"ProPublica","sameAs":["https://twitter.com/propublica","https://www.facebook.com/propublica/","https://en.wikipedia.org/wiki/ProPublica","https://www.youtube.com/user/propublica","https://github.com/propublica","https://www.linkedin.com/company/propublica/","https://www.instagram.com/propublica","https://www.pinterest.com/propublica","https://vimeo.com/propublica"],"telephone":"1-212-514-5250","url":"https://www.propublica.org"},{"@id":"#creator","@type":"Organization"},{"@type":"BreadcrumbList","description":"Breadcrumbs list","itemListElement":[{"@type":"ListItem","item":"https://www.propublica.org","name":"Homepage","position":1},{"@type":"ListItem","item":"https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis","name":"What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing","position":2}],"name":"Breadcrumbs"}]}</script></body>
</html>
